-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, B/ESIQWCd4CsWdpm8znMXJGgNoZ6mWLEAihACg59/VFDVlcqpN1GBirC09QMxB4f XJP2DqY0c6Mc69rdEDEqdg== 0000930413-08-003234.txt : 20080516 0000930413-08-003234.hdr.sgml : 20080516 20080516124310 ACCESSION NUMBER: 0000930413-08-003234 CONFORMED SUBMISSION TYPE: SC TO-T PUBLIC DOCUMENT COUNT: 15 FILED AS OF DATE: 20080516 DATE AS OF CHANGE: 20080516 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: GIVEN IMAGING LTD CENTRAL INDEX KEY: 0001126140 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: SC TO-T SEC ACT: 1934 Act SEC FILE NUMBER: 005-62155 FILM NUMBER: 08841207 BUSINESS ADDRESS: STREET 1: 2 HA CARMEL ST STREET 2: NEW INDUSTRIAL PARK CITY: YOQNEAM STATE: L4 ZIP: 20692 MAIL ADDRESS: STREET 1: 2 HA CARMEL ST CITY: YOQNEAM STATE: L4 ZIP: 20692 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: ELRON ELECTRONIC INDUSTRIES LTD /NY/ CENTRAL INDEX KEY: 0000315126 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-PREPACKAGED SOFTWARE [7372] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC TO-T BUSINESS ADDRESS: STREET 1: ADVANCED TECHNOLOGY CTR STREET 2: P O BOX 1573 CITY: HAIFA ISRAEL 31015 STATE: L3 SC TO-T 1 c53577_scto-t.htm 3B2 EDGAR HTML -- c53577_scto-t.htm



SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

SCHEDULE TO
(Rule 14d-100)
Tender Offer Statement under
Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934

GIVEN IMAGING LTD.
(Name of Subject Company (Issuer))

ELRON ELECTRONIC INDUSTRIES LTD.
(Name of Filing Person (Offeror))

ORDINARY SHARES, PAR VALUE NIS 0.05 PER SHARE
(Title of Class of Securities)

M52020100
(CUSIP Number of Class of Securities)

Donna Gershowitz, Adv.
Elron Electronic Industries Ltd.
3 Azrieli Center, Triangular Tower, 42nd Floor, Tel Aviv 67023, Israel
Telephone: (972) 3-607-5555

(Name, address and telephone numbers of person authorized to receive
notices and communications on behalf of filing persons)

 

 

 

With copies to:

Richard H. Gilden, Esq.
Kramer Levin Naftalis & Frankel LLP
1177 Avenue of the Americas
New York, New York 10036
Telephone: (212) 715-9100

 

Eytan Greenberg, Adv.
Dr. Shachar Hadar, Adv.
Gross, Kleinhendler, Hodak, Halevy, Greenberg & Co.
One Azrieli Center (Round Building)
Tel Aviv 67021, Israel
Telephone: (972)-3-607-4444

CALCULATION OF FILING FEE

Transaction Valuation*
$24,192,065

 

Amount of Filing Fee**
$950.75

 

 

 

 

 

*

 

For purposes of calculating the filing fee only, this amount is based on the offer to purchase 1,462,640 ordinary shares of Given Imaging Ltd. at a purchase price of $16.54 cash per share.

**

 

Calculated in accordance with Section 14(g) of the Securities Exchange Act of 1934, as amended.

£

 

Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

 

 

Amount Previously Paid: None.
Form or Registration No.: Not Applicable.

 

Filing Party: Not Applicable.
Date Filed: Not Applicable.

£

 

Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transaction to which the statement relates:

S

 

third-party tender offer subject to Rule 14d-1

£

 

issuer tender offer subject to Rule 13e-4

£

 

going-private transaction subject to Rule 13e-3

£

 

amendment to Schedule 13D under Rule 13d-2

Check the following box if the filing is a final amendment reporting the results of the tender offer: £




This Tender Offer Statement on Schedule TO (this “Schedule TO”) is filed by Elron Electronic Industries Ltd., an Israeli company (“Elron”), and relates to the offer by Elron to purchase 1,462,640 outstanding ordinary shares, nominal (par) value NIS 0.05 per share (the “Shares”), of Given Imaging Ltd. (“Given Imaging”), at $16.54 per Share, net to the seller in cash, less any applicable withholding taxes, and without interest, upon the terms of, and subject to the conditions to, the Offer to Purchase, dated May 16, 2008 (the “Offer to Purchase”) and the related Letter of Transmittal, copies of which are attached hereto as Exhibits (a)(1)(A) and (a)(1)(B), respectively (which, together with any amendments or supplements thereto, constitute the “Offer”).

This Schedule TO is intended to satisfy the reporting requirements of Rule 14d-1 under the Securities Exchange Act of 1934, as amended. Pursuant to General Instruction F to Schedule TO, the information contained in the Offer to Purchase and the Letter of Transmittal is incorporated herein by reference in response to all of the items of this Schedule TO as more particularly described below. Capitalized terms used herein but not otherwise defined have the meaning ascribed to such terms in the Offer to Purchase.

ITEM 1. SUMMARY TERM SHEET.

The information set forth under “Summary Term Sheet” in the Offer to Purchase is incorporated herein by reference.

ITEM 2. SUBJECT COMPANY INFORMATION.

(a) The information set forth in Section 8 (“Information Concerning Given Imaging”) of the Offer to Purchase is incorporated herein by reference.

(b) The information set forth under “Introduction” in the Offer to Purchase is incorporated herein by reference.

(c) The information set forth under “Introduction,” Section 6 (“Price Range of the Shares Etc.”) and Section 8 (“Information Concerning Given Imaging”) in the Offer to Purchase is incorporated herein by reference.

ITEM 3. IDENTITY AND BACKGROUND OF FILING PERSON.

(a), (b) and (c) The information set forth in the Offer to Purchase under “Introduction,” Section 9 (“Information Concerning Elron”) and in Schedule I to the Offer to Purchase is incorporated herein by reference.

ITEM 4. TERMS OF THE TRANSACTION.

(a) The information set forth in the following sections of the Offer to Purchase is incorporated herein by reference:

 

 

 

 

“Summary Term Sheet;”

 

 

 

 

“Introduction;”

 

 

 

 

“Background to the Offer;”

 

 

 

 

Section 1 (“Terms of the Offer; Proration; Expiration Date”);

 

 

 

 

Section 2 (“Acceptance for Payment and Payment”);

 

 

 

 

Section 3 (“Procedures for Tendering Shares or Notifying Us of Your Objection to the Offer”);

 

 

 

 

Section 4 (“Withdrawal Rights”);

 

 

 

 

Section 5 (“Material U.S. Federal Income Tax and Israeli Income Tax Considerations”);

 

 

 

 

Section 7 (“Effects of the Offer on the Market for Shares; Registration under the Exchange Act”);

 

 

 

 

Section 10 (“Sources and Amount of Funds”);

 

 

 

 

Section 11 (“Conditions to the Offer”);

 

 

 

 

Section 12 (“Legal Matters and Regulatory Approvals”); and

 

 

 

 

Section 14 (“Miscellaneous”).

The information set forth in the Letter of Transmittal and the Notice of Objection, copies of which are attached hereto as Exhibits (a)(1)(B) and (a)(1)(F), respectively, is also incorporated herein by reference.


ITEM 5. PAST CONTACTS, TRANSACTIONS, NEGOTIATIONS AND AGREEMENTS.

(a) and (b) The information set forth in the Offer to Purchase under “Introduction,” “Background to the Offer—Related Party Transactions,” Section 9 (“Information Concerning Elron”) and Schedule I to the Offer to Purchase is incorporated herein by reference.

ITEM 6. PURPOSES OF THE TRANSACTION AND PLANS OR PROPOSALS.

(a) The information set forth in the Offer to Purchase under “Summary Term Sheet,” “Background to the Offer—Background” and “Background to the Offer—Purpose of the Offer; Reasons for the Offer” is incorporated herein by reference.

(c)(1) through (c)(7) The information set forth in the Offer to Purchase under “Background to the Offer—Plans for Given Imaging after the Offer; Certain Effects of the Offer,” Section 7 (“Effects of the Offer on the Market for Shares; Registration under the Exchange Act”) and Section 9 (“Information Concerning Elron”) is incorporated herein by reference.

ITEM 7. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.

(a), (b) and (d) The information set forth in the Offer to Purchase under “Summary Term Sheet,” “Background to the Offer—Background” and Section 10 (“Sources and Amount of Funds”) is incorporated herein by reference.

ITEM 8. INTEREST IN SECURITIES OF THE SUBJECT COMPANY.

(a) and (b) The information set forth in the Offer to Purchase under “Introduction,” “Background to the Offer—Beneficial Ownership of Shares,” “Background to the Offer—Related Party Transactions,” Section 9 (“Information Concerning Elron”) and in Schedule I to the Offer to Purchase is incorporated herein by reference.

ITEM 9. PERSONS/ASSETS, RETAINED, EMPLOYED, COMPENSATED OR USED.

(a) The information set forth in the Offer to Purchase under Section 13 (“Fees and Expenses”) is incorporated herein by reference.

ITEM 10. FINANCIAL STATEMENTS.

(a) and (b) Financial and pro forma information with respect to Elron has not been included in this Schedule TO because Elron believes that such financial statements are not material to the decision of holders of Shares whether to sell, tender or hold the Shares in the Offer. Elron believes that its financial condition is not material because (i) the consideration offered for the Shares consists solely of cash, (ii) the Offer is not subject to any financing condition, and (iii) Elron has sufficient sources of cash, including credit lines, to purchase the Shares and, as described in the Offer to Purchase, (A) the Israeli Depositary has agreed to guarantee Elron’s obligation to pay for the Shares tendered in the Offer and (B) to secure this guarantee, Elron has engaged the Israeli Depositary to act as an escrow agent and, if requested by the Israeli Depositary, will deposit cash into an escrow account in an amount sufficient to pay for the maximum number of Shares that Elron is offering to purchase in the Offer. In addition, while the financial condition of a bidder may be material when a bidder seeks through a tender offer to acquire a significant equity stake in order to influence the management and affairs of the target (in which case shareholders of the target may need financial information for the prospective controlling shareholder to decide whether to tender in the offer or remain a continuing shareholder in the target company with a dominant or controlling shareholder), Elron believes that its financial condition is not material to holders of Shares because Elron’s significant existing equity stake means that the foregoing consequences will not occur as a result of the Offer in that they already exist. As described in the Offer to Purchase, Elron, together with its affiliates, already exerts substantial influence over Given Imaging and Given Imaging shareholders have had a prior opportunity to become familiar with Elron in light of its significant existing shareholdings. Moreover, Elron believes that there will be little substantive effect, if any, on such influence as a result of its increasing its ownership, taken together with the ownership of its affiliates, from 43.5% to 48.5%, with the only practical effects being (besides Elron and its affiliates having a larger investment in Given Imaging) that (i) Elron and its affiliates will no longer be subject to the special tender offer requirements in Israel (as described in the Offer to Purchase)


having crossed the 45% threshold and (ii) if Elron, together with its affiliates, increases its ownership from 43.5% to 48.5%, it will almost have sufficient voting power to guarantee the outcome of resolutions submitted to the shareholders of Given Imaging. In this regard, Elron notes that under the provisions of the Israeli Companies Law, (i) special disinterested shareholder approval requirements apply to transactions between Elron (or its affiliates) and Given Imaging or transactions of Given Imaging in which Elron (or its affiliates) has an interest (other than solely through Elron’s ownership of Given Imaging shares), where such transactions are material to Given Imaging, or not in its ordinary course of business or not on market terms, thus ensuring that Elron or its affiliates will not be able to use a near majority voting position to effectively approve transactions in which it or its affiliates have an interest by vote of Elron and its affiliates alone and (ii) the voting requirements for resolutions in shareholder meetings are measured off of a percentage of votes cast.

ITEM 11. ADDITIONAL INFORMATION.

(a) The information set forth in the Offer to Purchase under “Background to the Offer”—“Interest of Persons in the Offer,” “Background to the Offer”—“Related Party Transactions,” Section 7 (“Effect of the Offer on the Market for Shares; Registration Under the Exchange Act”), Section 9 (“Information Concerning Elron”) and Section 12 (“Legal Matters and Regulatory Approvals”) is incorporated herein by reference. Elron is not aware of any pending material legal proceedings relating to the Offer.

(b) The information set forth in the Offer to Purchase and the Letter of Transmittal is incorporated herein by reference.

On May 16, 2008, Elron issued a press release announcing the commencement of the Offer, a copy of which is filed as Exhibit (a)(5)(A) to this Schedule TO and is incorporated herein by reference.

ITEM 12. EXHIBITS.

 

 

 

NO.

 

DESCRIPTION

(a)(1)(A)

 

Offer to Purchase dated May 16, 2008.

(a)(1)(B)

 

Letter of Transmittal.

(a)(1)(C)

 

Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.

(a)(1)(D)

 

Letter to Clients for use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.

(a)(1)(E)

 

Guidelines for Certification of Taxpayer Identification Number on Substitute W-9.

(a)(1)(F)

 

Notice of Objection.

(a)(1)(G)

 

Declaration Form (“Declaration of Status for Israeli Income Tax Purposes”).

(a)(5)(A)

 

Text of Press Release issued by Elron on May 16, 2008.

(a)(5)(B)

 

Form of Cover of ‘Mifrat’ to be filed with the Israeli Securities Authority on May 16, 2008.*

(a)(5)(C)

 

Form of Acceptance Notice and Notice of Objection to be filed with the Israeli Securities Authority on May 16, 2008.*

(b)

 

Not applicable.

(d)

 

Document Setting Forth Terms of Registration Rights Agreement dated July 18, 2007

(g)

 

Not applicable.

(h)

 

Not applicable.


 

 

*

 

 

  English translation from Hebrew.

ITEM 13. INFORMATION REQUIRED BY SCHEDULE 13E-3.

Not applicable.


SIGNATURE

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

 

 

ELRON ELECTRONIC INDUSTRIES LTD.

By: /s/ Doron Birger

 

By: /s/ Rinat Remler

 

 

 

Name: Doron Birger
Title: President & Chief Executive Officer

 

Name: Rinat Remler
Title: Vice President & Chief Financial Officer

Dated: May 16, 2008


EXHIBIT INDEX

 

 

 

NO.

 

DESCRIPTION

(a)(1)(A)

 

Offer to Purchase dated May 16, 2008.

(a)(1)(B)

 

Letter of Transmittal.

(a)(1)(C)

 

Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.

(a)(1)(D)

 

Letter to Clients for use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.

(a)(1)(E)

 

Guidelines for Certification of Taxpayer Identification Number on Substitute W-9.

(a)(1)(F)

 

Notice of Objection.

(a)(1)(G)

 

Declaration Form (“Declaration of Status for Israeli Income Tax Purposes”).

(a)(5)(A)

 

Text of Press Release issued by Elron on May 16, 2008.

(a)(5)(B)

 

Form of Cover of ‘Mifrat’ to be filed with the Israeli Securities Authority on May 16, 2008.*

(a)(5)(C)

 

Form of Acceptance Notice and Notice of Objection to be filed with the Israeli Securities Authority on May 16, 2008.*

(b)

 

Not applicable.

(d)

 

Document Setting Forth Terms of Registration Rights Agreement dated July 18, 2007

(g)

 

Not applicable.

(h)

 

Not applicable.


 

 

*

 

 

  English translation from Hebrew


EX-99.(A)(1)(A) 2 c53577_ex99a1a.htm 3B2 EDGAR HTML -- c53577_ex99a1a.htm

OFFER TO PURCHASE FOR CASH
1,462,640 ORDINARY SHARES
of
GIVEN IMAGING LTD.
at
$16.54 NET PER SHARE
by
ELRON ELECTRONIC INDUSTRIES LTD.
IN AN OFFER BEING CONDUCTED IN THE UNITED STATES AND ISRAEL

THE INITIAL OFFER PERIOD AND WITHDRAWAL RIGHTS WILL EXPIRE AT 10:00 A.M., NEW YORK TIME, OR 5:00 P.M., ISRAEL TIME, ON MONDAY, JUNE 16, 2008, UNLESS THE OFFER IS EXTENDED.

We, Elron Electronic Industries Ltd., a company organized under the laws of the State of Israel, are offering to purchase 1,462,640 ordinary shares, NIS 0.05 par value per share, of Given Imaging Ltd., or Given Imaging shares, at the price of $16.54 per Given Imaging share, net to you (subject to withholding taxes, as applicable), in cash, without interest. As of April 8, 2008, there were 29,252,785 Given Imaging shares issued and outstanding.

THE OFFER IS SUBJECT TO THE CONDITIONS DESCRIBED IN SECTION 11. THE PRINCIPAL CONDITIONS ARE THAT:

 

 

 

 

GIVEN IMAGING SHARES THAT REPRESENT AT LEAST 5.0% OF THE ISSUED AND OUTSTANDING GIVEN IMAGING SHARES (CURRENTLY, AT LEAST 1,462,640 GIVEN IMAGING SHARES) ON THE INITIAL COMPLETION DATE (AS DEFINED BELOW) ARE VALIDLY TENDERED AND NOT PROPERLY WITHDRAWN PRIOR TO THE COMPLETION OF THE INITIAL OFFER PERIOD (AS DEFINED BELOW), SUCH THAT FOLLOWING THE CONSUMMATION OF THE OFFER WE WILL BENEFICIALLY OWN APPROXIMATELY 32.4% OF THE ISSUED AND OUTSTANDING GIVEN IMAGING SHARES OR, WHEN TAKEN TOGETHER WITH THE ISSUED AND OUTSTANDING GIVEN IMAGING SHARES OWNED BY OUR AFFILIATES, WE WILL BENEFICIALLY OWN APPROXIMATELY 48.5% OF THE ISSUED AND OUTSTANDING GIVEN IMAGING SHARES; AND

 

IN ACCORDANCE WITH ISRAELI LAW, AT THE COMPLETION OF THE INITIAL OFFER PERIOD, THE AGGREGATE NUMBER OF GIVEN IMAGING SHARES VALIDLY TENDERED AND NOT PROPERLY WITHDRAWN (EXCLUDING THE GIVEN IMAGING SHARES HELD BY US, CERTAIN OF OUR AFFILIATES OR CERTAIN OF GIVEN IMAGING’S AFFILIATES) MUST EXCEED THE AGGREGATE NUMBER OF GIVEN IMAGING SHARES REPRESENTED BY NOTICES OF OBJECTION TO THE CONSUMMATION OF THE OFFER.

THE OFFER IS NOT CONDITIONED ON THE AVAILABILITY OF FINANCING OR THE APPROVAL OF THE BOARD OF DIRECTORS OF GIVEN IMAGING LTD. PLEASE READ SECTION 11, WHICH SETS FORTH IN FULL THE CONDITIONS TO THE OFFER.

IF MORE THAN 5.0% OF THE ISSUED AND OUTSTANDING GIVEN IMAGING SHARES ARE VALIDLY TENDERED AND NOT PROPERLY WITHDRAWN IN THE UNITED STATES AND ISRAEL IN THE AGGREGATE, WE WILL PURCHASE 5.0% OF THE ISSUED AND OUTSTANDING GIVEN IMAGING SHARES ON A PRO RATA BASIS FROM ALL TENDERING SHAREHOLDERS, SO THAT WE WOULD PURCHASE NO MORE THAN 5.0% OF THE ISSUED AND OUTSTANDING GIVEN IMAGING SHARES (CURRENTLY 1,462,640 GIVEN IMAGING SHARES).

THE INITIAL PERIOD OF THE OFFER WILL EXPIRE AT 10:00 A.M., NEW YORK TIME, OR 5:00 P.M., ISRAEL TIME, ON MONDAY, JUNE 16, 2008, UNLESS THE INITIAL PERIOD OF THE OFFER IS EXTENDED. WE REFER TO THIS PERIOD, AS MAY BE EXTENDED, AS THE INITIAL OFFER PERIOD. UPON THE TERMS OF, AND SUBJECT TO THE CONDITIONS TO, THE OFFER, IF PRIOR TO THE COMPLETION OF THE INITIAL OFFER PERIOD, ALL THE CONDITIONS TO THE OFFER ARE SATISFIED OR, SUBJECT TO APPLICABLE LAW, WAIVED BY US, WE WILL PROVIDE YOU WITH AN ADDITIONAL FOUR CALENDAR-DAY PERIOD, UNTIL 10:00 A.M., NEW YORK TIME, OR 5:00 P.M., ISRAEL TIME, ON FRIDAY, JUNE 20, 2008, DURING WHICH YOU MAY TENDER YOUR GIVEN IMAGING SHARES, BUT MAY NOT WITHDRAW VALIDLY TENDERED GIVEN IMAGING SHARES. WE REFER TO THIS ADDITIONAL PERIOD AS THE ADDITIONAL OFFER PERIOD. THE EXPIRATION OF THE ADDITIONAL OFFER PERIOD WILL CHANGE IF WE DECIDE TO EXTEND THE INITIAL OFFER PERIOD. See Section 1 and Section 11.

On May 14, 2008, we received a letter from DIC indicating that DIC did not intend to tender Given Imaging shares that it owned in the offer. On May 14, 2008, we received substantially identical letters from Arie Mientkavich, our chairman, and Doron Birger, our president and chief executive officer, both of whom serve as directors on Given Imaging’s board of directors, indicating that they did not intend to tender Given Imaging shares that they beneficially owned in the offer.

The Given Imaging shares are listed on the Nasdaq Global Market, or Nasdaq, and on the Tel Aviv Stock Exchange Ltd., or the TASE, in each case under the ticker symbol “GIVN.” On May 15, 2008, the last trading day before commencement of the offer, the closing sale price of the Given Imaging shares was $15.75 on Nasdaq and NIS 54.49 ($15.91 based on an exchange rate of NIS 3.42 per U.S. dollar as of May 15, 2008) on the TASE. We encourage you to obtain current market quotations for the Given Imaging shares before deciding whether to tender your Given Imaging shares. See Section 6.


In the United States, the Information Agent for the offer is:
MacKenzie Partners, Inc.
In Israel, information concerning the offer is available from our legal counsel:
Gross, Kleinhendler, Hodak, Halevy, Greenberg & Co.

May 16, 2008


IMPORTANT

The offer is being conducted simultaneously in the United States and Israel. Pursuant to the Israeli Securities Law, 5728-1968 and the regulations promulgated thereunder relating to tender offers, to which we collectively refer as the Israeli Securities Law, we have filed this offer to purchase together with a cover statement in the Hebrew language with the Israeli Securities Authority, or the ISA, and the Tel Aviv Stock Exchange Ltd., or the TASE. We have also filed an English translation of the cover statement from the Hebrew language as an exhibit to the Schedule TO that we filed with the United States Securities and Exchange Commission, or the SEC.

The offer has not been approved or disapproved by the SEC, any state securities commission or the ISA, nor has the SEC, any state securities commission or the ISA passed upon the fairness or merits of the offer or upon the accuracy or adequacy of the information contained in this offer to purchase. Any representation to the contrary is a criminal offense.

We have not authorized any person to make any recommendation on our behalf as to whether you should or should not tender your Given Imaging shares in the offer. You should rely only on the information contained in this offer to purchase and the other related documents delivered to you or to which we have referred you. We have not authorized any person to give any information or to make any representation in connection with the offer, other than those contained in this offer to purchase and the other related documents delivered to you or to which we have referred you. If anyone makes any recommendation or representation to you or gives you any information, you must not rely on that recommendation, representation or information as having been authorized by us.


Holders of Given Imaging shares who hold their Given Imaging shares through a TASE member, or who are named as holders of Given Imaging shares in the Register of Shareholders of Given Imaging Ltd. in Israel, should tender their Given Imaging shares to Clal Finance Batucha Investment Management Ltd., who, with its affiliates, serves as the Israeli Depositary, pursuant to the applicable instructions in Section 3. All other holders of Given Imaging shares should tender their Given Imaging shares to American Stock Transfer & Trust Company, the U.S. Depositary (which we refer to, together with the Israeli Depositary, as the Depositaries), pursuant to the applicable instructions in Section 3. For the addresses and telephone numbers of our Depositaries, see the back cover of this offer to purchase.

Section 3 also describes a right that shareholders have to object to the offer.


Upon the terms of, and subject to the conditions to, the offer (including any terms of, and conditions to, any extension or amendment), subject to proration, we will accept for payment and pay for the Given Imaging shares that are validly tendered and not properly withdrawn prior to 10:00 a.m., New York time, or 5:00 p.m., Israel time, on Monday, June 16, 2008, unless and until we extend the period of time during which the initial period of the offer is open. This period, as may be extended, is referred to as the Initial Offer Period, and the date of completion of the Initial Offer Period is referred to as the Initial Completion Date. We will publicly announce in accordance with applicable law, and in any event issue a press release by 9:00 a.m., New York time, or 4:00 p.m., Israel time, on the U.S. business day following the Initial Completion Date, stating whether or not the conditions to the offer have been satisfied or, subject to applicable law, waived by us. As required by Israeli law, if the conditions to the offer are satisfied or, subject to applicable law, waived by us, then if, with respect to each Given Imaging share owned by you,

 

 

 

 

 

you have not yet responded to the offer,

 

 

 

 

you have notified us of your objection to the offer, or

 

 

 

 

you have validly tendered such Given Imaging share but have properly withdrawn your tender during the Initial Offer Period,

then you will be afforded an additional four calendar-day period, until 10:00 a.m., New York time, or 5:00 p.m., Israel time, on Friday, June 20, 2008, during which you may tender each such Given Imaging share, but may not withdraw validly tendered Given Imaging shares. We refer to this additional period as the Additional Offer Period. The date of completion of the Additional Offer


Period will change if we decide to extend the Initial Offer Period. Given Imaging shares tendered during the Initial Offer Period may be withdrawn at any time prior to 10:00 a.m., New York time, or 5:00 p.m., Israel time, on the Initial Completion Date, but not during the Additional Offer Period. See Section 1, Section 4 and Section 11.


Any questions and requests for assistance may be directed to MacKenzie Partners, Inc., our Information Agent in the United States, or Gross, Kleinhendler, Hodak, Halevy, Greenberg & Co., our legal counsel in Israel, at their addresses and telephone numbers set forth on the back cover of this offer to purchase.

Additional copies of this offer to purchase, the Letter of Transmittal and other related materials may be obtained from the Information Agent or the Israeli Depositary upon request.


TABLE OF CONTENTS

 

 

 

 

 

 

 

 

 

 

 

 

   

SUMMARY TERM SHEET

 

i

INTRODUCTION

 

1

FORWARD-LOOKING STATEMENTS

 

2

BACKGROUND TO THE OFFER

 

3

 

 

Background

 

3

 

 

Purpose of the Offer; Reasons for the Offer

 

6

 

 

Plans for Given Imaging after the Offer; Certain Effects of the Offer

 

6

 

 

Rights of Shareholders Who Do Not Accept the Offer

 

8

 

 

Interest of Persons in the Offer

 

8

 

 

Related Party Transactions

 

8

 

 

Beneficial Ownership of Shares

 

9

THE TENDER OFFER

 

11

 

 

1.

 

TERMS OF THE OFFER; PRORATION; EXPIRATION DATE

 

11

 

 

2.

 

ACCEPTANCE FOR PAYMENT AND PAYMENT

 

13

 

 

3.

 

PROCEDURES FOR TENDERING SHARES OR NOTIFYING US OF YOUR OBJECTION TO THE OFFER

 

15

 

 

4.

 

WITHDRAWAL RIGHTS

 

21

 

 

5.

 

MATERIAL U.S. FEDERAL INCOME TAX AND ISRAELI INCOME TAX CONSIDERATIONS

 

22

 

 

6.

 

PRICE RANGE OF THE SHARES ETC.

 

28

 

 

7.

 

EFFECTS OF THE OFFER ON THE MARKET FOR SHARES; REGISTRATION UNDER THE EXCHANGE ACT

 

30

 

 

8.

 

INFORMATION CONCERNING GIVEN IMAGING

 

30

 

 

9.

 

INFORMATION CONCERNING ELRON

 

31

 

 

10.

 

SOURCES AND AMOUNT OF FUNDS

 

32

 

 

11.

 

CONDITIONS TO THE OFFER

 

32

 

 

12.

 

LEGAL MATTERS AND REGULATORY APPROVALS

 

34

 

 

13.

 

FEES AND EXPENSES

 

35

 

 

14.

 

MISCELLANEOUS

 

36

ANNEX A

 

37

ANNEX B

 

38


Unless the context otherwise requires, all references in this offer to purchase to “Elron,” “us,” “we,” and “our” are to Elron Electronic Industries Ltd., all references to “Given Imaging” are to Given Imaging Ltd., all references to “Nasdaq” are to the Nasdaq Global Market, all references to “TASE” are to the Tel Aviv Stock Exchange Ltd., all references to “dollars” or “$” are to U.S. dollars, all references to “NIS” are to New Israeli Shekel, and all references to the “Israeli Companies Law” are to the Israeli Companies Law 5759-1999.

Unless the context otherwise requires, the percentages of the issued and outstanding Given Imaging shares stated throughout this offer to purchase are based on 29,252,785 Given Imaging shares issued and outstanding as of April 8, 2008, which includes vested restricted Given Imaging shares issued under the 2003 Plan and the 2006 Equity Incentive Plan of Given Imaging.

Unless otherwise indicated or the context otherwise requires, for purposes of this offer to purchase, (i) an “Israeli business day” means any day other than a Friday, Saturday, or any other day on which the banks in both Israel and the United States are permitted not to be open for business and (ii) a “U.S. business day” means any day other than a Saturday, Sunday, U.S. federal holiday or any other day on which the banks in the United States are permitted not to be open for business.

SUMMARY TERM SHEET

This summary term sheet is a brief summary of the material provisions of this offer to purchase 1,462,640 ordinary shares of Given Imaging, par value NIS 0.05 per share (which we refer to as Given Imaging shares) being made by Elron, and is meant to help you understand the offer. This summary term sheet is not meant to be a substitute for the information contained in the remainder of this offer to purchase, and the information contained in this summary term sheet is qualified in its entirety by the fuller descriptions and explanations contained in the later pages of this offer to purchase. The following are some of the questions you, as a shareholder of Given Imaging, may have about us and the offer and answers to those questions. We recommend that you read carefully this entire offer to purchase, the Letter of Transmittal and other related documents delivered to you prior to making any decision regarding whether to tender your shares.

Who is offering to buy my securities?

 

 

 

 

We, Elron Electronic Industries Ltd., are an Israeli company founded in 1962 and headquartered in Israel. Our shares are listed on the Nasdaq Global Select Market and the TASE, in each case under the ticker symbol “ELRN.” We are a high technology holding company that operates through subsidiaries and affiliated companies referred to as our group companies. We have been a major force in the development of Israeli high technology industry by building Israeli and Israel-related companies with technologies in the fields of medical imaging, advanced defense electronics, telecommunications, semiconductors and software products and services and today operate through our group companies in the fields of medical devices, information and communications technology, clean technology and semi-conductors. We are 48.6% owned by Discount Investment Corporation Ltd., or DIC, a holding company incorporated in Israel whose shares are listed on the TASE under the ticker symbol “DISI.” DIC is a majority owned subsidiary of IDB Holding Corporation Ltd., or IDBH, a holding company incorporated in Israel whose shares are listed on the TASE under the symbol “IDBH.” See Section 9.

How many shares are sought in the offer?

 

 

 

 

Subject to certain conditions, we are offering to purchase 1,462,640 Given Imaging shares, so as to increase our ownership percentage therein from approximately 27.4% to approximately 32.4% of the issued and outstanding Given Imaging shares or, when taken together with the issued and outstanding Given Imaging shares owned by our affiliates, from approximately 43.5% to approximately 48.5% of the issued and outstanding Given Imaging shares. See Section 1.

 

 

 

 

If more than 5.0% of the issued and outstanding Given Imaging shares (currently 1,462,640 Given Imaging shares) are validly tendered and not properly withdrawn, we will purchase

i


 

 

 

 

5.0% of the issued and outstanding Given Imaging shares on a pro rata basis from all shareholders who have validly tendered their Given Imaging shares in the Initial Offer Period and the Additional Offer Period and have not properly withdrawn their Given Imaging shares before the completion of the Initial Offer Period, so that we would purchase no more than 5.0% of the issued and outstanding Given Imaging shares. The number of Given Imaging shares that we will purchase from each tendering shareholder will be based on the total number of Given Imaging shares validly tendered by all shareholders in the Initial Offer Period and the Additional Offer Period and not properly withdrawn before the completion of the Initial Offer Period. You may only withdraw previously tendered shares prior to the completion of the Initial Offer Period. See Section 1 and Section 4.

Why are you making the offer?

 

 

 

 

We are making the offer to increase our interest in Given Imaging because we believe in the long-term potential of Given Imaging and in order to comply with the requirements of Israeli law. Under Israeli law, a purchase of shares of a public company may only be made by way of a “special tender offer” meeting certain requirements if, among other things, as a result of the purchase, the purchaser (together with its affiliates) would own more than 45.0% of the aggregate voting power of the company and no other person owns more than 45.0% of the aggregate voting power of the company. Accordingly, since we beneficially own approximately 43.5% of the issued and outstanding Given Imaging shares, when taken together with the Given Imaging shares owned by our affiliates, in order for us to purchase additional Given Imaging shares that would increase our voting power (together with that of our affiliates) of Given Imaging to more than 45.0%, we are required to conduct the offer as a “special tender offer” meeting the requirements of Israeli law. See “Background to the Offer—Background” and “Background to the Offer—Purpose of the Offer; Reasons for the Offer.”

How much are you offering to pay and what is the form of payment?

 

 

 

 

We are offering to pay $16.54 per Given Imaging share, net to you (subject to withholding taxes, as applicable), in cash, without interest. All shareholders tendering their Given Imaging shares in the offer will be paid solely in U.S. dollars. See “Introduction,” Section 1, Section 2 and, with respect to withholding taxes, Section 5.

What percentage of the Given Imaging shares do you currently own and how much will you own if the offer is completed?

 

 

 

 

We currently beneficially own 8,002,180 Given Imaging shares, representing approximately 27.4% of the issued and outstanding Given Imaging shares or, when taken together with the issued and outstanding shares owned by our affiliates, 12,721,708 Given Imaging shares, representing approximately 43.5% of the issued and outstanding shares of Given Imaging.

 

 

 

 

Following the consummation of the offer, we will purchase 1,462,640 Given Imaging shares and we will beneficially own approximately 32.4% of the issued and outstanding Given Imaging shares, or when taken together with the issued and outstanding Given Imaging shares owned by our affiliates, approximately 48.5% of the issued and outstanding Given Imaging shares. See “Introduction,” “Background to the Offer—Beneficial Ownership of Shares” and Section 11.

What is the market value of my Given Imaging shares as of a recent date?

 

 

 

 

On May 15, 2008, the last full trading day before we commenced the offer, the closing price per Given Imaging share as reported on Nasdaq was $15.75, and as reported on the TASE was NIS 54.49 ($15.91 based on an exchange rate of NIS 3.42 per U.S. dollar as of May 15, 2008). We recommend that you obtain a recent quotation for your Given Imaging shares prior to deciding whether or not to tender your Given Imaging shares. See Section 6.

ii


Do you have the financial resources to pay the purchase price in the offer?

 

 

 

 

Yes. The purchase of the Given Imaging shares in the offer will be financed by our own internal resources and credit lines. The offer is not conditioned on the availability of financing.

 

 

 

 

According to Israeli law, to secure the payment for the Given Imaging shares tendered in the offer, the Israeli Depositary, which is a member of the TASE, has agreed to guarantee our obligation to pay for the Given Imaging shares. To secure this guarantee, we have engaged the Israeli Depositary to act as an escrow agent and, if requested by the Israeli Depositary, will deposit cash into an escrow account in an amount sufficient to pay for the total number of Given Imaging shares that we are offering to purchase. See Section 2 and Section 10.

Can I object to the offer?

 

 

 

 

Yes. Pursuant to Israeli law, you may object to the offer. If you want to notify us of your objection to the offer you must complete and sign the accompanying Notice of Objection and deliver it prior to the completion of the Initial Offer Period on June 16, 2008 (as may be extended) by following the applicable procedures and instructions described in Section 3. You may not object to the offer during the Additional Offer Period. Under Israeli law, since the consummation of the offer will result in our (together with our affiliates) being the beneficial owners of more than 45.0% of the voting power of Given Imaging, the aggregate number of Given Imaging shares validly tendered in the offer and not properly withdrawn at the completion of the Initial Offer Period (excluding the Given Imaging shares held by us, certain of or our affiliates and certain of Given Imaging’s affiliates) must exceed the aggregate number of Given Imaging shares represented by Notices of Objection to the offer. This is one of the conditions to the offer and if it is not met we will be prohibited from purchasing any Given Imaging shares tendered in the offer. See the answer to the question “What are the most significant conditions to the offer?” below, “Background to the Offer—Rights of Shareholders Who Do Not Accept the Offer,” Section 3 and Section 11. For details of the Given Imaging shares held by us and our affiliates, see “Background to the Offer—Beneficial Ownership of Shares.”

What are the most significant conditions to the offer?

The offer is conditioned on, among other things, the following:

 

 

 

 

Given Imaging shares representing at least 5.0% of the issued and outstanding shares of Given Imaging on the Initial Completion Date (currently, at least 1,462,640 Given Imaging shares) must be validly tendered and not properly withdrawn prior to the completion of the Initial Offer Period, such that following the consummation of the offer, we will beneficially own approximately 32.4% of the issued and outstanding Given Imaging shares, or when taken together with the issued and outstanding shares owned by our affiliates, approximately 48.5% of the issued and outstanding Given Imaging shares; and

 

 

 

 

at the completion of the Initial Offer Period, the aggregate number of Given Imaging shares validly tendered in the offer and not properly withdrawn (excluding Given Imaging shares held by us, certain of our affiliates or certain of Given Imaging’s affiliates) must be greater than the aggregate number of Given Imaging shares represented by Notices of Objection to the offer.

The offer is not conditioned on the availability of financing or the approval of the board of directors of Given Imaging.

See “Background to the Offer—Rights of Shareholders Who Do Not Accept the Offer” and Section 11, which sets forth in full the conditions to the offer and describes those conditions to the offer that are waiveable by us.

iii


What will happen if the conditions to the offer are not satisfied?

 

 

 

 

If any condition is not satisfied, we may elect not to purchase, or may be prohibited from purchasing, any Given Imaging shares tendered in the offer, or, subject to applicable law, we may waive such conditions. See “Introduction,” Section 1 and Section 11.

How long do I have to decide whether to tender in the offer?

 

 

 

 

You may tender your Given Imaging shares until 10:00 a.m., New York time, or 5:00 p.m., Israel time, on June 16, 2008 (as may be extended). We refer to this period, as may be extended, as the Initial Offer Period, and the date of completion of the Initial Offer Period is referred to as the Initial Completion Date.

 

 

 

 

We will publicly announce in accordance with applicable law, and in any event issue a press release by 9:00 a.m., New York time, or 4:00 p.m., Israel time, on the U.S. business day following the Initial Completion Date, stating whether or not the conditions to the offer have been satisfied or, subject to applicable law, waived by us. As required by Israeli law, if the conditions to the offer are satisfied or, subject to applicable law, waived by us, then if, with respect to each Given Imaging share owned by you,

 

 

 

 

you have not yet responded to the offer,

 

 

 

 

you have notified us of your objection to the offer, or

 

 

 

 

you have validly tendered such Given Imaging share but have properly withdrawn your tender during the Initial Offer Period,

you will be afforded an additional four calendar-day period following the Initial Completion Date, until 10:00 a.m., New York time, or 5:00 p.m., Israel time, on Friday, June 20, 2008, during which you may tender each such Given Imaging share; however, you may not withdraw previously tendered Given Imaging shares during this additional period. We refer to this additional period as the Additional Offer Period and the date of expiration of the Additional Offer Period is referred to as the Final Expiration Date. The Final Expiration Date will change if we decide to extend the Initial Offer Period. See “Introduction,” Section 1, Section 3 and Section 11.

How do I tender my Given Imaging shares and to which depositary should I tender?

This depends on the manner in which you hold your Given Imaging shares:

 

 

 

 

if you hold your Given Imaging shares through a TASE member or you are named as a holder of the Given Imaging shares in the Register of Shareholders of Given Imaging in Israel, you should tender your Given Imaging shares to the Israeli Depositary by following the applicable procedures and instructions described in Section 3; and

 

 

 

 

All other holders of Given Imaging shares should tender their Given Imaging shares to the U.S. Depositary by following the applicable procedures and instructions described in Section 3.

Can I tender my Given Imaging shares using a guaranteed delivery procedure?

 

 

 

 

No. You may only tender your Given Imaging shares by following the applicable procedures and instructions described in Section 3.

When can I withdraw the Given Imaging shares I tendered in the offer?

 

 

 

 

You may withdraw any previously tendered Given Imaging shares at any time prior to the completion of the Initial Offer Period, but not during the Additional Offer Period. In addition, under U.S. law, tendered Given Imaging shares may be withdrawn at any time after 60 days from the date of the commencement of the offer if the Given Imaging shares have not yet been accepted for payment by us. See Section 1 and Section 4.

iv


When will you pay for the Given Imaging shares tendered in the offer?

 

 

 

 

All of the Given Imaging shares validly tendered in the offer and not properly withdrawn will be paid for promptly following the Final Expiration Date, subject to proration. We expect to make such payment, including in the event that proration of tendered Given Imaging shares is required, within four U.S. business days following the Final Expiration Date. See Section 1, Section 2 and Section 11.

Can the offer be extended, and under what circumstances?

 

 

 

 

We have the right, in our sole discretion, to extend the Initial Offer Period, subject to applicable law. In addition, in certain circumstances, we may be required by law to extend the Initial Offer Period. See Section 1.

How will I be notified if the offer is extended?

 

 

 

 

If we decide to extend the Initial Offer Period, we will inform the Depositaries, the Information Agent and our Israeli legal counsel of that fact. We will also publicly announce the new Initial Completion Date in accordance with applicable law, and in any event issue a press release to this effect no later than 9:00 a.m., New York time, or 4:00 p.m., Israel time, on the first U.S. business day following the day on which we decide to extend the Initial Offer Period. Under Israeli law, we are required to publicly announce the new expiration date no later than one Israeli business day prior to the Initial Completion Date. See Section 1.

Has Given Imaging or its board of directors adopted a position on the offer?

 

 

 

 

Under applicable U.S. law, no later than ten U.S. business days from the date of this offer to purchase, Given Imaging is required to publish, send or give to you a statement disclosing that it either recommends acceptance or rejection of the offer, expresses no opinion and remains neutral toward the offer, or is unable to take a position with respect to the offer.

 

 

 

 

Under Israeli law, Given Imaging’s board of directors is required, no later than five Israeli business days prior to the Initial Completion Date, to express its opinion to the shareholders on the advisability of the offer. Given Imaging’s board of directors may refrain from expressing an opinion if it cannot do so, as long as it gives a statement disclosing the reasons for not providing an opinion.

As of the date of this offer to purchase, neither Given Imaging nor its board of directors has made any such statement.

Are there any conflicts of interest in the offer?

 

 

 

 

Yes. As we beneficially own approximately 27.4% of the issued and outstanding Given Imaging shares or, when taken together with the issued and outstanding Given Imaging shares owned by our affiliates, approximately 43.5% of the issued and outstanding Given Imaging shares, we have significant influence over the election of directors of Given Imaging and other matters submitted to Given Imaging’s shareholders for a vote. DIC, our 48.6% shareholder, also beneficially owns shares of Given Imaging. Further, Arie Mientkavich, our Chairman, and Doron Birger, our President and Chief Executive Officer, each serve as a director on the board of directors of Given Imaging. In addition, Clal Finance Batucha Investment Management Ltd., the Israeli Depositary, is a majority indirectly owned subsidiary of Clal Insurance Enterprises Holdings Ltd. (“CIEH”), a shareholder of ours and a majority indirectly owned subsidiary of IDBH, an affiliate of ours.

See “Background to the Offer—Purpose of the Offer; Reasons for the Offer,” “Background to the Offer—Interest of Persons in the Offer,” “Background to the Offer—Beneficial Ownership of Shares” and Schedule I to this offer to purchase.

v


What are the tax consequences of the offer?

 

 

 

 

The receipt of cash for Given Imaging shares accepted for payment by us from tendering shareholders who are “U.S. Holders” (as defined below in Section 5) for U.S. federal income tax purposes will be treated as a taxable transaction for U.S. federal income tax purposes.

 

 

 

 

The receipt of cash for Given Imaging shares accepted for payment by us from tendering shareholders generally will be a taxable transaction for Israeli income tax purposes for both Israeli residents and non-Israeli residents, unless a specific exemption is available or a tax treaty between Israel and the shareholder’s country of residence provides otherwise.

 

 

 

 

The receipt of cash for Given Imaging shares accepted for payment by us from tendering shareholders is generally subject to the withholding of Israeli tax at the source, at a rate of 20% for individuals or 25% for corporations of the shareholder’s gain on such sale. We have obtained an approval from the Israeli Tax Authority, or ITA with respect to the Israeli withholding tax rates applicable to shareholders as a result of the purchase of Given Imaging shares in the offer. The approval provides, among other things, that (1) tendering shareholders who acquired their Given Imaging shares after Given Imaging’s initial public offering on Nasdaq (i.e., after October 3, 2001) and who certify that they are NOT “residents of Israel” for purposes of the Israeli Income Tax Ordinance [New Version], 5721-1961, or the Ordinance, (and, in the case of a corporation, that no Israeli residents (x) hold 25% or more of the means to control such corporation or (y) are the beneficiaries of, or is entitled to, 25% or more of the revenues or profits of such corporation, whether directly or indirectly), will not be subject to Israeli withholding tax, (2) eligible Israeli brokers or financial institutions holding Given Imaging shares solely on behalf of a tendering shareholder will not be subject to Israeli withholding tax, (3) tendering shareholders who are Israeli residents and who acquired their Given Imaging shares prior to Given Imaging’s initial public offering on Nasdaq, will be subject to Israeli withholding tax at a rate of 25% of the amount received by the tendering shareholder, (4) tendering shareholders who are NOT “residents of Israel” and who acquired their Given Imaging shares prior to Given Imaging’s initial public offering on Nasdaq, will be subject to Israeli withholding tax at a rate of 25% of the amount received by the tendering shareholder unless the tendering shareholder submits an A-114 Form approving such shareholder’s residence in a country with whom Israel has a tax treaty which exempts Israeli capital gains tax, duly signed by the tendering shareholder and authorized by the tax authority of such country, in which event such tendering shareholder will not be subject to Israeli withholding tax, and (5) tendering shareholders who are not described in clauses (1),(2), (3) and (4) above, will be subject to Israeli withholding tax at a fixed rate of 8.61% of the amount received by the tendering shareholder pursuant to the offer. Notwithstanding the foregoing, should any tendering shareholder present us with a valid approval from the ITA applying withholding tax at a lesser rate than those described above or otherwise granting a specific exemption from Israeli withholding tax, we will act in accordance with such approval.

We recommend that you seek professional advice from your own tax advisors concerning the tax consequences applicable to your particular situation. See Section 5.

Will the offer result in the delisting of the Given Imaging shares?

 

 

 

 

No. We expect that the Given Imaging shares will continue to trade on Nasdaq and the TASE following completion of the offer. See Section 7.

With whom may I talk if I have questions about the offer?

 

 

 

  You can call MacKenzie Partners, Inc., our Information Agent in the United States, at 212-929-5500 or 800-322-2885, or our legal counsel in Israel, Gross, Kleinhendler, Hodak, Halevy, Greenberg & Co., at +972-3-607-4444, during their respective normal business hours. See the back cover of this offer to purchase.

vi


INTRODUCTION

We, Elron Electronic Industries Ltd., hereby offer to purchase 1,462,640 ordinary shares, par value NIS 0.05 per share, of Given Imaging Ltd., or Given Imaging shares, at a price of $16.54 per share, net to you (subject to withholding taxes, as applicable), in cash, without interest. The offer is subject to the terms and conditions set forth in this offer to purchase, the Letter of Transmittal and the other related documents delivered to you.

Given Imaging shares are listed on the Nasdaq Global Market, or Nasdaq, and on the Tel Aviv Stock Exchange Ltd., or the TASE, in each case under the ticker symbol “GIVN.” As of April 8, 2008, there were 29,252,785 Given Imaging shares issued and outstanding. As of the date of this offer to purchase, we beneficially own 8,002,180 Given Imaging shares, representing 27.4% of the issued and outstanding Given Imaging shares or, when taken together with the issued and outstanding Given Imaging shares owned by our affiliates, 12,721,708 Given Imaging shares, representing approximately 43.5% of the issued and outstanding Given Imaging shares. As a result, if we purchase 1,462,640 Given Imaging shares in the offer, we would beneficially own 9,464,820 Given Imaging shares, or approximately 32.4% of the issued and outstanding Given Imaging shares, or when taken together with the issued and outstanding Given Imaging shares owned by our affiliates, 14,184,348 Given Imaging shares, or approximately 48.5% of the issued and outstanding Given Imaging shares.

We are an Israeli company founded in 1962 and headquartered in Israel. Our shares are listed on the Nasdaq Global Select Market and the TASE, in each case under the ticker symbol “ELRN.” We are a high technology holding company that operates through subsidiaries and affiliated companies referred to as our group companies. We have been a major force in the development of Israeli high technology industry by building Israeli and Israel-related companies with technologies in the fields of medical imaging, advanced defense electronics, telecommunications, semiconductors and software products and services and today operate through our group companies in the fields of medical devices, information and communication technology, clean technology and semiconductors. We are 48.6% owned by Discount Investment Corporation Ltd., or DIC, a holding company incorporated in Israel whose shares are listed on the TASE under the ticker symbol “DISI.” DIC is a majority owned subsidiary of IDB Holding Corporation Ltd., or IDBH, a holding company incorporated in Israel whose shares are listed on the TASE under the symbol “IDBH.” Please read Section 9 for additional information concerning us.

The offer is being conducted simultaneously in the United States and in Israel. The initial period of the offer will be completed at 10:00 a.m., New York time, or 5:00 p.m., Israel time, on June 16, 2008. We refer to this period, as may be extended, as the Initial Offer Period, and the date of completion of the Initial Offer Period is referred to as the Initial Completion Date. We will publicly announce in accordance with applicable law, and in any event issue a press release by 9:00 a.m., New York time, or 4:00 p.m., Israel time, on the U.S. business day following the Initial Completion Date, stating whether or not the conditions to the offer have been satisfied or, subject to applicable law, waived by us. As required by Israeli law, if the conditions to the offer have been satisfied or, subject to applicable law, waived by us, then if, with respect to each Given Imaging share owned by you, (a) you have not yet responded to the offer, (b) you have notified us of your objection to the offer, or (c) you have validly tendered such Given Imaging share but have properly withdrawn your tender during the Initial Offer Period, then you will be afforded an additional four calendar- day period, until 10:00 a.m., New York time, or 5:00 p.m., Israel time, on June 20, 2008, during which you may tender each such Given Imaging share, but may not withdraw validly tendered Given Imaging shares. We refer to this additional period as the Additional Offer Period and the date of expiration of the Additional Offer Period is referred to as the Final Expiration Date. The Final Expiration Date will change if we decide to extend the Initial Offer Period.

If you are a record owner of Given Imaging shares and tender directly to American Stock Transfer & Trust Company, the U.S. Depositary, or to Clal Finance Batucha Investment Management Ltd., the Israeli Depositary (which we refer to, together with the U.S. Depositary, as the Depositaries), you generally will not be obligated to pay brokerage fees or commissions, service fees or commissions or, except as set forth in the Letter of Transmittal, share transfer taxes with

1


respect to the purchase of Given Imaging shares in the offer. If you hold your Given Imaging shares through a bank or broker, we recommend that you check whether they charge any service or other fees. The Israeli Depositary is an affiliate of Elron. See “Background of the Offer—Interest of Persons in the Offer,” for additional details.

We will pay the fees and expenses of the Depositaries in connection with the offer. The Depositaries will act as agents for tendering shareholders for the purpose of receiving payment from us and transmitting payments to tendering shareholders whose Given Imaging shares are accepted for payment. We will also pay the fees and expenses of MacKenzie Partners, Inc., our Information Agent, and Gross, Kleinhendler, Hodak, Halevy, Greenberg & Co., our Israeli legal counsel, who will both facilitate and answer questions concerning the offer during their respective normal business hours.

The offer is conditioned on Given Imaging shares representing at least 5.0% of the issued and outstanding shares of Given Imaging on the Initial Completion Date (currently, at least 1,462,640 Given Imaging shares), being validly tendered and not properly withdrawn, and we may terminate the offer if the total number of Given Imaging shares validly tendered and not properly withdrawn prior to 10:00 a.m., New York time, or 5:00 p.m., Israel time, on the Initial Completion Date is less than 5.0% of the issued and outstanding shares of Given Imaging on the Initial Completion Date. Certain other conditions to the consummation of the offer are described in Section 11. We reserve the right (subject to applicable law and the rules of the SEC and ISA) to amend or, other than the conditions set forth in clause (a) and clause (c) of Section 11, waive any one or more of the terms of, and conditions to, the offer. However, if any of these conditions are not satisfied, we may elect not to purchase, or may be prohibited from purchasing any Given Imaging shares tendered in the offer. The offer is not conditioned on the availability of financing or the approval of the board of directors of Given Imaging. See Section 1, Section 10 and Section 11.

Under applicable U.S. law, no later than ten U.S. business days from the date of this offer to purchase, Given Imaging is required to publish, send or give to you a statement disclosing that it either recommends acceptance or rejection of the offer, expresses no opinion and remains neutral toward the offer, or is unable to take a position with respect to the offer. Under Israeli law, Given Imaging’s board of directors is required, no later than five Israeli business days prior to the Initial Completion Date, to express its opinion to the shareholders on the advisability of the offer. Given Imaging’s board of directors may refrain from expressing an opinion if it cannot do so, as long as it gives the reasons for not providing an opinion. As of the date of this offer to purchase, neither Given Imaging nor its board of directors has made such a statement.

This offer to purchase, the Letter of Transmittal and the other related documents delivered to you contain important information which should be read carefully before any decision is made with respect to the offer.

FORWARD-LOOKING STATEMENTS

This offer to purchase, the Letter of Transmittal and the other related documents delivered to you and/or incorporated by reference herein include “forward-looking statements” that are not purely historical regarding our intentions, hopes, beliefs, expectations and strategies for the future, including, without limitation:

 

 

 

 

any statements of the plans, objectives or expectations regarding the future operations or status of us or Given Imaging;

 

 

 

 

any anticipated trends;

 

 

 

 

any statements regarding future economic conditions or performance; and

 

 

 

 

any statement of assumptions underlying any of the foregoing.

Forward-looking statements that are based on various assumptions (some of which are beyond our control) may be identified by the use of forward-looking terminology, such as “may,” “can be,” “will,” “expects,” “anticipates,” “intends,” “believes,” “projects,” “potential,” “are optimistic,” “view” and similar words and phrases. Such forward-looking statements are inherently subject to known and

2


unknown risks and uncertainties. Actual results could differ materially from those set forth in forward-looking statements due to a variety of factors, including, but not limited to:

 

 

 

 

changes in domestic and foreign economic and market conditions;

 

 

 

 

uncertainty as to the completion of the offer; and

 

 

 

 

the risk factors detailed in Given Imaging’s most recent annual report on Form 20-F (“2007 Form 20-F”) and its other filings with the SEC.

See Section 9 of this offer to purchase for a discussion of certain information relating to us. Except as may be required by law, we do not undertake, and specifically disclaim, any obligation to publicly release the results of any revisions which may be made to any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such forward-looking statements.

You should assume that the information appearing in this offer to purchase is accurate as of the date on the front cover of this offer to purchase only.

BACKGROUND TO THE OFFER

Background

Given Imaging was incorporated in January 1998 by RDC Rafael Development Corporation Ltd., or RDC, our 50.1% subsidiary. We, together with DIC, which holds 48.6% of our outstanding shares, made investments in Given Imaging from April 1998 until Given Imaging’s initial public offering in October 2001 through several privately negotiated transactions. We, together with DIC, beneficially owned approximately 12.2 million Given Imaging shares, representing approximately 48.6% of the outstanding Given Imaging shares immediately after Given Imaging’s initial public offering. In May 2003, we purchased 1 million Given Imaging shares from RDC in a transaction in which RDC also sold 1 million Given Imaging shares to its other shareholder, Rafael Advanced Defense Systems Ltd. Between August 2004 and June 2007, we periodically increased our holdings by way of executing open market purchases on Nasdaq or TASE in the aggregate amount of approximately 3.63 million Given Imaging shares, including on two occasions making such purchases together with DIC who purchased an aggregate amount of approximately 1.26 million Given Imaging shares.

In addition, from time to time between 2002 and 2005, RDC sold in the aggregate approximately 3 million Given Imaging shares (without taking into account RDC’s sale of 1 million Given Imaging shares to us in May 2003 described above) in open market purchases, privately negotiated transactions and Given Imaging’s secondary public offering. In addition, during 2002 we sold approximately 100,000 Given Imaging shares and DIC sold approximately 200,000 Given Imaging shares in open market transactions.

The following table summarizes our purchases and sales from 2002 through 2007:

 

 

 

 

 

 

 

 

 

Year

 

Starting
Balance

 

Purchases

 

Sales

 

Ending
Balance

 

2002

 

 

 

1,829,886

   

 

 

 

98,666

   

 

 

1,731,220

 

 

2003

 

 

 

1,731,220

   

 

 

1,000,000

   

 

 

 

2,731,220

 

 

2004

 

 

 

2,731,220

   

 

 

1,373,513

   

 

 

21,751

   

 

 

4,082,982

 

 

2005

 

 

 

4,082,982

   

 

 

 

 

4,082,982

 

 

2006

 

 

 

4,082,982

   

 

 

539,721

   

 

 

 

4,622,703

 

 

2007

 

 

 

4,622,703

   

 

 

717,367

   

 

 

 

5,340,070

 

3


The following table summaries RDC’s purchases and sales from 2002 through 2007:

 

 

 

 

 

 

 

 

 

Year

 

Starting
Balance

 

Purchases

 

Sales

 

Ending
Balance

 

2002

 

 

 

6,683,877

   

 

 

   

 

 

697,967

   

 

 

5,985,910

 

 

2003

 

 

 

5,985,910

   

 

 

   

 

 

2,753,600

   

 

 

3,232,310

 

 

2004

 

 

 

3,232,310

   

 

 

   

 

 

500,000

   

 

 

2,732,310

 

 

2005

 

 

 

2,732,310

   

 

 

   

 

 

70,200

   

 

 

2,662,110

 

 

2006

 

 

 

2,662,110

   

 

 

   

 

 

 

2,662,110

 

 

2007

 

 

 

2,662,110

   

 

 

   

 

 

 

2,662,110

 

The following table summaries DIC’s purchases and sales from 2002 through 2007:

 

 

 

 

 

 

 

 

 

Year

 

Starting
Balance

 

Purchases

 

Sales

 

Ending
Balance

 

2002

 

 

 

3,659,775

   

 

 

 

197,334

   

 

 

3,462,441

 

 

2003

 

 

 

3,462,441

   

 

 

 

 

3,462,441

 

 

2004

 

 

 

3,462,441

   

 

 

 

 

3,462,441

 

 

2005

 

 

 

3,462,441

   

 

 

 

 

3,462,441

 

 

2006

 

 

 

3,462,441

   

 

 

539,721

   

 

 

 

4,002,162

 

 

2007

 

 

 

4,002,162

   

 

 

717,366

   

 

 

 

4,719,528

 

We currently own directly 5,340,070 Given Imaging shares and beneficially own an additional 2,662,110 Given Imaging shares that are held by RDC, representing an aggregate beneficial ownership of 27.4%. In addition, DIC currently beneficially owns an additional 4,719,528 Given Imaging shares (excluding any Given Imaging shares directly owned by Elron and RDC). In this offer to purchase, all references to Given Imaging shares owned, purchased or sold by us together with our affiliates exclude those Given Imaging shares (currently an aggregate of 679,979 Given Imaging shares) held by subsidiaries of CIEH, all of which entities are controlled by IDBH, for members of the public through, among others, mutual funds, provident funds, pension funds and life insurance policies and 84,056 Given Imaging shares held for members of the public through hedge traded funds, in each case managed by companies controlled by CIEH, and 9,220 Given Imaging shares held for members of the public through mutual funds managed by a company controlled by IDBH, which disclaims beneficial ownership of these Given Imaging shares. In light of the foregoing, as of the date of this offer to purchase, we, together with our affiliates, beneficially own an aggregate of 12,721,708 Given Imaging shares, representing approximately 43.5% of the issued and outstanding Given Imaging shares.

All ownership percentages of Given Imaging used in this offer to purchase, unless otherwise indicated, are based on an aggregate of 29,252,785 issued and outstanding ordinary shares of Given Imaging as of April 8, 2008.

In the ordinary course of our business, we review the performance of our investee companies on an ongoing basis and consider possible strategies for enhancing value. Accordingly, we closely follow the performance and progress of Given Imaging and explore, from time to time, the possibilities of acquiring additional Given Imaging shares or disposing of Given Imaging shares.

In late February 2008, our management began considering the possibility of purchasing additional Given Imaging shares to increase our holding in Given Imaging by 5.0% of the issued and outstanding Given Imaging shares. We conducted a preliminary analysis of the legal requirements relating to a tender offer for the purchase of Given Imaging shares from Given Imaging’s shareholders, including the feasibility of conducting a simultaneous tender offer in the United States and Israel. The analysis was made with the assistance of Israeli and U.S. legal counsel.

Under Israeli law, a purchase of the shares of a public company must be made by way of a “special tender offer” meeting certain requirements, if, among other things, as a result of the

4


purchase, the purchaser would own more than 45.0% of the aggregate voting power of the company and no other person owns more than 45.0% of the voting power. For purposes of calculating the 45.0% ownership threshold, we are required by the Israeli Companies Law to include Given Imaging shares held by our affiliates as well as Given Imaging shares held by us. Accordingly, since we and our affiliates beneficially own approximately 43.5% of the issued and outstanding shares and voting power of Given Imaging, in order for us to purchase additional Given Imaging shares that would increase our voting power to more than 45.0%, we are required to conduct the offer as a “special tender offer” meeting the requirements of Israeli law. Under Israeli law, in a special tender offer we must purchase shares representing no less than 5.0% of the voting power of Given Imaging. In addition, under Israeli law, once a shareholder together with its affiliates owns in excess of 45.0% of the voting power of a company, the shareholder may purchase shares in the open market or through private transactions, and not solely through a tender offer, unless as a result of the purchase the shareholder (together with its affiliates) would own in excess of 90.0% of the issued and outstanding shares of the company. Accordingly, we preliminarily determined to set the minimum condition of the offer such that we would comply with the provisions of Israeli law and own (together with our affiliates) in the aggregate over 45.0% of the voting power of Given Imaging following the consummation of the offer.

In mid-March 2008, the possibility of our purchase of additional Given Imaging shares was brought to our board of directors for discussion, although no decision was made concerning the matter at that meeting. In early April 2008, Mr. Doron Birger, our President and Chief Executive Officer and a director of Given Imaging, contacted Mr. Homi (Nahum) Shamir, the Chief Executive Officer of Given Imaging, to inform him that we were preliminarily considering the commencement of a tender offer in order to increase our holdings (together with the holdings of our affiliates) to more than 45.0% of the outstanding Given Imaging shares. Beginning in April 2008 through the date of this offer to purchase, we continued with preparations in order to present to our board of directors for approval of a proposal to commence the offer. In this connection, we requested assistance of Given Imaging’s legal counsel to obtain certain information relating to beneficial ownership of Given Imaging shares from the TASE and Given Imaging’s transfer agent and we consulted with Given Imaging’s chief financial officer regarding certain tax related information. In addition, we, with the assistance of Israeli and U.S. legal counsel, applied to the ISA and the SEC for relief from certain provisions of the Israeli and U.S. securities law to enable us to structure a tender offer that would comply with applicable law and regulations in both Israel and the United States. We also requested from the ITA, an approval with respect to the Israeli withholding tax rates applicable to the offer. In addition, on May 4, 2008, we filed an application with respect to the offer with the Israeli Restrictive Trade Commissioner, which we also refer to in this offer to purchase as the Israeli Antitrust Authority.

On April 30, 2008, we received the approval of the ITA with respect to the Israeli withholding tax rates applicable to the offer. On May 6, 2008, we received approval from the Israeli Antitrust Authority not requiring us to submit merger notices pursuant to the Israeli Restricted Trade Practices, 5748-1988 in connection with the offer. See Section 12. On May 15, 2008, we received the exemptive and no-action relief that we requested from the SEC. On May 14, 2008, we convened a meeting of our board of directors. At this meeting, our board of directors resolved to authorize our management to commence a tender offer to purchase 5.0% of the issued and outstanding Given Imaging shares and appointed a special committee, consisting of members of our board of directors, empowered to approve the final terms and timing of the offer.

On May 11, 2008, we received the exemptive relief that we requested from the ISA.

On May 13, 2008, Doron Birger, our President and Chief Executive Officer, and Donna Gershowitz, our General Counsel and Corporate Secretary, participated in discussions with Nachum (Homi) Shamir, President and Chief Executive Officer of Given Imaging, Yuval Yanai, Chief Financial Officer of Given Imaging, Israel Makov, Chairman of Given Imaging’s board of directors and Ido Warshavski, General Counsel and Corporate Secretary of Given Imaging, to verify that we did not possess any material non-public information with regard to Given Imaging.

5


On May 15, 2008, the special committee of our board of directors approved the final terms of the offer and resolved to commence the offer. On May 14, 2008, we received a letter from DIC indicating that DIC did not intend to tender Given Imaging shares it owned in the offer. On May 14, 2008, we received substantially identical letters from Arie Mientkavich, our Chairman, and Doron Birger, our President and Chief Executive Officer, both of whom serve as directors on Given Imaging’s board of directors, indicating that they did not intend to tender Given Imaging shares that they beneficially owned in the offer. We commenced the offer on May 16, 2008.

Purpose of the Offer; Reasons for the Offer

The purpose of the offer is for us to increase our beneficial ownership of Given Imaging shares from its current level of approximately 27.4% to approximately 32.4% or, when taken together with the Given Imaging shares beneficially owned by our affiliates, from approximately 43.5% to approximately 48.5%. We seek to increase our ownership of Given Imaging shares because we believe in the long-term potential of Given Imaging. The transaction was structured as a tender offer because, under Israeli law, in light of our current ownership position (together with our affiliates) we are not permitted to acquire additional Given Imaging shares if such acquisition would result in our affiliates and us having the power to vote more than 45.0% of Given Imaging’s shares other than by means of a tender offer. In addition, increasing our group’s beneficial ownership of Given Imaging shares above 45.0% will permit greater flexibility under Israeli law should we or our affiliates decide in the future to increase our stake in Given Imaging.

As a result of our current share ownership we and our affiliates exert significant influence over the election of directors and all other resolutions submitted to Given Imaging’s shareholders, including those that relate to approval or rejection of any merger or sale of Given Imaging. If we complete the offer, we and our affiliates will beneficially own approximately 14,184,348 of the issued and outstanding Given Imaging shares. In that case, we would have sufficient voting power to guarantee a near majority vote for the election of all of Given Imaging’s directors (subject to the provisions of the Israeli Companies Law with regard to external directors) and all other resolutions submitted to Given Imaging’s shareholders which require a majority vote, such as a merger, consolidation or other similar change of control transaction involving Given Imaging. However, under Israeli law, transactions between us and Given Imaging, and transactions of Given Imaging in which we have an interest (other than solely through our ownership of Given Imaging shares), which are material, or not in the ordinary course of business or not on market terms, require the approval of Given Imaging’s shareholders by a special majority. Specifically, in addition to approval by Given Imaging’s audit committee and board of directors, in that order, such transactions require approval by at least one-third of the disinterested shareholders voting on the matter, or that the votes of disinterested shareholders who voted against it do not constitute more than 1.0% of the issued and outstanding Given Imaging shares.

Plans for Given Imaging after the Offer; Certain Effects of the Offer

Except as otherwise described below or elsewhere in this offer to purchase, we and our directors and officers and, to our knowledge after due inquiry of the relevant person or entity, the other persons and entities set forth on Schedule I, have no current plans, proposals or negotiations that relate to or would result in the following:

 

 

 

 

an extraordinary corporate transaction, merger, reorganization or liquidation involving Given Imaging or any of its subsidiaries;

 

 

 

 

a purchase, sale or transfer of a material amount of the assets of Given Imaging or any of its subsidiaries;

 

 

 

 

any material change in the present dividend rate or policy or indebtedness or capitalization of Given Imaging;

 

 

 

 

any change in the present board of directors and management of Given Imaging (including any plan or proposal to change the number or term of directors or to fill any existing vacancy

6


 

 

 

 

on the board or to change any material term of the employment contract of any executive officer);

 

 

 

 

any other material change in Given Imaging’s corporate structure or business;

 

 

 

 

a delisting of the Given Imaging shares; or

 

 

 

 

Given Imaging’s shares becoming eligible for termination of registration under Section 12(g)(4) of the U.S. Securities Exchange Act of 1934, as amended, or the Exchange Act.

We currently account for our investment in Given Imaging pursuant to the equity method and will continue to account for our investment in Given Imaging pursuant to the equity method.

We expect that from time to time there may be significant developments or transactions involving our group companies (including Given Imaging and its subsidiaries) or their securities, or offers, proposals or discussions related to our group companies or their securities, which may involve acquisitions or sales by us of our holdings in such entities (including Given Imaging and its subsidiaries) or acquisitions or sales of securities, assets or business operations by such entities.

We intend to closely follow our investment in Given Imaging shares and take such actions with respect to our investment as we deem appropriate in light of the circumstances existing from time to time. Such actions could include, among other things, additional purchases of Given Imaging shares pursuant to one or more open-market purchase programs, through private transactions or through tender offers or otherwise, subject to applicable U.S. and Israeli law, and discussing with Given Imaging management or other significant shareholders matters related to Given Imaging. Future purchases may be on the same terms or on terms that are more or less favorable to Given Imaging’s shareholders than the terms of the offer. Any possible future purchases will depend on many factors, including the results of the offer, the market price of Given Imaging shares, our business and financial position, and general economic and market conditions. In addition, following the consummation of the offer, we may also determine to dispose of our Given Imaging shares, in whole or in part, at any time and from time to time, subject to applicable laws. Any such decision would be based on our assessment of a number of different factors, including, without limitation, the business, prospects and affairs of Given Imaging, the market for the Given Imaging shares, the condition of the securities markets, general economic, and industry conditions and other opportunities available to us.

Under Israeli law, if a shareholder together with its affiliates owns in excess of 45.0% of the voting power of a company, the shareholder may purchase shares in the open market or through private transactions, and not solely by means of a tender offer, unless as a result of the purchase the shareholder, together with its affiliates, would own in excess of 90.0% of the issued and outstanding shares of the company. Accordingly, following the consummation of the offer, we may purchase Given Imaging shares in the open market or through private transactions, and not solely by means of a tender offer, as long as the aggregate percentage ownership by us and our affiliates of issued and outstanding Given Imaging shares does not reach 90.0%.

However, under Israeli law, we, the shareholders which may be deemed to control us and any corporation under our or their control, are prohibited from conducting an additional tender offer for Given Imaging shares and from merging with Given Imaging within 12 months from the date of this offer to purchase.

Past and future transactions and the offer may limit Given Imaging’s ability to use Given Imaging, Inc.’s U.S. federal income tax net operating loss carry forwards. Given Imaging’s 2007 Form 20- F states that as of December 31, 2007, Given Imaging, Inc., a wholly owned U.S. subsidiary of Given Imaging, had U.S. federal income tax net operating loss carry forwards of approximately $31.1 million, which begin to expire in the year 2023. Subject to certain limitations, net operating loss carry forwards may be used to offset future taxable income and thereby reduce U.S. federal income taxes otherwise payable. Section 382 of the U.S. Internal Revenue Code of 1986, as amended, referred to as the Code, imposes an annual limitation on the ability of a corporation that undergoes an “ownership change” to use its net operating loss carry forwards to reduce its U.S. federal income tax liability. Given Imaging, Inc. may have experienced “ownership changes” as defined in Section 382 of the Code in the past and it is possible that it will experience “ownership

7


changes” in the future because of changes in Given Imaging’s stock ownership, including possibly as a result of consummation of the offer. Accordingly, Given Imaging, Inc.’s use of its net operating loss carry forwards may be limited by the annual limitation described in Section 382 of the Code. Any limitation on the use of Given Imaging Inc.’s net operating loss carry forwards could increase its U.S. federal income tax liability. Limitations similar to Code Section 382 may apply to Given Imaging, Inc.’s U.S. state and local net operating carry forwards and possibly Given Imaging’s net operating loss carry forwards outside of the United States.

Rights of Shareholders Who Do Not Accept the Offer

You will have no appraisal or similar rights with respect to the offer. Under Section 331 of the Israeli Companies Law, you may respond to the offer by accepting the offer or notifying us of your objection to the offer. Alternatively, you may simply not respond to the offer and not tender your Given Imaging shares. It is a condition to the offer that, at the completion of the Initial Offer Period, the aggregate number of Given Imaging shares validly tendered in the offer and not properly withdrawn is greater than the aggregate number of Given Imaging shares represented by Notices of Objection. As required by Section 331(c) of the Israeli Companies Law, in making this calculation, we exclude Given Imaging shares held by us or certain of our affiliates or Given Imaging’s affiliates. Such affiliates include DIC and RDC, as appears under the caption “Beneficial Ownership of Shares—Our Equity Interest in Given Imaging.” An excerpt of Section 331 of the Israeli Companies Law is attached as Annex A. Please see Section 3 for instructions on how to notify us of your objection to the offer.

Interest of Persons in the Offer

As a result of our current beneficial ownership (together with our affiliates) of approximately 43.5% of the issued and outstanding Given Imaging shares and our significant influence over the election of Given Imaging’s directors, we may be deemed to exert substantial influence over Given Imaging.

DIC, our 48.6% shareholder, also beneficially owns Given Imaging shares, as discussed elsewhere in this section. Further, Arie Mientkavich, our Chairman, and Doron Birger, our President and Chief Executive Officer, each serve as directors on the board of directors of Given Imaging. In addition, Clal Finance Batucha Investment Management Ltd., the Israeli Depositary, is a majority indirectly owned subsidiary of Clal Insurance Enterprises Holdings Ltd., one of our shareholders and which is in turn a majority indirectly owned subsidiary of IDBH.

Related Party Transactions

Neither we, our directors and officers nor, to our knowledge after due inquiry of the relevant person or entity, any of the other persons and entities listed on Schedule I, have had any transaction during the past two years with Given Imaging or any of its executive officers, directors or affiliates that is required to be described in this offer to purchase under applicable law. Except as set forth in this offer to purchase and Schedule I, there have been no negotiations, transactions or material contacts during the past two years between us, any of our subsidiaries, officers or directors, or to our knowledge after due inquiry of the relevant person or entity, any of the other persons or entities listed in Schedule I, on the one hand, and Given Imaging and its affiliates, on the other hand, concerning a merger, consolidation or acquisition, tender offer, exchange offer or other acquisitions of Given Imaging’s securities, an election of Given Imaging’s directors (other than changes in the board of directors in the ordinary course of business) or a sale or other transfer of a material amount of assets of Given Imaging.

Beneficial Ownership of Shares

Our Equity Interest in Given Imaging. The amount of 1,462,640 Given Imaging shares we are offering to purchase represents 5.0% of the 29,252,785 issued and outstanding Given Imaging shares as of April 8, 2008.

8


The following table identifies the aggregate number and percentage, on an issued and outstanding basis, of the Given Imaging shares beneficially owned, as of the date of this offer to purchase, by (1) us and (2) certain individuals or entities that are either listed on Schedule I and known by us to be beneficial owners of Given Imaging shares or options, or are otherwise associated with us and known by us to be beneficial owners of Given Imaging shares or options:

 

 

 

 

 

Name and Address

 

Number of Given
Imaging shares
beneficially owned

 

Percentage of
Given Imaging shares
beneficially owned *

 

Elron Electronic Industries Ltd. (1)
3 Azrieli Center
42nd Floor
Tel-Aviv, Israel
67023

 

 

 

8,002,180

   

 

 

27.4

%

 

 

IDBH (2)
3 Azrieli Center
45th Floor
Tel-Aviv, Israel
67023

 

 

 

12,721,708

   

 

 

43.5

%

 

 

Directors & Officers of Elron and entities listed on Schedule I (3)

 

 

 

65,628

   

 

 

0.002

%

 


 

 

*

 

 

 

Based on 29,252,785 issued and outstanding Given Imaging shares as of April 8, 2008.

 

(1)

 

 

 

Elron owns all of the outstanding shares of DEP Technology Holdings Ltd., which in turn, holds 50.1% of the voting power of RDC and accordingly, Elron may be deemed to be the beneficial owner of the Given Imaging shares owned by RDC. Accordingly, the number of Given Imaging shares beneficially owned by Elron includes 5,340,070 Given Imaging shares owned by Elron and 2,662,110 Given Imaging shares owned by RDC.

 

(2)

 

 

 

Elron’s direct parent and 48.6% shareholder is DIC. DIC is controlled by IDB Development Corporation Ltd, or IDBD, which in turn is controlled by IDBH. IDBH is controlled by a group comprised of Ganden Holdings Ltd., or Ganden, Manor Holdings B.A. Ltd., or Manor, and Avraham Livnat Ltd., or Livnat, all of which are private Israeli companies. Ganden, Manor and Livnat are controlled by Nochi Dankner and his sister Shelly Bergman, Ruth Manor and Avraham Livnat, respectively. Based on the foregoing, IDBD (by reason of its control of DIC), IDB Holding (by reason of its control of IDBD), Ganden, Manor and Livnat (by reason of their control of IDBH) and Nochi Dankner, Shelly Bergman, Ruth Manor, and Avraham Livnat (by reason of their control of Ganden, Manor and Livnat, respectively), or, collectively, the Controlling Persons, may be deemed to share with Elron the power to vote and dispose of Given Imaging shares beneficially owned by DIC, Elron and the Given Imaging shares held by subsidiaries of CIEH for their own account, which amounts to approximately 43.5% of Given Imaging shares. See Schedule I for additional details.

Accordingly, the number of Given Imaging shares beneficially owned by IDBH includes 8,002,180 Given Imaging shares beneficially owned by Elron and 4,719,528 Given Imaging shares beneficially owned by DIC, but does not include 679,979 Given Imaging shares held for members of the public through, among others, mutual funds, provident funds, pension funds and life insurance policies and 84,056 Given Imaging shares held for members of the public through hedge traded funds, in each case managed by companies controlled by CIEH and 9,220 Given Imaging shares held for members of the public through mutual funds managed by a company controlled by IDBH, which disclaims beneficial ownership of these Given Imaging shares.

 

(3)

 

 

 

Includes options to purchase 62,750 Given Imaging shares exercisable within 60 days.

Neither we and our officers and directors nor, to our knowledge after due inquiry of the relevant person or entity, any of the other persons and entities listed on Schedule I, or any associate or majority owned subsidiary of ours, has effected any transaction in the Given Imaging shares during the past 60 days, except for transactions in the open market made in the ordinary course of

9


business by provident funds, mutual funds, pension funds, life insurance companies and/or similar financial bodies, which are managed by companies controlled by CIEH and IDBH.

Elron’s Shareholders. The following table sets forth the aggregate number and percentage of the ordinary shares of Elron beneficially owned, as of the date of this offer to purchase, by certain individuals or entities who are known by us to be either (1) the beneficial owners of 5.0% or more of Elron’s shares or (2) the beneficial owners of Elron’s shares or options that are deemed to be “interested parties” of ours (as such term is defined under the Israeli Securities Law):

 

 

 

 

 

Name and Address

 

Number of Elron shares
beneficially owned

 

Percent of Elron shares
outstanding and fully diluted

 

Discount Investment
Corporation Ltd. (1)
3 Azrieli Center
44th Floor
Tel-Aviv 67023, Israel

 

 

 

14,400,796

   

 

 

48.57

%

 

 

Clal Insurance Group (2)
48 Menachem Begin Road
Tel-Aviv 66184, Israel

 

 

 

89,864

   

 

 

0.30

%

 


 

 

(1)

 

 

 

IDBH is the parent of IDBD which, in turn, is the parent of DIC and CIEH. See Note (2) in the preceding table of our beneficial ownership of Given Imaging shares for the beneficial ownership of IDBH. The number of shares held by DIC excludes shares held for members of the public through mutual funds managed by a company controlled by IDBH, which disclaims beneficial ownership of these shares.

 

(2)

 

 

 

Clal Insurance Group is comprised of CIEH and its subsidiary companies. CIEH is majority owned by IDBD, the parent company of DIC, which in turn is a 48.6% shareholder of Elron. The number of shares held by Clal Insurance Group is based on the most recently available report and excludes shares held for members of the public through mutual funds, provident funds, pension funds, exchange traded funds and insurance policies which are managed by companies controlled by CIEH, which disclaims beneficial ownership of these shares.

10


THE TENDER OFFER

YOU SHOULD READ THIS OFFER TO PURCHASE, THE LETTER OF TRANSMITTAL AND THE OTHER RELATED DOCUMENTS DELIVERED TO YOU CAREFULLY BEFORE YOU MAKE ANY DECISION WITH RESPECT TO THE OFFER.

1.  TERMS OF THE OFFER; PRORATION; EXPIRATION DATE.

The offer is being made to all of Given Imaging’s shareholders. Upon the terms of, and subject to the conditions to, the offer (including any terms of, and conditions to, any extension or amendment), subject to proration, we will accept for payment and pay for Given Imaging shares, that are validly tendered and not properly withdrawn in accordance with Section 4 prior to 10:00 a.m., New York time, or 5:00 p.m., Israel time, on June 16, 2008, unless and until we extend the period of time during which the initial period of the offer is open. We refer to this period, as may be extended (as described below), as the Initial Offer Period, and the date of completion of the Initial Offer Period is referred to as the Initial Completion Date. DIC indicated, by letter dated May 14, 2008, that DIC did not intend to tender Given Imaging shares that it owned in the offer. On May 14, 2008, we received substantially identical letters from Arie Mientkavich, our Chairman, and Doron Birger, our President and Chief Executive Officer, both of whom serve as directors on Given Imaging’s board of directors, indicating that they did not intend to tender Given Imaging shares that they beneficially owned in the offer.

We will publicly announce in accordance with applicable law, and in any event issue a press release by 9:00 a.m., New York time, or 4:00 p.m., Israel time, on the U.S. business day following the Initial Completion Date, stating whether or not the conditions to the offer have been satisfied or, subject to applicable law, waived by us. Under Israeli law, if the conditions to the offer have been satisfied or, subject to applicable law, waived by us, then the shareholders who have, with respect to each Given Imaging share owned by them,

 

 

 

 

not responded to the offer,

 

 

 

 

notified us of their objection to the offer, or

 

 

 

 

validly tendered such Given Imaging share but have properly withdrawn their tender during the Initial Offer Period,

will be entitled to tender each such Given Imaging share during an additional four calendar-day period commencing at the completion of the Initial Offer Period. We refer to this period as the Additional Offer Period and to the expiration of such period as the Final Expiration Date. Shares tendered during the Initial Offer Period may be withdrawn at any time prior to 10:00 a.m., New York time, or 5:00 p.m., Israel time, on the Initial Completion Date, but not during the Additional Offer Period. In this respect, we recommend that you read Section 4 and Section 11 of this offer to purchase.

Subject to proration, we will also accept for payment and pay for all Given Imaging shares validly tendered and not properly withdrawn in accordance with Section 4 prior to 10:00 a.m., New York time, or 5:00 p.m., Israel time, on the Final Expiration Date. We expect to make such payment, including in the event that proration of tendered Given Imaging shares is required, within four U.S. business days following the Final Expiration Date.

No fractional Given Imaging shares will be purchased by us in the offer.

Conditions to the offer include, among other things, that:

 

 

 

 

prior to 10:00 a.m., New York time, or 5:00 p.m., Israel time, on the Initial Completion Date, there shall have been validly tendered and not properly withdrawn Given Imaging shares representing at least 5.0% of the issued and outstanding Given Imaging shares on the Initial Completion Date (currently, at least 1,462,640 Given Imaging shares), such that following the consummation of the offer, we will beneficially own approximately 32.4% of the issued and outstanding Given Imaging shares or, when taken together with the issued and outstanding Given Imaging shares owned by our affiliates, approximately 48.5% of the issued and outstanding Given Imaging shares; and

11


 

 

 

 

as required by Israeli law, at 10:00 a.m., New York time, or 5:00 p.m., Israel time, on the Initial Completion Date, the aggregate number of Given Imaging shares validly tendered in the offer and not properly withdrawn (excluding the Given Imaging shares held by us, certain of our affiliates or certain of Given Imaging’s affiliates) is greater than the aggregate number of Given Imaging shares represented by Notices of Objection to the offer.

The offer is also subject to certain other conditions set forth in Section 11. If any of these conditions are not satisfied, we may elect not to purchase, or may be prohibited from purchasing, any Given Imaging shares tendered in the offer. The offer is not conditioned on the availability of financing or the approval of the board of directors of Given Imaging. See Section 11, which sets forth in full the conditions to the offer and specifies those conditions to the offer that are waiveable by us.

If more than 5.0% of the issued and outstanding Given Imaging shares (currently 1,462,640 Given Imaging shares) are validly tendered and not properly withdrawn prior to 10:00 a.m., New York time, or 5:00 p.m., Israel time, on the Final Expiration Date, we will purchase 5.0% of the issued and outstanding Given Imaging shares on a pro rata basis from all tendering shareholders who have validly tendered their Given Imaging shares in the Initial Offer Period and the Additional Offer Period and have not properly withdrawn their Given Imaging shares before the completion of the Initial Offer Period, so that we would purchase no more than 5.0% of the issued and outstanding Given Imaging shares. The number of Given Imaging shares that we will purchase from each tendering shareholder will be based on the total number of Given Imaging shares validly tendered by all shareholders prior to 10:00 a.m., New York time, or 5:00 p.m., Israel time, on the Final Expiration Date and not properly withdrawn before the completion of the Initial Offering Period. The proration factor, if any, will be calculated by dividing (x) 5.0% of the issued and outstanding Given Imaging shares, the total number of Given Imaging shares that we are offering to purchase, by (y) the aggregate number of Given Imaging shares validly tendered in the offer and not properly withdrawn in the United States and Israel.

We will publicly announce in accordance with applicable law and in any event issue a press release by 9:00 a.m., New York time, or 4:00 p.m., Israel time, on the U.S. business day following the Initial Completion Date, stating whether the conditions to the offer have been satisfied or, subject to applicable law, waived by us. Promptly following the Final Expiration Date, we will announce the results of the offer and the proration factor, if any. If we are unable to promptly determine the proration factor, we will announce the preliminary results. We will pay for all Given Imaging shares accepted for payment pursuant to the offer promptly following the calculation of the proration factor. We expect to make such payment within four U.S. business days following the Final Expiration Date.

Under Israeli law, once we announce following the completion of the Initial Offer Period that the offer has been accepted, or, in other words, that all the conditions to the offer have been satisfied or, subject to applicable law, waived by us, no further conditions to the offer would apply and we will become irrevocably bound to purchase the Given Imaging shares validly tendered in the offer and not properly withdrawn prior to 10:00 a.m., New York time, or 5:00 p.m., Israel time, on the Final Expiration Date (subject to proration, if any).

Subject to applicable laws and regulations, if any condition has not been satisfied as of the Initial Completion Date, we may decide to:

 

 

 

 

extend the Initial Offer Period (except that, pursuant to the Israeli Securities Law, we must generally provide notice to that effect at least one Israeli business day prior to the Initial Completion Date) and, subject to applicable withdrawal rights until the Initial Completion Date, retain all tendered Given Imaging shares until the Final Expiration Date;

 

 

 

 

if only the condition set forth in clause (b) of Section 11 below has not been satisfied, waive such condition(s) and, subject to proration, accept for payment and promptly pay for all Given Imaging shares validly tendered and not properly withdrawn prior to 10:00 a.m., New York time, or 5:00 p.m., Israel time, on the Final Expiration Date; or

12


 

 

 

 

terminate the offer and not accept for payment or pay for any Given Imaging shares and promptly return all tendered Given Imaging shares to tendering shareholders.

Under Israeli law, however, the offer may not remain open for more than 60 days following the date of this offer to purchase, except that if a third party commences a tender offer for Given Imaging shares during the Initial Offer Period, we will be permitted to extend the Initial Offer Period so that the Initial Completion Date will correspond with the expiration date of the third party’s tender offer.

In the event that we extend the Initial Offer Period, we will inform the Depositaries, the Information Agent and our Israeli legal counsel of that fact. Accordingly, we will also:

 

 

 

 

within one Israeli business day following the Initial Completion Date (or within two business days, in the event our decision to extend the Initial Offer Period was made toward the late evening hours, Israel time, on one Israeli business day prior to the Initial Completion Date), publish the notice in two daily newspapers having a mass circulation and published in Israel in Hebrew; and

 

 

 

 

issue a press release announcing a new Initial Completion Date no later than 9:00 a.m., New York time, or 4:00 p.m., Israel time, on the first U.S. business day following the day on which we decide to extend the Initial Offer Period.

Without limiting the manner in which we may choose to make any public announcement, subject to applicable law (including Rule 14e-1(d) and Rule 14d-4(d) under the Exchange Act, which require that material changes be promptly disseminated to holders of Given Imaging shares in a manner reasonably designed to inform such holders of such changes), we currently intend to make announcements regarding the offer by distributing a press release to “Business Wire” and publishing the aforesaid notices in two daily Israeli newspapers.

Under Israeli law, however, we will not be permitted to extend the Initial Offer Period, unless either (1) the Israeli Depositary, which guarantees our obligation to pay for the Given Imaging shares, confirms that, under the new circumstances, it will maintain such guarantee or (2) such a guarantee is obtained by us from another TASE member.

If we make a material change in the terms of the offer (as may be permitted under applicable law) or in the information concerning the offer, or if we waive a material condition to the offer (if permitted pursuant to the Exchange Act, the rules of the SEC and the Israeli Securities Law), we will extend the Initial Offer Period to the extent required by the Exchange Act, the rules of the SEC and the Israeli Securities Law. If, before the Final Expiration Date, we decide to increase the consideration being offered, such increase will be applicable to all shareholders whose Given Imaging shares are accepted for payment pursuant to the offer. If, at the time that the notice of any increase in the offered consideration is first published, sent or given, the Initial Offer Period is scheduled to be completed at any time earlier than the tenth business day from and including the date that the notice is first so published, sent or given, the Initial Offer Period will be extended until the expiration of at least ten business days after that notice. For purposes of this paragraph, a “business day” shall mean a business day as defined in Rule 14d-1(g)(3) under the Exchange Act.

Given Imaging has made its shareholders list and security position listings available to us for the purpose of disseminating the offer to Given Imaging’s shareholders. This offer to purchase, the Letter of Transmittal and the other related documents to be furnished will be mailed to the record holders of Given Imaging shares whose names appear as of the date of this offer to purchase on Given Imaging’s shareholder list. They will also be furnished to brokers, dealers, commercial banks, trust companies and similar persons whose names, or the names of whose nominees, appear as of the date of this offer to purchase on the shareholder list or, if applicable, who are listed as of the date of this offer to purchase as participants in a clearing agency’s security position listing, for subsequent transmittal to beneficial owners of Given Imaging shares.

2.  ACCEPTANCE FOR PAYMENT AND PAYMENT.

General. According to Israeli law, to secure the payment for the Given Imaging shares tendered in the offer, the Israeli Depositary, which is a TASE member, has agreed to guarantee our

13


obligation to pay for the Given Imaging shares tendered and accepted by us for payment pursuant to the offer. To secure this guarantee, we have engaged the Israeli Depositary to act as an escrow agent, and if requested by the Israeli Depositary, we will deposit cash into an escrow account in an amount sufficient to pay for the total number of Given Imaging shares that we are offering to purchase in the offer.

Promptly following the Final Expiration Date and upon the terms of, and subject to the conditions to, the offer (including, if the Initial Offer Period is extended or the offer is otherwise amended, the terms of, and conditions to, any such extension or amendment), subject to proration, we will accept for payment and, subject to any applicable withholding tax duties, pay, from the funds deposited into escrow, for all Given Imaging shares validly tendered prior to 10:00 a.m., New York time, or 5:00 p.m., Israel time, on the Final Expiration Date and not properly withdrawn in accordance with Section 4. We expect to make such payment, including in the event that proration of tendered Given Imaging shares is required, within four U.S. business days following the Final Expiration Date. Please see Section 1.

In all cases, we will pay for Given Imaging shares validly tendered and accepted for payment pursuant to the offer only after timely receipt by the Depositaries of the required documents to substantiate a valid tender, as set forth in Section 3.

For purposes of the offer, we will be deemed to have purchased Given Imaging shares that have been validly tendered and not properly withdrawn if and when we give oral or written notice to the Depositaries of our acceptance for payment of Given Imaging shares pursuant to the offer. Upon the terms of, and subject to the conditions to, the offer, payment for the Given Imaging shares will be made by the Depositaries.

Under no circumstances will interest be paid on the purchase price to be paid, regardless of any extension of the offer or any delay in making payment.

If, pursuant to the terms of, and conditions to, the offer, we do not accept tendered Given Imaging shares for payment for any reason or if certificates are submitted representing more Given Imaging shares than are tendered (including by reason of proration), certificates evidencing unpurchased Given Imaging shares will be returned to the tendering shareholder (or, in the case of Given Imaging shares tendered by book-entry transfer pursuant to the procedure set forth in Section 3, the Given Imaging shares will be credited to the relevant account), promptly following the expiration, termination or withdrawal of the offer.

If, prior to the Final Expiration Date, we increase the consideration per share offered to the shareholders pursuant to the offer, the increased consideration per share will be paid to all holders of Given Imaging shares that are purchased pursuant to the offer, whether or not such Given Imaging shares were tendered prior to the increase in consideration.

Form of Payment. All shareholders tendering their Given Imaging shares to either the U.S. Depositary or the Israeli Depositary will be paid solely in U.S. dollars.

Withholding Tax. Please note that under the “Backup Withholding” provisions of U.S. federal income tax law, the U.S. Depositary may be required to withhold, at applicable rates (currently 28%), on amounts received by a tendering shareholder or other payee pursuant to the offer. To prevent such withholding from the purchase price received for Given Imaging shares tendered in the offer to the U.S. Depositary, each tendering shareholder who tenders its shares to the U.S. Depositary and who does not otherwise establish an exemption from such withholding, must properly complete the Substitute Form W-9 included in the Letter of Transmittal or a Form W-8, as applicable. See Section 5.

Also, under the “withholding tax” provisions of Israeli income tax law, the gross proceeds payable to a tendering shareholder in the offer generally will be subject to Israeli withholding tax at a rate of 20% for individuals or 25% for corporations, of the shareholder’s gain on such sale. However, based on an approval that we received from the ITA:

(1) tendering shareholders who acquired their Given Imaging shares after Given Imaging’s initial public offering on the Nasdaq (i.e., after October 3, 2001) and who, certify that they are NOT “residents of Israel” (and, in the case of a corporation, that no Israeli resident(s) (x) holds 25% or

14


more of the means of control of such corporation or (y) is the beneficiary of, or is entitled to, 25% or more of the revenues or profits of such corporation, whether directly or indirectly) will not be subject to Israeli withholding tax;

(2) eligible Israeli brokers or financial institutions holding Given Imaging shares solely on behalf of a tendering shareholder will not be subject to Israeli withholding tax;

(3) tendering shareholders who are Israeli residents and who acquired their Given Imaging shares prior to Given Imaging’s initial public offering on Nasdaq, will be subject to Israeli withholding tax at a rate of 25% of the amount received by the tendering shareholder;

(4) tendering shareholders who are NOT “residents of Israel” and who acquired their Given Imaging shares prior to Given Imaging’s initial public offering on Nasdaq, will be subject to Israeli withholding tax at a rate of 25% of the amount received by the tendering shareholder, unless the tendering shareholder submits an A-114 Form approving such shareholder’s residence in a country with whom Israel has a tax treaty which exempts Israeli capital gains tax, duly signed by the tendering shareholder and authorized by the tax authority of such country, in which event such tendering shareholder will not be subject to Israeli withholding tax; and

(5) tendering shareholders who are not described in clauses (1),(2), (3) and (4) above, will be subject to Israeli withholding tax at a fixed rate of 8.61% of the amount received by the tendering shareholder pursuant to the offer.

Notwithstanding the foregoing, should any tendering shareholder present us with a valid approval from the ITA applying withholding tax at a lesser rate than those described above or otherwise granting a specific exemption from Israeli withholding tax, we will act in accordance with such approval.

See Section 5 and the Letter of Transmittal for instructions on how to prevent us from withholding Israeli income tax from the gross proceeds payable to you (if any) pursuant to the offer.

3.  PROCEDURES FOR TENDERING SHARES OR NOTIFYING US OF YOUR OBJECTION TO THE OFFER.

Overview

This Section 3 is divided into two parts. Holders of Given Imaging shares who wish to tender their Given Imaging shares or object to the offer, and

 

 

 

 

hold their Given Imaging shares through a TASE member, or Unlisted Holders, or who are named as holders of Given Imaging shares in the Register of Shareholders of Given Imaging in Israel, or Listed Holders, should tender their Given Imaging shares to, or object to the offer through, the Israeli Depositary pursuant to the instructions described under the caption “Tenders to Clal Finance Batucha Investment Management Ltd., our Israeli Depositary” below, or

 

 

 

 

all other holders of Given Imaging shares should tender their Given Imaging shares to, or object to the offer through, the U.S. Depositary pursuant to the instructions described under the caption “Tenders to American Stock Transfer & Trust Company, our U.S. Depositary” below.

You may only tender your Given Imaging shares or object to the offer by following the procedures described in this Section 3. You may not tender your Given Imaging shares using a guaranteed delivery procedure.

Tenders to American Stock Transfer & Trust Company, our U.S. Depositary

Eligibility; Who May Tender to, or Object to the Offer through, the U.S. Depositary. Shareholders who are not Unlisted Holders or Listed Holders, should tender their Given Imaging shares to, or object to the offer through, the U.S. Depositary.

Valid Tender. In order for you to validly tender Given Imaging shares pursuant to the offer, a properly completed and duly executed Letter of Transmittal, together with any required signature

15


guarantees, or in the case of a book-entry transfer, an agent’s message, and any other documents required by the Letter of Transmittal, must be received by the U.S. Depositary at its address set forth on the back cover of this offer to purchase prior to 10:00 a.m., New York time, or 5:00 p.m., Israel time, on the Initial Completion Date or Final Expiration Date, as applicable. In addition, certificates evidencing tendered Given Imaging shares must be received by the U.S. Depositary at its address or the shares must be delivered to the U.S. Depositary (including an agent’s message if you did not deliver a Letter of Transmittal), in each case prior to 10:00 a.m., New York time, or 5:00 p.m., Israel time, on the Initial Completion Date or Final Expiration Date, as applicable.

The term “agent’s message” means a message, transmitted by the Depository Trust Company, or DTC, to, and received by, the U.S. Depositary and forming part of the Book-Entry Confirmation that states that DTC has received an express acknowledgement from the participant in DTC tendering the Given Imaging shares that are the subject of the Book-Entry Confirmation, that the participant has received and agrees to be bound by the Letter of Transmittal and that we may enforce that agreement against that participant.

If certificates evidencing tendered Given Imaging shares are forwarded to the U.S. Depositary in multiple deliveries, a properly completed and duly executed Letter of Transmittal must accompany each delivery. No alternative, conditional or contingent tenders will be accepted and no fractional Given Imaging shares will be purchased.

The method of delivery of share certificates and all other required documents, including through DTC, is at your option and risk, and the delivery will be deemed made only when actually received by the U.S. Depositary. If delivery is by mail, registered mail with return receipt requested, properly insured, is recommended. In all cases, sufficient time should be allowed to ensure timely delivery.

Book-Entry Transfer. The U.S. Depositary will establish an account with respect to the Given Imaging shares at DTC for purposes of the offer within two U.S. business days after the date of this offer to purchase. Any financial institution that is a participant in the DTC system may make book-entry delivery of Given Imaging shares by causing DTC to transfer such Given Imaging shares into the U.S. Depositary’s account at DTC in accordance with DTC’s procedures. However, although delivery of Given Imaging shares may be effected through book-entry transfer into the U.S. Depositary’s account at DTC, the Letter of Transmittal, properly completed and duly executed, with any required signature guarantees, or an agent’s message, and any other required documents must, in any case, be transmitted to, and received by, the U.S. Depositary at its address set forth on the back cover of this offer to purchase prior to 10:00 a.m., New York time, or 5:00 p.m., Israel time, on the Initial Completion Date or Final Expiration Date, as applicable. Delivery of the documents to DTC or any other party does not constitute delivery to the U.S. Depositary.

Signature Guarantees. Signatures on all Letters of Transmittal must be guaranteed by a firm that is a member of the Securities Transfer Agents Medallion Program, or by any other “eligible guarantor institution,” as that term is defined in Rule 17Ad-15 under the Exchange Act, except in cases where Given Imaging shares are tendered:

 

 

 

 

by a registered holder of Given Imaging shares who has not completed either the box entitled “Special Delivery Instructions” or the box entitled “Special Payment Instructions” on the Letter of Transmittal; or

 

 

 

 

for the account of an eligible guarantor institution.

If a share certificate is registered in the name of a person other than the signer of the Letter of Transmittal, or if payment is to be made, or a share certificate not accepted for payment or not tendered is to be returned, to a person other than the registered holder(s), then the tendered certificate must be endorsed or accompanied by appropriate stock powers, in either case, signed exactly as the name(s) of the registered holder(s) appear on the certificate, with the signature(s) on the certificate or stock powers guaranteed by an eligible guarantor institution. See Instruction 1 and Instruction 5 to the Letter of Transmittal.

Condition to Payment. In all cases, payment for Given Imaging shares tendered and accepted for payment pursuant to the offer will be made only after timely receipt by the U.S. Depositary of the certificate(s) evidencing Given Imaging shares, or a timely Book-Entry Confirmation for the

16


delivery of Given Imaging shares, the Letter of Transmittal, properly completed and duly executed, with any required signature guarantees, or, in the case of a book-entry transfer, an agent’s message, and any other documents required by the Letter of Transmittal.

The valid tender of Given Imaging shares pursuant to the applicable procedure described above will constitute a binding agreement between you and us upon the terms of, and subject to the conditions to, the offer.

Appointment. By executing the Letter of Transmittal as set forth above (including delivery by way of an agent’s message), you irrevocably appoint our designees as your agents, attorneys-in-fact and proxies in the manner set forth in the Letter of Transmittal, each with full power of substitution, to the full extent of your rights with respect to the Given Imaging shares you tendered. These powers of attorney and proxies will be considered coupled with an interest in the tendered Given Imaging shares. The appointment will be effective if, as and when, and only to the extent that, we accept your Given Imaging shares for payment. Upon our acceptance for payment, all prior powers of attorney, proxies and consents given by you with respect to such Given Imaging shares (and any and all Given Imaging shares or other securities issued or issuable in respect of your Given Imaging shares) will be revoked, without further action, and no subsequent powers of attorney or proxies may be given nor any subsequent written consent executed by you (and, if given or executed, will not be deemed effective). Our designees will, with respect to the Given Imaging shares for which the appointment is effective, be empowered to exercise all of your voting and other rights as they in their sole discretion may deem proper at any annual or special meeting of Given Imaging’s shareholders or any adjournment or postponement of that meeting, by written consent in lieu of any meeting or otherwise. We reserve the right to require that, in order for Given Imaging shares to be deemed validly tendered, immediately upon our payment for the Given Imaging shares, we must be able to exercise full voting rights with respect to the Given Imaging shares at any meeting of Given Imaging’s shareholders with a record date subsequent to the consummation of the offer (and at any meeting of Given Imaging’s shareholders with a record date prior to the consummation of the offer if such Given Imaging shares were held by such tendering shareholder as of such record date).

Objecting to the Offer. If you want to notify us of your objection to the offer with respect to all or any portion of your Given Imaging shares, and:

 

 

 

 

you hold such Given Imaging shares directly, complete and sign the accompanying Notice of Objection and mail or deliver it to the U.S. Depositary prior to 10:00 a.m., New York time, or 5:00 p.m., Israel time, on the Initial Completion Date; or

 

 

 

 

you hold such Given Imaging shares through a broker, dealer, commercial bank, trust company or other nominee, request such broker, dealer, commercial bank, trust company or other nominee to provide on your behalf the Notice of Objection to the U.S. Depositary prior to 10:00 a.m., New York time, or 5:00 p.m., Israel time, on the Initial Completion Date.

We will disregard any Notices of Objection received by the U.S. Depositary after such deadline. In addition, if you submit a Notice of Objection with respect to Given Imaging shares and thereafter you deliver a Letter of Transmittal by which you tender those Given Imaging shares, we will disregard your Notice of Objection. Similarly, if you submit a Letter of Transmittal by which you tender Given Imaging shares, and thereafter you deliver to us a Notice of Objection with respect to those Given Imaging shares, we will disregard your Letter of Transmittal. If you submit a Letter of Transmittal and a Notice of Objection concurrently with respect to the same Given Imaging shares, we will disregard the Notice of Objection.

Withdrawing your Objection. You may withdraw a previously submitted Notice of Objection at any time prior to 10:00 a.m., New York time, or 5:00 p.m., Israel time, on the Initial Completion Date. For a withdrawal to be effective, a written notice of withdrawal must be timely received by the U.S. Depositary at its address set forth on the back cover of this offer to purchase. Any notice of withdrawal must specify the name of the person(s) who submitted the Notice of Objection to be withdrawn and the number of Given Imaging shares to which the Notice of Objection to be withdrawn relates. Following the withdrawal of a Notice of Objection, a new Notice of Objection

17


may be submitted at any time prior to 10:00 a.m., New York time, or 5:00 p.m., Israel time, on the Initial Completion Date by following the procedures described above.

If, with respect to all or any portion of your Given Imaging shares, you object to the offer during the Initial Offer Period and the conditions to the offer have been satisfied or, subject to applicable law, waived by us, you may tender such Given Imaging shares during the Additional Offer Period. See Section 1 and Section 11.

Determination of Validity. All questions as to the validity, form, eligibility (including time of receipt) and acceptance for payment of any tender of Given Imaging shares or Notice of Objection will be determined by us, in our sole discretion. This determination will be final and binding on all parties. We reserve the absolute right to reject any or all tenders or Notices of Objection that we determine not to be in proper form or, in the case of tenders, the acceptance for payment of which may be unlawful. We also reserve the absolute right, in our sole discretion, to waive any defect or irregularity in any tender of Given Imaging shares or Notice of Objection of any particular shareholder, whether or not similar defects or irregularities are waived in the case of other shareholders. A tender of Given Imaging shares or Notice of Objection will not have been made until all defects and irregularities have been cured or waived. None of us, our affiliates, our assigns, the Depositaries, the Information Agent, our Israeli legal counsel or any other person will be under any duty to give notification of any defects or irregularities in tenders of Given Imaging shares or Notices of Objection or incur any liability for failure to give any notification. Subject to applicable law, our interpretation of the terms of, and conditions to, the offer (including the Letter of Transmittal and the instructions thereto) will be final and binding.

If you tender your Given Imaging shares pursuant to the applicable procedure described above, it will constitute your acceptance of the terms of, and conditions to, the offer, as well as your representation and warranty to us that:

 

 

 

 

you have the full power and authority to tender, sell, assign and transfer the tendered Given Imaging shares (and any and all Given Imaging shares or other securities issued or issuable in respect of your Given Imaging shares); and

 

 

 

 

when we accept your Given Imaging shares for payment, we will acquire good and unencumbered title to your Given Imaging shares, free and clear of all liens, restrictions, charges and encumbrances and not subject to any adverse claims.

Tenders to Clal Finance Batucha Investment Management Ltd., our Israeli Depositary

Eligibility; Who May Tender to, or Object to the Offer through, the Israeli Depositary. Shareholders who are either Unlisted Holders or Listed Holders should tender their Given Imaging shares to, or object to the offer through, the Israeli Depositary. All other shareholders should tender to the U.S. Depositary, as described above.

Valid Tender.

 

 

 

 

By Unlisted Holders: in order for an Unlisted Holder to validly tender Given Imaging shares in the offer to the Israeli Depositary, such Unlisted Holder must notify the Israeli Depositary, via the TASE member with which its securities deposit is managed, of its tender by delivery of a notice or an “Acceptance Notice” of an Unlisted Holder to the TASE member, duly signed by the Unlisted Holder or its duly authorized attorney-in-fact.

An Acceptance Notice of an Unlisted Holder must be submitted to a TASE member with which the securities deposit of the Unlisted Holder is being managed, on an Israeli business day, generally between the hours of 9:00 a.m. and 5:00 p.m., Israel time (2:00 a.m. and 10:00 a.m., New York time), during the Initial Offer Period or Additional Offer Period, as applicable. We recommend that you check at what times you may submit the Acceptance Notice with the TASE member with which your securities deposit is managed.

An Unlisted Holder who wishes to submit an Acceptance Notice at any time on the Final Expiration Date must send an Acceptance Notice to the Israeli Depositary at its address set

18


 

 

 

 

forth on the back cover of this offer to purchase. We refer to this as the Late Acceptance Notice of an Unlisted Holder. The Late Acceptance Notice of an Unlisted Holder will be valid only if the Unlisted Holder properly completes and submits a copy of such Acceptance Notice to the TASE member with which its securities deposit is managed by the following Israeli business day by 9:30 a.m., Israel time (2:30 a.m., New York time), and provided that such TASE member provides the Israeli Depositary with an additional Acceptance Notice of TASE Member (as described below), by that same day by 11:00 a.m., Israel time (4:00 a.m., New York time).

Each TASE member is required to deliver to the Israeli Depositary, at its address set forth on the back cover of this offer to purchase, on the Initial Completion Date and again on the Final Expiration Date, one Acceptance Notice of TASE Member, representing all Acceptance Notices delivered to such TASE member by any Unlisted Holder. In addition, each TASE member is required to deliver to the Israeli Depositary, if applicable, an additional Acceptance Notice of TASE Member, if such TASE member receives, in a timely manner, any Late Acceptance Notices of an Unlisted Holder.

If the conditions to the offer are satisfied or, subject to applicable law, waived by us, the purchase price for the Given Imaging shares validly tendered in the offer and accepted by us for payment will be transferred to the Unlisted Holder by the Israeli Depositary promptly following the Final Expiration Date, by crediting within four U.S. business days following the Final Expiration Date the Unlisted Holder’s bank account according to the particulars given to the Israeli Depositary through the relevant TASE member.

If any condition to the offer is not satisfied prior to the Initial Completion Date and not waived by us, or if we withdraw the offer, we will promptly return all the Acceptance Notices to the TASE members (and through them, to the Unlisted Holders) via the Israeli Depositary.

 

 

 

 

By Listed Holders: in order for a Listed Holder to validly tender Given Imaging shares in the offer to the Israeli Depositary, such Listed Holder must deliver, prior to 5:00 p.m., Israel time (10:00 a.m., New York time), on the Initial Completion Date or Final Expiration Date, as applicable, (1) a share certificate or share certificates representing its Given Imaging shares accompanied by (2) an Acceptance Notice of a Listed Holder duly signed by the Listed Holder or its duly authorized attorney-in-fact. A Listed Holder must deliver the share certificate(s) and the accompanying Acceptance Notice of Listed Holder to the Israeli Depositary at its address set forth on the back cover of this offer to purchase. Delivery of the documents described above to the Israeli Depositary will be made against a certificate of receipt given by the Israeli Depositary during normal business hours.

The Israeli Depositary will hold all documents delivered to it by Listed Holders as trustee until the Final Expiration Date, even if the conditions were not met at the end of the Initial Offer Period.

If the conditions to the offer are satisfied or, subject to applicable law, waived by us, the purchase price for the Given Imaging shares validly tendered in the offer and accepted by us for payment will be transferred to a Listed Holder by the Israeli Depositary promptly following the Final Expiration Date, by crediting within four U.S. business days following the Final Expiration Date the Listed Holder’s bank account according to the particulars delivered to the Israeli Depositary.

If any condition to the offer is not satisfied prior to the completion of the Initial Offer Period and not waived by us, or if we withdraw the offer, we will promptly return to the Listed Holders, via the Israeli Depositary, all the Acceptance Notices, share certificates and other documentation attached to the Acceptance Notices delivered by the respective Listed Holders.

The valid tender of Given Imaging shares pursuant to the applicable procedure described above will constitute a binding agreement between you and us upon the terms of, and subject to the conditions to, the offer.

19


Objecting to the Offer. If you want to notify us of your objection to the offer with respect to all or any portion of your Given Imaging shares, and:

 

 

 

 

you are an Unlisted Holder with respect to such Given Imaging shares, you must notify us, through the TASE member, of your objection to the offer by delivering the Notice of Objection to the TASE member duly signed by you or your duly authorized attorney-in-fact. We refer to this as the Notice of Objection of an Unlisted Holder.

 

 

 

 

 

Each of the TASE members is required to deliver to the Israeli Depositary, at its address set forth on the back cover of this offer to purchase, prior to 5:00 p.m., Israel time (10:00 a.m., New York time), on the Initial Completion Date, one Notice of Objection, referred to as the Notice of Objection of TASE Member, representing all Notices of Objection delivered by each Unlisted Holder to such TASE member; or

 

 

 

 

you are a Listed Holder with respect to such Given Imaging shares, you must notify us, through the Israeli Depositary, of your objection to the offer by delivering the Notice of Objection to the Israeli Depositary at its address set forth on the back cover of this offer to purchase, duly signed by you, prior to 5:00 p.m., Israel time (10:00 a.m., New York time), on the Initial Completion Date. Delivery of the documents set forth above to the Israeli Depositary will be made against a certificate of receipt given by the Israeli Depositary.

We will disregard any Notices of Objection (whether Notices of Objection of TASE Members or Notices of Objection of Listed Holders) received by the Israeli Depositary after such deadline. In addition, if you (or the TASE member on your behalf) submit a Notice of Objection with respect to Given Imaging shares and thereafter you (or the TASE member on your behalf) deliver an Acceptance Notice by which you tender those Given Imaging shares, we will disregard your Notice of Objection. Similarly, if you (or the TASE member on your behalf) submit an Acceptance Notice by which you tender Given Imaging shares, and thereafter you (or the TASE member on your behalf) deliver to us a Notice of Objection with respect to those Given Imaging shares, we will disregard your Acceptance Notice. If you (or the TASE member on your behalf) submit an Acceptance Notice and a Notice of Objection concurrently with respect to the same Given Imaging shares, we will disregard the Notice of Objection.

Withdrawing your Objection. You may withdraw a previously submitted Notice of Objection at any time prior to 5:00 p.m., Israel time (10:00 a.m., New York time), on the Initial Completion Date, as follows:

 

 

 

 

if you are an Unlisted Holder, you may withdraw your Notice of Objection by delivering to the TASE member to which you delivered your Notice of Objection, a copy of the Notice of Objection which was delivered by you, marked “Notice of Objection Cancelled” and accompanied by the date and time of delivery of your Notice of Objection to the TASE member, and your signature or the signature of your duly authorized attorney-in-fact; and

 

 

 

 

if you are a Listed Holder, you may withdraw your Notice of Objection by delivering to the Israeli Depositary a copy of the Notice of Objection which was delivered by you, marked “Notice of Objection Cancelled,” accompanied by the date and time of delivery of your Notice of Objection to the Israeli Depositary, and your signature or the signature of your duly authorized attorney-in-fact, and by returning the certificate of receipt to the Israeli Depositary.

Following the withdrawal of a Notice of Objection, a new Notice of Objection may be submitted at any time prior to 5:00 p.m., Israel time (10:00 a.m., New York time), on the Initial Completion Date by following the procedures described above.

If, with respect to all or any portion of your Given Imaging shares, you object to the offer during the Initial Offer Period and the conditions to the offer have been satisfied or, subject to applicable law, waived by us, you may tender such Given Imaging shares during the Additional Offer Period, if applicable. See Section 1 and Section 11.

Determination of Validity. All questions as to the validity, form, eligibility (including time of receipt) and acceptance for payment of any tender of Given Imaging shares or Notice of Objection will be determined by us, in our sole discretion. This determination will be final and binding on all

20


parties. We reserve the absolute right to reject any or all tenders or Notices of Objection that we determine not to be in proper form or, in the case of tenders, the acceptance for payment of which may be unlawful. We also reserve the absolute right, in our sole discretion, to waive any defect or irregularity in any tender of Given Imaging shares or Notice of Objection of any particular shareholder, whether or not similar defects or irregularities are waived in the case of other shareholders. A tender of Given Imaging shares or Notice of Objection will not have been made until all defects and irregularities have been cured or waived. None of us, our affiliates, our assigns, the Depositaries, the Information Agent, our Israeli legal counsel or any other person will be under any duty to give notification of any defects or irregularities in tenders or Notices of Objection or incur any liability for failure to give any notification. Subject to applicable law, our interpretation of the terms of, and conditions to, the offer (including the Acceptance Notices and instructions thereto) will be final and binding.

If you tender your Given Imaging shares pursuant to the applicable procedure described above, it will constitute your acceptance of the terms of, and conditions to, the offer, as well as your representation and warranty to us that:

 

 

 

 

you have the full power and authority to tender, sell, assign and transfer the tendered Given Imaging shares (and any and all Given Imaging shares or other securities issued or issuable in respect of your Given Imaging shares); and

 

 

 

 

when we accept your Given Imaging shares for payment, we will acquire good and unencumbered title to your Given Imaging shares, free and clear of all liens, restrictions, charges and encumbrances and not subject to any adverse claims.

4.  WITHDRAWAL RIGHTS.

You may withdraw previously tendered Given Imaging shares at any time prior to 10:00 a.m., New York time, or 5:00 p.m., Israel time, on the Initial Completion Date, but not during the Additional Offer Period (see Section 1 and Section 11). In addition, under U.S. law, tendered Given Imaging shares may be withdrawn at any time after 60 days from the date of the commencement of the offer if the Given Imaging shares have not yet been accepted for payment by us. If we extend the Initial Offer Period, delay our acceptance for payment of Given Imaging shares or are unable to accept Given Imaging shares for payment pursuant to the offer for any reason, then, without prejudice to our rights under the offer but subject to applicable law, the Depositaries may, nevertheless, on our behalf, retain tendered Given Imaging shares, and those Given Imaging shares may not be withdrawn except to the extent that tendering shareholders are entitled to withdrawal rights as described in this Section 4. However, our ability to delay the payment for Given Imaging shares that we have accepted for payment is limited by applicable law, including Rule 14e-1(c) under the Exchange Act, which requires that a bidder pay the consideration offered or return the securities deposited by or on behalf of securityholders promptly after the termination or withdrawal of such bidder’s offer. Any delay will be by an extension of the offer to the extent required by law.

Withdrawal procedure for tenders to American Stock Transfer & Trust Company, our U.S. Depositary

If you tendered your Given Imaging shares to the U.S. Depositary, for a withdrawal to be effective, a written notice of withdrawal must be timely received by the U.S. Depositary at the address set forth on the back cover of this offer to purchase. Any notice of withdrawal must specify the name of the person who tendered the Given Imaging shares to be withdrawn, the number of Given Imaging shares to be withdrawn and the name of the registered holder of the Given Imaging shares, if different from the name of the person who tendered the Given Imaging shares. If certificates evidencing Given Imaging shares to be withdrawn have been delivered or otherwise identified to the U.S. Depositary, then, prior to the physical release of the certificates, the serial numbers shown on the certificates must be submitted to the U.S. Depositary and the signature(s) on the notice of withdrawal must be guaranteed by an eligible guarantor institution, unless the Given Imaging shares have been tendered for the account of an eligible guarantor institution. If Given Imaging shares have been delivered pursuant to the procedures for book-entry transfer as set forth in Section 3, any notice of withdrawal must also specify the name and number of the account at

21


DTC to be credited with the withdrawn Given Imaging shares and otherwise comply with DTC’s procedures.

Withdrawals of tendered Given Imaging shares may not be rescinded. If you have properly withdrawn your Given Imaging shares, they will be deemed not to have been validly tendered for purposes of the offer. However, withdrawn Given Imaging shares may be re-tendered at any time prior to 10:00 a.m., New York time (5:00 p.m., Israel Time), on the Final Expiration Date by following the applicable procedure described in Section 3.

Withdrawal procedure for tenders to Clal Finance Batucha Investment Management Ltd., our Israeli Depositary

If you tendered your shares to the Israeli Depositary, you may withdraw your shares as follows:

 

 

 

 

if you are an Unlisted Holder, you may withdraw your Given Imaging shares at any time prior to 5:00 p.m., Israel time (10:00 a.m., New York time), by delivering to the TASE member to which you delivered your Acceptance Notice, a copy of the Acceptance Notice of an Unlisted Holder which was delivered by you, marked “Acceptance Notice Cancelled” and accompanied by the date and time of delivery of your Acceptance Notice to the TASE member, and your signature or the signature of your duly authorized attorney-in-fact; and

 

 

 

 

if you are a Listed Holder, you may withdraw your Given Imaging shares by delivering to the Israeli Depositary a copy of the Acceptance Notice of a Listed Holder which was delivered by you, marked “Acceptance Notice Cancelled,” accompanied by the date and time of delivery of your Acceptance Notice to the Israeli Depositary, and your signature or the signature of your duly authorized attorney-in-fact, and by returning the certificate of receipt to the Israeli Depositary. Promptly thereafter, the Israeli Depositary will return to you the share certificate(s) and Acceptance Notice delivered to the Israeli Depositary by you. Withdrawal of an Acceptance Notice by a Listed Holder may only be performed by delivering the cancelled Acceptance Notice to the Israeli Depositary at its address set forth on the back cover of this offer to purchase, at any time prior to 5:00 p.m., Israel time (10:00 a.m., New York time), on the Initial Completion Date.

Withdrawals of tendered Given Imaging shares may not be rescinded. If you have properly withdrawn Given Imaging shares, they will be deemed not to have been validly tendered for purposes of the offer. However, withdrawn Given Imaging shares may be re-tendered at any time prior to 5:00 p.m., Israel time (10:00 a.m., New York time), on the Final Expiration Date by following the applicable procedure described in Section 3.

Determination of Validity

All questions as to the form and validity (including time of receipt) of notices of withdrawal will be determined by us, in our sole discretion, subject to applicable law, which determination will be final and binding on all parties. None of us or our affiliates or assigns, the Depositaries, the Information Agent, our Israeli legal counsel or any other person will be under any duty to give notification of any defects or irregularities in any notice of withdrawal or incur any liability for failure to give any such notification.

5.  MATERIAL U.S. FEDERAL INCOME TAX AND ISRAELI INCOME TAX CONSIDERATIONS.

Material U.S. Federal Income Tax Considerations.

U.S. Holders. The following discussion summarizes the material U.S. federal income tax considerations of the offer applicable to the shareholders of Given Imaging who are U.S. Holders and whose Given Imaging shares are tendered and accepted for payment pursuant to the offer. A “U.S. Holder” means a holder of Given Imaging shares who is:

 

 

 

 

a citizen or resident of the United States;

22


 

 

 

 

a corporation (or other entity taxable as a corporation for U.S. federal income tax purposes) created or organized under the laws of the United Sates, any state or political subdivision thereof or the District of Columbia;

 

 

 

 

an estate, the income of which is subject to U.S. federal income tax regardless of its source; or

 

 

 

 

a trust (A) if a court within the United States is able to exercise primary jurisdiction over its administration and one or more U.S. Persons (as defined in the Code) have authority to control all of its substantial decisions, or (B) if, it has a valid election in effect under applicable Treasury Regulations to be treated as a U.S. Person.

This discussion is based on current provisions of the Internal Revenue Code of 1986, as amended, referred to as the Code, current and proposed Treasury Regulations promulgated under the Code, administrative pronouncements and judicial decisions and interpretations as of the date hereof, all of which are subject to differing interpretations or change, which change may apply retroactively and could materially affect the continued validity of this summary and the tax considerations described in this Section 5. Subject to the discussion set forth below under the heading entitled “Characterization of the Purchase if Given Imaging is a Passive Foreign Investment Company,” this discussion assumes that Given Imaging is not and has never been a “passive foreign investment company,” “controlled foreign corporation,” “foreign investment company” or “foreign personal holding company” for U.S. federal income tax purposes.

This discussion addresses only Given Imaging shares that are held as capital assets within the meaning of Section 1221 of the Code (generally, for investment). No ruling has been or will be sought from the U.S. Internal Revenue Service, or IRS, and no opinion of counsel has been or will be rendered, as to the U.S. federal income tax consequences of the offer. This discussion does not address all of the tax considerations that may be relevant to shareholders in light of their particular circumstances or certain types of shareholders subject to special treatment, including, without limitation:

 

 

 

 

regulated investment companies;

 

 

 

 

broker-dealers (including in securities or foreign currency) or insurance companies;

 

 

 

 

persons who have elected to apply a mark-to-market method of accounting;

 

 

 

 

tax-exempt organizations or retirement plans;

 

 

 

 

certain former citizens or former long-term residents of the United States;

 

 

 

 

persons subject to the alternative minimum tax;

 

 

 

 

banks and other financial institutions;

 

 

 

 

persons who hold their Given Imaging shares as part of a position in a straddle or as part of a hedging, conversion, constructive sale, synthetic security, or other integrated investment;

 

 

 

 

holders who received their Given Imaging shares through the exercise of employee stock options or otherwise as compensation;

 

 

 

 

partnerships or other pass-through entities or persons who hold their Given Imaging shares through partnerships or other pass-through entities;

 

 

 

 

holders who own directly, indirectly or by attribution at least 10.0% of the voting power of Given Imaging; and

 

 

 

 

persons whose functional currency is not the U.S. dollar.

In addition, this summary does not discuss any foreign, state, or local tax consequences or any U.S. tax consequences (e.g., estate or gift tax) relevant to U.S. Holders other than U.S. federal income tax consequences.

WE RECOMMEND THAT GIVEN IMAGING SHAREHOLDERS WHO ARE U.S. HOLDERS CONSULT THEIR TAX ADVISORS AS TO THE PARTICULAR TAX CONSEQUENCES OF THE OFFER TO THEM, INCLUDING THE EFFECTS OF

23


APPLICABLE STATE, LOCAL, FOREIGN OR OTHER TAX LAWS AND POSSIBLE CHANGES IN THE TAX LAWS.

FOR A DISCUSSION OF CERTAIN ISRAELI INCOME TAX CONSIDERATIONS THAT MAY APPLY TO U.S. HOLDERS, SEE BELOW UNDER “MATERIAL ISRAELI INCOME TAX CONSIDERATIONS.”

Characterization of the Purchase if Given Imaging is not a Passive Foreign Investment Company. The receipt of cash for Given Imaging shares pursuant to the offer will be treated as a taxable transaction for U.S. federal income tax purposes. In general, a U.S. Holder who sells Given Imaging shares pursuant to the offer will recognize gain or loss for U.S. federal income tax purposes equal to the difference, if any, between the amount of cash received and the U.S. Holder’s adjusted tax basis in the Given Imaging shares sold pursuant to the offer. Gain or loss will be determined separately for each block of Given Imaging shares (i.e., Given Imaging shares acquired at the same cost in a single transaction) tendered pursuant to the offer. The gain or loss will be long-term capital gain or loss if the U.S. Holder has held the Given Imaging shares for more than one year at the time of the consummation of the offer. Long-term capital gains are currently subject to a maximum rate of 15%. Special limitations apply to the use of capital losses.

Characterization of the Purchase if Given Imaging is a Passive Foreign Investment Company. In general, a non-U.S. corporation will be classified as a passive foreign investment company within the meaning of Section 1297(a) of the Code (“PFIC”) if, for any taxable year, at least 75% of its gross income consists of passive income (such as dividends, interest, rents, royalties, or gains on certain securities or commodities transactions), or at least 50% of the average value of its assets (determined on a quarterly basis) consists of assets that produce or are held for the production of, passive income. Given Imaging’s 2007 Form 20-F provides that Given Imaging, subject to the discussion therein, believes that in 2007 it was not a PFIC. The 2007 Form 20-F also provides that the determination of PFIC status is a factual determination that must be made annually at the close of each taxable year.

In general, if Given Imaging was characterized as a PFIC for 2007 or any prior taxable year or is a PFIC for 2008, any gain recognized by a U.S. Holder who sells Given Imaging shares pursuant to the offer would be treated as ordinary income and would be subject to tax as if the gain had been realized ratably over the holding period of the Given Imaging shares. The amount allocated to the current taxable year and any taxable year with respect to which Given Imaging was not a PFIC would be taxed as ordinary income (rather than capital gain) earned in the current taxable year. The amount allocated to other taxable years would be taxed at the highest marginal rates applicable to ordinary income for such taxable years, and the U.S. Holder also would be liable for an additional tax equal to the interest on such tax liability for such years. We recommend that U.S. Holders consult their tax advisors regarding the potential application of the PFIC rules to the sale of Given Imaging shares pursuant to the offer.

Information Reporting and Backup Withholding. Payments made by the U.S. Depositary in connection with the offer may be subject to information reporting to the IRS and possible backup withholding. Under the U.S. federal backup withholding tax rules, 28% of the gross proceeds payable to a shareholder or other payee pursuant to the offer must be withheld and remitted to the U.S. Treasury, unless the U.S. Holder (or other payee) who tenders its Given Imaging shares to the U.S. Depositary provides such shareholder’s (or other payee’s) taxpayer identification number (employer identification number or social security number) to the U.S. Depositary and otherwise complies with the backup withholding rules. Each U.S. Holder tendering its shares to the U.S. Depositary should complete and sign the Substitute Form W-9 included as part of the Letter of Transmittal or a Form W-8, as applicable, in order to provide the information and certificate necessary to avoid backup withholding. Amounts withheld under the backup withholding rules are not an additional tax and may be refunded or credited against the holders’ U.S. federal income tax liability, provided the required information is furnished to the IRS.

24


Material Israeli Tax Considerations.

The following discussion summarizes the material Israeli tax considerations of the offer applicable to Given Imaging’s shareholders whose Given Imaging shares are tendered and accepted for payment pursuant to the offer. The following discussion is based on the Ordinance, the regulations promulgated thereunder, administrative rulings and pronouncements, all of which are subject to change, possibly with retroactive effect. Any such change could alter the tax considerations discussed below. There can be no assurance that the Israeli Tax Authority, or the ITA, or a court will not take a position contrary to the Israeli income tax considerations discussed herein or that any such contrary position taken by the ITA or a court would not be sustained. This discussion addresses only Given Imaging shares that are held as capital assets (generally, assets held for investment) within the meaning of the Ordinance. This discussion does not address all of the tax consequences that may be relevant to shareholders in light of their particular circumstances or certain types of shareholders subject to special treatment.

The tax discussion set forth below is based on present law. Because individual circumstances may differ, we recommend that holders consult their tax advisors to determine the applicability of the rules discussed below to you and the particular tax effects of the offer, including the application of Israeli or other tax laws.

The summary below does not discuss the effects of any non-Israeli tax laws. We recommend that holders of Given Imaging shares who are U.S. Holders consult their tax advisors regarding the U.S. federal, state and local income tax consequences of the offer. For a discussion of material U.S. federal income tax considerations, see above under “Material U.S. Federal Income Tax Considerations.”

Characterization of the Purchase. The receipt of cash for Given Imaging shares pursuant to the offer generally will be treated as a taxable transaction for Israeli income tax purposes, pursuant to which a holder of Given Imaging shares will be treated as having sold such Given Imaging shares.

General. Israeli law generally imposes a capital gains tax on a sale or disposition of any capital assets by Israeli residents, as defined for Israeli tax purposes (see Annex B), and on the sale of assets located in Israel, including Given Imaging shares in Israeli companies (such as Given Imaging), by non-Israeli residents, unless a specific exemption is available or unless a tax treaty between Israel and the shareholder’s country of residence provides otherwise.

Tax Rates. Pursuant to the Ordinance and the regulations promulgated thereunder, as of January 1, 2006, the tax rate applicable to capital gains derived from the sale of Given Imaging shares, whether listed on a stock market or not, is 20% for Israeli individuals, unless such shareholder claims a deduction for financing expenses in connection with such Given Imaging shares, in which case the gain generally will be taxed at a rate of 25%. Additionally, if such shareholder is considered a “significant shareholder” at any time during the 12-month period preceding such sale, i.e., such shareholder holds directly or indirectly, including with others, at least 10% of any means of control in the company, the tax rate is 25%. Companies are subject to the corporate tax rate on capital gains derived from the sale of Given Imaging shares (currently 27%), unless such companies were not subject to the Israeli Income Tax Law (Inflationary Adjustments), 1985 (or certain regulations), or the Inflationary Adjustments Law, prior to August 10, 2005, in which case the applicable tax rate is 25%. However, the foregoing tax rates will not apply to: (i) dealers in securities; (ii) shareholders who acquired their Given Imaging shares prior to Given Imaging’s initial public offering on Nasdaq (that may be subject to a different tax arrangement); and (iii) in some cases, shareholders who received their Given Imaging shares through the exercise of employee stock options or otherwise as compensation. The tax basis of Given Imaging shares acquired prior to January 1, 2003 by individuals and by companies that were not subject to the Inflationary Adjustments Law will be determined in accordance with the average closing share price on the TASE or Nasdaq, as applicable, for the three trading days preceding January 1, 2003. However, a request may be made to the tax authorities to consider the actual adjusted cost of the Given Imaging shares as the tax basis if it is higher than such average price.

Non-Israeli residents. Non-Israeli residents generally will be exempt from capital gains tax on the sale of the Given Imaging shares, provided that such shareholders did not acquire their Given

25


Imaging shares prior to Given Imaging’s initial public offering and that the gains did not derive from a permanent establishment of such shareholders in Israel. However, non-Israeli corporations will not be entitled to such exemption if Israeli residents (i) have a controlling interest of 25% or more in such non-Israeli corporation, or (ii) are the beneficiary of, or are entitled to, 25% or more of the revenues or profits of such non-Israeli corporation, whether directly or indirectly.

In addition, pursuant to the Convention between the Government of the United States of America and the Government of Israel with Respect to Taxes on Income, as amended, or the U.S.- Israel Tax Treaty, the sale, exchange or disposition of Given Imaging shares by a person who (i) holds the Given Imaging shares as a capital asset, (ii) qualifies as a resident of the United States within the meaning of the U.S.-Israel Tax Treaty, and (iii) is entitled to claim the benefits afforded to such U.S. resident by the U.S.-Israel Tax Treaty (such person is referred to as a U.S. Treaty Resident), generally will not be subject to Israeli capital gains tax unless such U.S. Treaty Resident held, directly or indirectly, Given Imaging shares representing 10% or more of the voting power of Given Imaging during any part of the 12-month period preceding the sale, exchange or disposition, subject to certain conditions, or the capital gains can be allocated to a permanent establishment of such U.S. Treaty Resident in Israel. If the exemption is not available, such sale, exchange or disposition would be subject to Israeli capital gains tax to the extent applicable. Under the U.S.-Israel tax Treaty, such U.S. Treaty Resident would be permitted to claim a credit for Israeli income tax against the U.S. federal income tax imposed on the disposition, subject to the limitations in the U.S. tax laws applicable to foreign tax credits.

Israeli Withholding Tax. The gross proceeds payable to a tendering shareholder in the offer generally will be subject to Israeli withholding tax at the rate of 20% for individuals or 25% in the case of corporations, of the shareholder’s gain on such sale. An approval from the ITA was obtained with respect to the withholding tax rates applicable to shareholders as a result of the purchase of Given Imaging shares pursuant to the offer. The approval provides, among other things, that:

(1) tendering shareholders who acquired their Given Imaging shares after Given Imaging’s initial public offering on the Nasdaq and who, certify that they are NOT “residents of Israel” (and, in the case of a corporation, that no Israeli resident(s) (x) holds 25% or more of the means of control such corporation or (y) is the beneficiary of, or is entitled to, 25% or more of the revenues or profits of such corporation, whether directly or indirectly) will not be subject to Israeli withholding tax;

(2) eligible Israeli brokers or financial institutions holding Given Imaging shares solely on behalf of tendering shareholders will not be subject to Israeli withholding tax;

(3) tendering shareholders who are Israeli residents and who acquired their Given Imaging shares prior to Given Imaging’s initial public offering on Nasdaq, will be subject to Israeli withholding tax at a rate of 25% of the amount received by the tendering shareholder;

(4) tendering shareholders who are NOT “residents of Israel” and who acquired their Given Imaging shares prior to Given Imaging’s initial public offering on Nasdaq, will be subject to Israeli withholding tax at a rate of 25% of the amount received by the tendering shareholder, unless the tendering shareholder submits an A-114 Form approving such shareholder’s residence in a country with whom Israel has a tax treaty which exempts Israeli capital gains tax, duly signed by the tendering shareholder and authorized by the tax authority of such country, in which event such tendering shareholder will not be subject to Israeli withholding tax; and

(5) tendering shareholders who are not described in clauses (1),(2), (3) and (4) above, will be subject to Israeli withholding tax at a fixed rate of 8.61% of the amount received by the tendering shareholder pursuant to the offer.

Notwithstanding the foregoing, should any tendering shareholder present us with a valid approval from the ITA applying withholding tax at a lesser rate than those described above or otherwise granting a specific exemption from Israeli withholding tax, we will act in accordance with such approval.

26


More specifically, based on the approval, if a Given Imaging shareholder tenders its Given Imaging shares to:

 

 

 

 

the U.S. Depositary, the U.S. Depositary may be required to withhold 25% of the gross proceeds payable to such shareholder pursuant to the offer, unless such shareholder, upon the terms and conditions set forth in the Letter of Transmittal, either:

 

 

 

 

certify, by completing the Declaration Form (Declaration of Status for Israeli Income Tax Purposes), or the Declaration Form, included in the Letter of Transmittal or otherwise delivered to such shareholder, that (1) such shareholder is NOT a “resident of Israel” for purposes of the Ordinance, and if it is a corporation that is NOT a “resident of Israel” — that Israeli residents are NOT “controlling shareholders” (as defined under Section 68A of the Ordinance) of such corporation, nor are Israeli residents the beneficiaries of, and are not entitled to, 25% or more of such corporation’s revenues or profits, whether directly or indirectly and either (A) acquired their Given Imaging shares after Given Imaging’s initial public offering on Nasdaq (i.e., after October 3, 2001), or (B) acquired their Given Imaging shares prior to Given Imaging’s initial public offering on Nasdaq and submit an A-114 Form approving such shareholder’s residence in a country with whom Israel has a tax treaty, which exempts Israeli capital gains tax, duly signed by the tendering shareholder and authorized by the tax authority of such country, or (2) such shareholder is a bank, broker or financial institution resident in Israel that (A) is holding the Given Imaging shares solely on behalf of beneficial shareholder(s) (so-called “street name” holders) and (B) is subject to the provisions of the Ordinance and regulations promulgated thereunder relating to the withholding of Israeli tax, including with respect to the gross proceeds (if any) paid by such shareholder to the beneficial shareholder(s) with respect to the Given Imaging shares tendered by such shareholder on their behalf. In such case, the U.S. Depositary will not withhold any Israeli withholding tax from the gross proceeds payable to you pursuant to the offer; or

 

 

 

 

provide the U.S. Depositary, with a copy (which shall not constitute notice) to Gross, Kleinhendler, Hodak, Halevy, Greenberg & Co., our legal counsel in Israel, at its address set forth on the back cover of this offer to purchase, a valid certificate from the ITA entitling such shareholder to an exemption or a specified withholding tax rate, referred to as the ITA Waiver. In such case, the U.S. Depositary will withhold Israeli withholding tax (or not withhold, if such shareholder is entitled to an exemption) from the gross proceeds payable to it pursuant to the offer in accordance with such ITA Waiver; or

 

 

 

 

certify, by completing the Declaration Form, that (1) such shareholder is a “resident of Israel” and acquired his Given Imaging shares after Given Imaging’s initial public offering on Nasdaq (i.e., after October 3, 2001). In such case, the U.S. Depositary will withhold 8.61% from the gross proceeds payable to such tendering shareholder pursuant to the offer.

 

 

 

 

the Israeli Depositary, and such shareholder

 

 

 

 

holds its Given Imaging shares through a TASE member, such TASE member will withhold Israeli income tax, if applicable, at the rate of up to 20% for individuals and up to 25% for corporations, of the gain realized by such shareholder from the sale of Given Imaging shares in the offer, in accordance with the Israeli Income Tax Regulations (Withholding from Consideration, Payment or Capital Gains on the Sale of a Security or Forward Transaction), 5763-2000; or

 

 

 

 

is named as a holder of Given Imaging shares in the Register of Shareholders of Given Imaging in Israel, the Israeli Depositary may be required to withhold 25% if the Given Imaging shares were acquired prior to Given Imaging’s initial public offering on Nasdaq of the amount received by the tendering shareholder pursuant to the offer, unless such shareholder provides the Israeli Depositary, with a copy (which shall not constitute notice) to Gross, Kleinhendler, Hodak, Halevy, Greenberg & Co., our legal counsel in Israel, at its address set forth on the back cover of this offer to purchase, with a valid ITA Waiver, in which case, the Israeli Depositary will withhold Israeli withholding tax (or not withhold,

27


 

 

 

 

if such shareholder is entitled to an exemption) from the gross proceeds payable to it pursuant to the offer in accordance with such ITA Waiver.

We recommend that you consult your tax advisors regarding the application of Israeli income and withholding taxes (including eligibility for any withholding tax reduction or exemption, and the refund procedure).

Please note that if a shareholder tenders its Given Imaging shares to the U.S. Depositary and provides a Declaration Form, you also consent to the provision of such Declaration Form to us and to the ITA in case the ITA so requests for purposes of audit or otherwise.

All questions as to the validity, form or eligibility of any Declaration Form or ITA Waiver (including time of receipt) and, subject to applicable law, the withholding of Israeli taxes, will be determined by us, in our sole discretion. This determination will be final and binding on all parties. We reserve the absolute right to reject any or all Declaration Forms or ITA Waivers that we determine not to be in proper form or pursuant to which the failure to withhold any Israeli taxes may be unlawful. We also reserve, subject to applicable law, the absolute right, in our sole discretion, to waive any defect or irregularity in any Declaration Form or ITA Waiver of any particular shareholder, whether or not similar defects or irregularities are waived in the case of other shareholders. None of us, our affiliates, our assigns, the Depositaries, the Information Agent, our Israeli legal counsel or any other person will be under any duty to give notification of any defects or irregularities or incur any liability for failure to give any notification.

An excerpt of the definition of an Israeli resident in the Ordinance is attached as Annex B.

The Israeli withholding tax is not an additional tax. Rather, the Israeli income tax liability of shareholders subject to Israeli withholding tax will be reduced by the amount of Israeli tax withheld. If Israeli withholding tax results in an overpayment of Israeli taxes, the holder may apply to the ITA in order to obtain a refund. However, no assurance is given as to whether and when the ITA will grant such refund.

The foregoing discussion is intended only as a summary and does not purport to be a complete analysis or listing of all potential Israeli tax effects of the offer. We recommend that Given Imaging shareholders consult their tax advisors concerning the Israeli and non-Israeli tax consequences to them of tendering their shares in the offer.

6.  PRICE RANGE OF THE SHARES ETC.

Given Imaging shares are listed and traded on Nasdaq and the TASE in each case under the ticker symbol “GIVN.” Given Imaging shares commenced trading on Nasdaq in October 2001 and on the TASE in March 2004.

The following table sets forth, for each of the fiscal quarters indicated, the high and low closing sale price per share on Nasdaq and the TASE as reported in published financial sources. All share prices on Nasdaq are reported in U.S. dollars and all share prices on the TASE are reported in NIS. On May 12, 2008, the prevailing exchange rate was $1.00 for NIS 3.45.

28


 

 

 

 

 

 

 

 

 

 

 

 

 

Quarter

 

Nasdaq Global Market

 

The Tel Aviv Stock Exchange

 

 

High

 

Low

 

High

 

Low

2006

 

 

 

 

 

 

 

 

 

 

 

 

First Quarter

 

 

$

 

28.37

   

 

$

 

21.65

   

 

 

NIS

   

 

 

132.60

   

 

 

NIS

   

 

 

101.60

 

Second Quarter

 

 

$

 

24.07

   

 

$

 

15.06

   

 

 

NIS

   

 

 

109.80

   

 

 

NIS

   

 

 

67.36

 

Third Quarter

 

 

$

 

19.85

   

 

$

 

14.46

   

 

 

NIS

   

 

 

86.50

   

 

 

NIS

   

 

 

65.02

 

Fourth Quarter

 

 

$

 

22.76

   

 

$

 

18.85

   

 

 

NIS

   

 

 

98.27

   

 

 

NIS

   

 

 

80.54

 

2007

 

 

 

 

 

 

 

 

 

 

 

 

First Quarter

 

 

$

 

22.04

   

 

$

 

19.25

   

 

 

NIS

   

 

 

92.74

   

 

 

NIS

   

 

 

81.47

 

Second Quarter

 

 

$

 

31.42

   

 

$

 

21.22

   

 

 

NIS

   

 

 

125.10

   

 

 

NIS

   

 

 

86.14

 

Third Quarter

 

 

$

 

31.49

   

 

$

 

25.02

   

 

 

NIS

   

 

 

135.90

   

 

 

NIS

   

 

 

102.70

 

Fourth Quarter

 

 

$

 

30.19

   

 

$

 

22.43

   

 

 

NIS

   

 

 

123.60

   

 

 

NIS

   

 

 

47.17

 

2008

 

 

 

 

 

 

 

 

 

 

 

 

First Quarter

 

 

$

 

23.29

   

 

$

 

14.36

   

 

 

NIS

   

 

 

90.58

   

 

 

NIS

   

 

 

47.17

 

Second Quarter*

 

 

$

 

17.39

   

 

$

 

14.90

   

 

 

NIS

   

 

 

61.48

   

 

 

NIS

   

 

 

51.03

 


 

 

*

 

 

 

Through May 12, 2008.

The following table sets forth, for each of the months indicated, the high and low closing sale price per share on Nasdaq and the TASE as reported in published financial sources. All share prices on Nasdaq are reported in U.S. dollars and all share prices on the TASE are reported in NIS. On May 12, 2008, the prevailing exchange rate was $1.00 for NIS 3.45.

 

 

 

 

 

 

 

 

 

 

 

 

 

Month

 

Nasdaq Global Market

 

The Tel Aviv Stock Exchange

 

 

High

 

Low

 

High

 

Low

March 2007

 

 

$

 

22.04

   

 

$

 

19.79

   

 

 

NIS

   

 

 

92.63

   

 

 

NIS

   

 

 

83.88

 

April 2007

 

 

$

 

24.09

   

 

$

 

21.22

   

 

 

NIS

   

 

 

99.91

   

 

 

NIS

   

 

 

86.14

 

May 2007

 

 

$

 

27.07

   

 

$

 

24.46

   

 

 

NIS

   

 

 

109.30

   

 

 

NIS

   

 

 

97.22

 

June 2007

 

 

$

 

31.42

   

 

$

 

24.81

   

 

 

NIS

   

 

 

125.10

   

 

 

NIS

   

 

 

102.40

 

July 2007

 

 

$

 

31.49

   

 

$

 

27.42

   

 

 

NIS

   

 

 

135.90

   

 

 

NIS

   

 

 

117.10

 

August 2007

 

 

$

 

29.13

   

 

$

 

25.02

   

 

 

NIS

   

 

 

126.60

   

 

 

NIS

   

 

 

104.10

 

September 2007

 

 

$

 

27.76

   

 

$

 

25.47

   

 

 

NIS

   

 

 

112.80

   

 

 

NIS

   

 

 

102.70

 

October 2007

 

 

$

 

30.19

   

 

$

 

28.25

   

 

 

NIS

   

 

 

123.60

   

 

 

NIS

   

 

 

111.40

 

November 2007

 

 

$

 

27.20

   

 

$

 

23.12

   

 

 

NIS

   

 

 

108.60

   

 

 

NIS

   

 

 

90.26

 

December 2007

 

 

$

 

23.75

   

 

$

 

22.43

   

 

 

NIS

   

 

 

91.50

   

 

 

NIS

   

 

 

87.53

 

January 2008

 

 

$

 

23.29

   

 

$

 

15.59

   

 

 

NIS

   

 

 

90.58

   

 

 

NIS

   

 

 

58.49

 

February 2008

 

 

$

 

17.06

   

 

$

 

14.36

   

 

 

NIS

   

 

 

61.98

   

 

 

NIS

   

 

 

47.17

 

March 2008

 

 

$

 

17.30

   

 

$

 

14.88

   

 

 

NIS

   

 

 

59.62

   

 

 

NIS

   

 

 

49.91

 

April 2008

 

 

$

 

17.11

   

 

$

 

14.90

   

 

 

NIS

   

 

 

61.48

   

 

 

NIS

   

 

 

51.03

 

May 2008*

 

 

$

 

17.39

   

 

$

 

16.18

   

 

 

NIS

   

 

 

60.00

   

 

 

NIS

   

 

 

57.00

 


 

 

*

 

 

 

Through May 12, 2008.

The average closing sale price for Given Imaging shares on Nasdaq during the six months prior to the date of this offer to purchase, i.e., between December 12, 2007 and May 12, 2008 was $17.49 per share. Accordingly, the purchase price in the offer is 5.4% lower than the said average closing price on Nasdaq and is 2.2% higher than the closing price on Nasdaq on May 12, 2008.

The average closing sale price for Given Imaging shares on the TASE during the six months prior to the date of this offer to purchase, i.e., between December 12, 2007 and May 12, 2008, was NIS 63.99 ($18.54 based on an exchange rate of NIS 3.45 per U.S. dollar as of May 12, 2008) per share. Accordingly, the purchase price in the offer (NIS 57.06 based on an exchange rate of NIS 3.45 per U.S. dollar as of May 12, 2008) is 10.8% lower than the said average closing price on the TASE and is 0.1% lower than the closing price on the TASE on May 12, 2008.

29


On May 15, 2008, the last full trading day prior to the commencement of the offer, the closing sale price per share as reported on Nasdaq was $15.75, and as reported on the TASE was NIS 54.49 ($15.91 based on an exchange rate of NIS 3.42 per U.S. dollar as of May 15, 2008).

We recommend that you obtain a current market quotation for Given Imaging shares.

Based on Given Imaging’s consolidated financial statements for the year ended December 31, 2007, Given Imaging’s shareholders equity was $133.6 million and its shareholders’ equity per share (based on 29,241,785 Given Imaging shares outstanding on such date) was $4.57, in each case as of December 31, 2007.

7.  EFFECTS OF THE OFFER ON THE MARKET FOR SHARES; REGISTRATION UNDER THE EXCHANGE ACT.

Our purchase of Given Imaging shares pursuant to the offer will reduce the number of Given Imaging shares that might otherwise be traded publicly and may reduce the number of Given Imaging shareholders. In particular, if the offer is consummated, Given Imaging’s “public float,” that is the number of Given Imaging shares owned by Given Imaging’s non-affiliated shareholders and available for trading in the securities markets, will be reduced. This may result in lower share prices or reduced liquidity in the trading market for Given Imaging shares in the future. Nonetheless, we anticipate that there will be a sufficient number of Given Imaging shares issued and outstanding and publicly-traded following consummation of the offer to ensure a continued trading market for the Given Imaging shares. Based upon published guidelines of Nasdaq and the TASE, we believe that our purchase of Given Imaging shares pursuant to the offer will not, in itself, cause the remaining Given Imaging shares to be delisted from Nasdaq or the TASE.

The Given Imaging shares are currently “margin securities” under the rules and regulations of the Board of Governors of the Federal Reserve System. This has the effect, among other things, of allowing brokers to extend credit to their customers using such Given Imaging shares as collateral. We believe that, following the purchase of Given Imaging shares pursuant to the offer, the Given Imaging shares will continue to be “margin securities” for purposes of the margin rules and regulations of the Board of Governors of the Federal Reserve System.

Given Imaging shares are registered under the Exchange Act, which requires, among other things, that Given Imaging furnish certain information to its shareholders and the SEC. We believe that our purchase of Given Imaging shares pursuant to the offer will not result in deregistration of the Given Imaging shares under the Exchange Act or otherwise cause Given Imaging to no longer be subject to the reporting requirements of the Exchange Act applicable to it (as a “foreign private issuer”).

8.  INFORMATION CONCERNING GIVEN IMAGING.

Except as otherwise set forth in this offer to purchase, the information concerning Given Imaging contained in this offer to purchase has been taken from or is based upon publicly available documents and records on file with the SEC and other public sources. The summary information set forth below is qualified in its entirety by reference to these documents and records. We assume no responsibility for the accuracy or completeness of the information contained in such documents or records or for any failure by Given Imaging to disclose events that may have occurred and may affect the significance or accuracy of any such information.

Overview. Given Imaging’s legal and commercial name is Given Imaging Ltd. and its legal form is a company limited by shares. It was incorporated under the laws of the State of Israel in 1998 under the name of Given Imaging Ltd. Given Imaging’s corporate headquarters and principal executive offices are located at Hermon Building, New Industrial Park, Yoqneam 20692, Israel. Its telephone number in Israel is +972-4-909-7777. Given Imaging’s website address is www.givenimaging.com. However, information contained on Given Imaging’s website does not constitute a part of this offer to purchase.

30


Given Imaging manufactures and markets innovative diagnostic products for visualization and detection of disorders of the gastrointestinal tract. In October 2001, Given Imaging conducted an initial public offering of its shares and its shares commenced trading on the Nasdaq National Market (now the Nasdaq Global Market) and, in March 2004, its shares also commenced trading on the TASE. Given Imaging shares are listed on both Nasdaq and the TASE under the ticker symbol “GIVN.”

Available Information. Given Imaging is subject to the informational filing requirements of the Exchange Act applicable to “foreign private issuers” and, in accordance therewith, is obligated to file reports, including annual reports on Form 20-F, and other information with the SEC relating to its business, financial condition and other matters.

These reports and other information should be available for inspection at the public reference facilities of the SEC at 100 F. Street, N.E., Room 1580, Washington, D.C. 20549, and at the regional offices of the SEC. Copies of this information should be obtainable by mail, upon payment of the SEC’s customary charges, by writing to the SEC’s principal office at 100 F. Street, N.E., Room 1580, Washington, D.C. 20549. Given Imaging’s filings are also available on the SEC’s website (http://www.sec.gov).

According to Chapter E’3 of the Israeli Securities Law and regulations promulgated thereunder, Given Imaging is required to file with the ISA and the TASE any document it is required to file or that it has furnished or made public to its investors in accordance with U.S. law and any other information that it receives from its shareholders regarding their holdings in Given Imaging, and which was furnished or that has to be furnished, according to U.S. law, to Given Imaging’s shareholders. Such filings are available on the TASE’s website (http://maya.tase.co.il/bursa/index.asp) and on the ISA’s website (http://www.magna.isa.gov.il).

9. INFORMATION CONCERNING ELRON.

Elron. Our legal and commercial name is Elron Electronic Industries Ltd. and our legal form is a company limited by shares. We are an Israeli company founded in 1962 and headquartered in Israel. Our corporate headquarters and principal executive offices are located at 3 Azrieli Center, 42nd Floor, The Triangular Tower, Tel-Aviv 67023, Israel. Our telephone number is +972-3-607-5555. Our website address is www.elron.net. However, information contained on our website does not constitute a part of this offer to purchase.

Our shares are listed on the Nasdaq Global Select Market and the TASE, in each case under the ticker symbol “ELRN.” We are a high technology holding company that operates through subsidiaries and affiliated companies referred to as our group companies. We have been a major force in the development of Israeli high technology industry by building Israeli and Israel-related companies with technologies in the fields of medical imaging, advanced defense electronics, telecommunications, semiconductors and software products and services and today operates through its group companies in the fields of medical devices, information and communication technology, clean technology and semi-conductors.

We are 48.6% owned by Discount Investment Corporation Ltd., or DIC, a holding company incorporated in Israel whose shares are listed on the TASE under the ticker symbol “DISI.” DIC is a majority owned subsidiary of IDB Holding Corporation Ltd., or IDBH, a holding company incorporated in Israel whose shares are listed on the TASE under the symbol “IDBH.” Please read Section 9 for additional information concerning us.

Additional Information. The name, citizenship, business address, present principal occupation and material positions held during the past five years of each of our executive officers, directors and other “senior office holders” (as such term is defined under the Israeli Securities Law) are set forth in Schedule I to this offer to purchase. Schedule I also sets forth the name, business address, telephone number and certain other information with respect to DIC and IDBH, our “controlling shareholders” for purposes of this offer to purchase, and certain other persons who may be deemed to ultimately control us.

31


None of Elron, our directors, our officers or, to our knowledge after due inquiry of the relevant person or entity, the other persons or entities listed on Schedule I:

 

 

 

 

has been convicted in a criminal proceeding in the past five years (excluding traffic violations or similar misdemeanors);

 

 

 

 

has been party to any judicial or administrative proceeding during the past five years (except for matters that were dismissed without sanction or settlement) that resulted in a judgment, decree or final order enjoining the person from future violations of, or prohibiting activities subject to, U.S. federal or state securities laws, or a finding of any violation of U.S. federal or state securities laws; or

 

 

 

 

has been otherwise convicted in a criminal proceeding and the statute of limitation regarding such conviction, pursuant to the Israeli Criminal Registration and Rehabilitation Law, 1981, has not elapsed prior to the date of this offer to purchase.

Available Information. We have filed with the SEC a Schedule TO, which includes this offer to purchase as an exhibit thereto and contains additional information concerning the offer.

We are subject to the informational filing requirements of the Exchange Act applicable to “foreign private issuers” and, in accordance therewith, are obligated to file reports, including annual reports on Form 20-F, and other information with the SEC relating to our business, financial condition and other matters.

These reports and other information should be available for inspection at the public reference facilities of the SEC at 100 F. Street, N.E., Room 1580, Washington, D.C. 20549, and at the regional offices of the SEC. Copies of this information should be obtainable by mail, upon payment of the SEC’s customary charges, by writing to the SEC’s principal office at 100 F. Street, N.E., Room 1580, Washington, D.C. 20549. Elron’s filings are also available on the SEC’s website (http://www.sec.gov).

According to Chapter E’3 of the Israeli Securities Law and regulations promulgated thereunder, Elron is required to file with the ISA and the TASE any document it is required to file or that it has furnished or made public to its investors in accordance with U.S. law and any other information that it receives from its shareholders regarding their holdings in Elron, and which was furnished or that has to be furnished, according to U.S. law, to Elron’s shareholders. Such filings are available on the TASE’s website (http://maya.tase.co.il/bursa/index.asp) and on the ISA’s website (http://www.magna.isa.gov.il).

10.  SOURCES AND AMOUNT OF FUNDS.

The offer is not conditioned on the availability of financing. We estimate that the total amount of funds that we will require to consummate the offer, including fees and expenses, is approximately $24.5 million. The offer will be financed by our own internal resources and credit lines. We possess all necessary funds to consummate the offer from cash on hand. To secure the payment for the Given Imaging shares tendered in the offer, the Israeli Depositary, who is a member of the TASE, has agreed to guarantee our obligation to pay for the Given Imaging shares. In addition, to secure this guarantee, we have engaged the Israeli Depositary to act as an escrow agent and, if requested by the Israeli Depositary, we will deposit cash into an escrow account in an amount sufficient to pay for the total number of Given Imaging shares that we are offering to purchase in the offer.

11.  CONDITIONS TO THE OFFER.

Under Israeli law, we will become irrevocably bound to purchase, subject to proration, the Given Imaging shares validly tendered in the offer and not properly withdrawn prior to 10:00 a.m., New York time, or 5:00 p.m., Israel time, on the Final Expiration Date, subject to the following conditions. Notwithstanding any other provisions of the offer, and in addition to (and not in limitation of) our rights to extend the Initial Offer Period or otherwise amend the terms of the offer at any time, we shall not be required to accept for payment and, subject to Israeli law, the Exchange Act and any applicable rules and regulations of the SEC, including our obligation to either pay for or return tendered Given Imaging shares promptly after the termination or withdrawal

32


of the offer under Rule 14e-1(c) under the Exchange Act, pay for, and may delay the acceptance for payment of and accordingly the payment for, any tendered Given Imaging shares, and terminate the offer, if, in our reasonable judgment, any of the following occurs:

(a) at 10:00 a.m., New York time, or 5:00 p.m., Israel time, on the Initial Completion Date, either of the following conditions has not been satisfied:

(1) there shall have been validly tendered and not properly withdrawn Given Imaging shares representing at least 5.0% of the issued and outstanding shares of Given Imaging on the Initial Completion Date (currently, at least 1,462,640 Given Imaging shares), such that following the consummation of the offer, we will beneficially own approximately 32.4% of the issued and outstanding Given Imaging shares or, when taken together with the issued and outstanding Given Imaging shares owned by our affiliates, we will beneficially own approximately 48.5% of the issued and outstanding Given Imaging shares; or

(2) as required by Israeli law, at the completion of the Initial Offer Period, the aggregate number of Given Imaging shares validly tendered in the offer and not properly withdrawn (excluding Given Imaging shares held by us, certain of our affiliates or certain of Given Imaging’s affiliates pursuant to Section 331(c) of the Israeli Companies Law) is greater than the aggregate number of Given Imaging shares represented by Notices of Objection to the offer;

(b) (1) at any time on or after commencement of the offer and prior to 10:00 a.m., New York time, or 5:00 p.m., Israel time, on the Initial Completion Date,

 

 

 

 

any “event” (as such term is defined below) shall have occurred,

 

 

 

 

we did not know and could not have known of, and we did not foresee and could not have foreseen, in each case, on the date of this offer to purchase, the occurrence of such “event,” and

 

 

 

 

such “event” would cause the terms of the offer as a result of such event to become materially different from the terms which a reasonable offeror would have proposed had it known of such “event” on the date of this offer to purchase;

For purposes of this paragraph (b)(1), an “event” shall mean any of the following:

 

(A)

 

 

 

any action taken, or any statute, rule, regulation, legislation, interpretation, judgment, order or injunction enacted, enforced, promulgated, amended, issued or deemed applicable to the offer, by any legislative body, court, government or governmental, administrative or regulatory authority or agency of competent jurisdiction, domestic or foreign;

 

(B)

 

 

 

any action or proceeding threatened, instituted or pending by any governmental entity or third party before a court or other authority of competent jurisdiction, domestic or foreign; or

 

(C)

 

 

 

any change that has or will have occurred (or any development that has or will have occurred involving prospective changes) in the business, assets, liabilities, conditions (financial or otherwise), prospects or results of operations of Given Imaging that has, or could reasonably be expected to have, in our reasonable discretion, a material adverse effect on Given Imaging or, assuming consummation of the offer, on us; or

(2) at any time on or after commencement of the offer and prior to 10:00 a.m., New York time, or 5:00 p.m., Israel time, on the Initial Completion Date, there has or will have occurred, and continue to exist, any of the following:

 

 

 

 

any general suspension of, or limitation on prices for, trading in securities on Nasdaq or the TASE;

 

 

 

 

a declaration of a banking moratorium or any suspension of payments in respect of banks in the United States or Israel (whether or not mandatory) or a material limitation (whether or not mandatory) by any governmental entity on the extension of credit by banks or other lending institutions;

33


 

 

 

 

a commencement of a war, armed hostilities or other national or international crisis directly or indirectly involving the United States or Israel;

 

 

 

 

in the case of any of the foregoing existing at the time of the commencement of the offer, a material escalation or the worsening thereof;

 

 

 

 

any change in the general political, market, economic or financial conditions in the United States, Israel or abroad that could, in our reasonable judgment, have a material adverse effect on us, Given Imaging or the trading of Given Imaging shares; or

 

 

 

 

a tender offer or exchange offer for any or all of Given Imaging shares, or any merger, acquisition, business combination or other similar transaction with or involving Given Imaging or any of its subsidiaries, shall have been proposed, announced or made by any person or has been publicly disclosed; or

(c) at least one Israeli business day prior to the Initial Completion Date, we shall not have obtained any approvals, licenses, permits or consents of any competent authority or any other approval, which is required under applicable law in order to purchase the Given Imaging shares pursuant to the offer (see Section 12). This includes any requirement that any governmental, administrative or regulatory authority or agency has imposed, or has sought to impose, to the terms of, or the disclosure with respect to, the offer, the compliance with which would (1) result in unreasonable cost or expense to us, (2) require unreasonable commercial efforts by us, or (3) otherwise would prohibit consummation of the offer or prevent consummation thereof within the time periods prescribed by applicable law.

The foregoing conditions may be asserted by us regardless of the circumstances giving rise to any such conditions and, in the case of clause (b) above, subject to applicable law, may be waived by us in whole or in part at any time and from time to time until the Initial Completion Date (as may be extended), in each case, in the exercise of our reasonable judgment. You should be aware that, under Israeli law, we may not waive the conditions set forth in clause (a) and clause (c) above.

Our failure at any time to exercise any of the foregoing rights shall not be deemed a waiver of any such right and each such right shall be deemed an ongoing right that may be asserted at any time and from time to time prior to 10:00 a.m., New York time, or 5:00 p.m., Israel time, on the Initial Completion Date. Any determination by us concerning any condition described in this Section 11 shall be final and binding on all parties. A public announcement may be made of a material change in, or waiver of, such conditions, and the Initial Offer Period may, in certain circumstances, be extended in connection with any such change or waiver.

Should the offer be terminated pursuant to the foregoing provisions, all tendered Given Imaging shares not theretofore accepted for payment shall promptly be returned by the Depositaries to the tendering shareholders.

The offer is not conditioned on our obtaining financing or the approval of the board of directors of Given Imaging.

12.  LEGAL MATTERS AND REGULATORY APPROVALS.

Israeli Antitrust Authority. On May 4, 2008, we filed an application with respect to the offer with the Israeli Antitrust Authority. In the application, we sought the approval of the Israeli Antitrust Authority that the purchase by us of additional Given Imaging shares which would result in our owning approximately 48.5% of the outstanding Given Imaging shares would not require the filing of merger notices pursuant to the Israeli Restricted Trade Practices Law, 5748-1988. On May 6, 2008, we received the approval of the Israeli Antitrust Authority to proceed with the offer.

The Israeli Securities Authority. Pursuant to the Israeli Securities Law, if the ISA, including an employee it authorized for that purpose, determines that this offer to purchase and related materials do not contain all the information that the ISA believes is important for a reasonable offeree, or that this offer to purchase and related materials do not comply with the provisions of the Israeli Securities Law, the ISA may direct, during the period in which the offer is open, that the Initial Completion Date be postponed, and the ISA may direct, after having given us appropriate opportunity for a fair hearing before it, that an amendment to this offer to purchase and related

34


materials be published within one Israeli business day (unless it stipulates another time), or that an amended offer to purchase and related materials should be provided in the form and manner it directs. The ISA may order the postponement of the Initial Completion Date, if it sees fit to do so, for the protection of the interests of the offerees.

The U.S. Securities and Exchange Commission. The SEC may or may not review and comment on this offer to purchase and related documents. However, the offer has not been approved or disapproved by the SEC (or, for that matter, any state securities commission or the ISA), nor has the SEC (or any state securities commission or the ISA) passed upon the fairness or merits of the offer or upon the accuracy or adequacy of the information contained in this offer to purchase. Any representation to the contrary is a criminal offense.

General. In addition, we must receive any necessary material approval, permit, authorization or consent of any U.S., Israeli or other governmental, administrative or regulatory agency (federal, state, local, provincial or otherwise) prior to the Initial Completion Date. Except as set forth above, we are not aware of any license or regulatory permit that appears to be material to the business of Given Imaging and its subsidiaries, taken as a whole, that might be adversely affected by our acquisition of Given Imaging shares pursuant to the offer. If any such material approval or other action is required, we presently contemplate to use our reasonable commercial efforts to obtain such approval or take such action. While, except as otherwise described in this offer to purchase, we do not presently intend to delay the acceptance for payment of, or payment for, Given Imaging shares tendered in the offer pending the outcome of any such matter, there can be no assurance that any such approval or other action, if needed, would be obtained or would be obtained without substantial conditions, or that failure to obtain any such approval or other action might not result in unknown or unforeseen consequences adverse to Given Imaging’s business. See Section 11 for conditions to the offer, including conditions with respect to regulatory approvals.

13.  FEES AND EXPENSES.

We have retained MacKenzie Partners, Inc. to serve as the Information Agent for the offer, American Stock Transfer & Trust Company, Given Imaging’s U.S. transfer agent, to serve as the U.S. Depositary for the offer, and Clal Finance Batucha Investment Management Ltd. to serve as the Israeli Depositary for the offer.

The Information Agent may contact holders of Given Imaging shares by personal interview, mail, telephone, facsimile and other methods of electronic communication and may request brokers, dealers, banks, trust companies and other nominees to forward the materials relating to the offer to beneficial holders. As compensation for acting as Information Agent in connection with the offer, MacKenzie Partners, Inc. will be paid a reasonable and customary fee for its services and will also be reimbursed for reasonable out-of-pocket expenses and may be indemnified against specified liabilities and expenses in connection with the offer, including specified liabilities under the federal securities laws. We will pay the Depositaries reasonable and customary compensation for their services in connection with the offer and reimburse them for reasonable out-of-pocket expenses, and will indemnify them against specified liabilities and expenses in connection with their services, including specified liabilities under the federal securities laws.

It is estimated that the expenses incurred in connection with the offer will be approximately as set forth below:

 

 

 

Information Agent Fees and Expenses

 

 

$

 

15,000.00

 

U.S. and Israeli Depositaries’ Fees and Expenses

 

 

 

35,000.00

 

Filing Fees

 

 

 

950.75

 

Legal Fees

 

 

 

170,000.00

 

Printing and Mailing Costs

 

 

 

28,000.00

 

Miscellaneous

 

 

 

10,000.00

 

 

 

 

Total

 

 

$

 

258,950.75

 

 

 

 

35


Except as set forth above, we will not pay any fees or commissions to any broker or dealer or other person or entity in connection with the solicitation of tenders of Given Imaging shares pursuant to the offer. We will, upon request, reimburse brokers, dealers, commercial banks and trust companies for customary mailing and handling expenses incurred by them in forwarding materials relating to the offer to their customers.

14.  MISCELLANEOUS.

We are making the offer to shareholders of Given Imaging by this offer to purchase and the related documents delivered to you. We are not aware of any jurisdiction where the making of the offer is prohibited by administrative or judicial action pursuant to any valid state statute. If we become aware of any valid state statute prohibiting the making of the offer or the acceptance of the Given Imaging shares pursuant thereto, we will make a good faith effort to comply with such statute or seek to have such statute declared inapplicable to the offer. If, after this good faith effort, we cannot comply with the state statute, subject to applicable law, the offer will not be made to (nor will tenders be accepted from or on behalf of) holders of Given Imaging shares in that state. In those jurisdictions where the securities, blue sky or other laws require the offer to be made by a licensed broker or dealer, we will endeavor to make arrangements to have the offer made on our behalf by one or more registered brokers or dealers licensed under the laws of such jurisdictions.

No person has been authorized to give any information or to make any representation on our behalf not contained herein or in the related documents delivered to you and, if given or made, such information or representation must not be relied upon as having been authorized.

Pursuant to Rule 14d-3 under the Exchange Act, we have filed with the SEC the Schedule TO, together with exhibits, furnishing additional information with respect to the offer. The Schedule TO and any amendments thereto, including exhibits, should be available for inspection at the public reference facilities of the SEC at 100 F. Street, N.E., Room 1580, Washington, D.C. 20549, and at the regional offices of the SEC. Copies of this information should be obtainable by mail, upon payment of the SEC’s customary charges, by writing to the SEC’s principal office at 100 F. Street, N.E., Room 1580, Washington, D.C. 20549. The SEC also maintains a website http://www.sec.gov that contains reports and other information filed electronically with the SEC.

Pursuant to the Securities Regulations (Tender Offer), 5760-2000, we have filed a copy of this offer to purchase with the ISA and the TASE.

 

 

 

 

 

 

 

 

 

 

 

Elron Electronic Industries Ltd.

By:

 

/s/ Doron Birger  

 

By:

 

/s/ Rinat Remler  

 

 

Name: Doron Birger

 

 

 

Name: Rinat Remler

 

 

Title:

 

President & Chief Executive
Officer

 

 

 

Title:

 

Vice President & Chief Financial
Officer

May 16, 2008

36


ANNEX A
Excerpt of Section 331 of the Israeli Companies Law 5759-1999
(Unofficial Translation from Hebrew)

“331. Consent of shareholders

 

(a)

 

 

 

A special tender offer shall be addressed to all offerees, and the offerees may announce their consent to the special tender offer or their objection thereto.

 

(b)

 

 

 

A special tender offer may not be accepted unless a majority of the votes of offerees, who announced their position with respect thereto, agreed to the offer.

 

(c)

 

 

 

In counting the votes of the offerees, the votes of a controlling shareholder of the offeror, a shareholder who owns a controlling parcel of shares in the company, or of persons on their behalf or on behalf of the offeror, including their relatives and corporations under their control, shall be excluded.

 

(d)

 

 

 

If a special tender offer is accepted, then all offerees, who had not announced their position with respect the offer or who objected to the offer, may agree to the offer, not later than four days after the last date for acceptance of the tender offer, or by another date to be set by the Minister for this purpose, and they shall be treated like persons who agreed to the offer from the start.”

37


ANNEX B
Definition of Israeli Resident for Israeli Tax Purposes
(Unofficial Translation from Hebrew)

The following is an excerpt of Section 1 of the Israeli Income Tax Ordinance [New Version], 1961, as amended, which defines a “resident of Israel” or a “resident” as follows:

 

(A)

 

 

 

with respect to an individual–a person whose center of vital interests is in Israel; for this purpose the following provisions will apply:

 

(1)

 

 

 

in order to determine the center of vital interests of an individual, account will be taken of the individual’s family, economic and social connections, including, among others:

 

(a)

 

 

 

place of permanent home;

 

(b)

 

 

 

place of residential dwelling of the individual and the individual’s immediate family;

 

(c)

 

 

 

place of the individual’s regular or permanent occupation or the place of his permanent employment;

 

(d)

 

 

 

place of the individual’s active and substantial economic interests;

 

(e)

 

 

 

place of the individual’s activities in organizations, associations and other institutions;

 

(2)

 

 

 

the center of vital interests of an individual will be presumed to be in Israel:

 

(a)

 

 

 

if the individual was present in Israel for 183 days or more in the tax year;

 

(b)

 

 

 

if the individual was present in Israel for 30 days or more in the tax year, and the total period of the individual’s presence in Israel that tax year and the two previous tax years is 425 days or more.

For the purposes of this provision, “day” includes a part of a day;

 

(3)

 

 

 

the presumption in subparagraph (2) may be rebutted either by the individual or by the assessing officer;

 

(4)

 

 

 

.  .  .  ;

 

(B)

 

 

 

with respect to a body of persons–a body of persons which meets one of the following:

 

(1)

 

 

 

it was incorporated in Israel;

 

(2)

 

 

 

the “control and management” of its business is exercised in Israel.”

38


SCHEDULE I

A. DIRECTORS, EXECUTIVE OFFICERS AND OTHER SENIOR OFFICE HOLDERS OF ELRON, DIC, IDBD AND IDBH

The following table sets forth the name, address, age, present principal occupation or employment and material occupations, positions, offices or employments for the past five years, of the directors, executive officers and other “senior office holders” (as such term is defined under the Israeli Securities Law) of each of Elron, DIC, IDBD and IDBH.

Directors and Executive Officers
of
Elron Electronic Industries Ltd.

Unless otherwise indicated, all of Elron’s directors, executive officers and other senior office holders are citizens of Israel and their address is 3 Azrieli Center, 42nd Floor, The Triangular Tower, Tel-Aviv 67023, Israel.

 

 

 

 

 

 

 

Name & Address

 

Age

 

Position

 

Current Principal Occupation &
Material Positions in Past 5 Years

Arie Mientkavich

 

65

 

Chairman of the Board of Directors

 

Current principal occupation: Chairman of Elron, Deputy Chairman of Gazit Globe Ltd. and Chairman of Gazit Globe Israel (Development) Ltd., a real estate investment group.

 

 

 

 

 

 

Material positions in past 5 years: Deputy Chairman of IDBH since May 2006 and Chairman of Clal Tourism Ltd.(1) (“Clal Tourism”) since January 2007. Chairman of Israel Discount Bank Ltd. and several subsidiaries from 1997 to 2006.

Ami Erel

 

61

 

Director

 

Current principal occupation: President & Chief Executive Officer of DIC (2), Chairman of NetVision Ltd. (3), Cellcom Israel Ltd. (4) and Koor Industries Ltd. (5)
Material positions in past 5 years: Chairman of Elron from November 1999 to January 2007. Chief Executive Officer of Elron from November 1999 to December 2001. Chief Executive Officer of NetVision Ltd. from March until September 2007, director of various companies held by DIC (“DIC Group”).

Avraham Asheri
12 Yoshpe Street
Apt. 7
Mevasseret Zion 90805
Israel

 

70

 

Director

 

Current principal occupation: Director of companies.
Material positions in past 5 years: President of Israel Discount Bank from November 1991 until July 1998.

 

 

 

 

 

 

39


 

 

 

 

 

 

 

Name & Address

 

Age

 

Position

 

Current Principal Occupation &
Material Positions in Past 5 Years

Prof. Yair B’ery
6 Sweden Street
Petah Tikva 49317
Israel

 

51

 

Director

 

Current principal occupation: Professor—Department of Electrical Engineering, Tel Aviv University.
Material positions in past 5 years: From 1998 until 2005, worked with Benny Steinmetz’s Group and co-founded STI- Ventures, a high technology investment group.

Yaacov Goldman
39 Nachlieli Street
Hod Hasharon 45355
Israel

 

52

 

Director

 

Current principal occupation: Director of companies.
Material positions in past 5 years: From 1991 until 2000, senior partner of Kesselman and Kesselman (member firm of PricewaterhouseCoopers).

Prof. Gabriel Barbash
14 Zisman Street
Ramat Gan 53521
Israel

 

58

 

Director

 

Current principal occupation: Director General of the Tel Aviv Sourasky Medical Center.
Material positions in past 5 years: Director General of the Tel Aviv Sourasky Medical Center since 1999. Chairman of Teuza Venture Capital Fund from 2000 to 2003;

Nochi Danker (6)
3 Azrieli Center
The Triangular Tower,
44nd Floor
Tel-Aviv 67023
Israel

 

53

 

Director

 

Current principal occupation: Chairman and Chief Executive Officer of IDBH; Chairman of IDBD, DIC and Clal Industries and Investments Ltd. (“CII”), director of companies.
Material positions in past 5 years: Director of various companies affiliated with IDBH (“IDB Group”) in the IDB Group since May 2003; Chairman and CEO of various companies held by Ganden Holdings Ltd (7) (“Ganden” and “Ganden Group”); director, including Chairman of Credit Committee of Bank Hapoalim B.M. (8) from November 1997 until May 2003; and a partner in the law office of Danker-Lusky (9) until 2004.

Avraham Fischer
3 Azrieli Center
The Triangular Tower,
44nd Floor
Tel-Aviv 67023
Israel

 

51

 

Director

 

Current principal occupation: Executive Vice President of IDBH, Deputy Chairman of IDBD, Co-Chief Executive Officer of CII.
Material positions in past 5 years: Director of various companies in the IDB Group since May 2003; co-managing partner of Fischer, Behar, Chen, Well, Orion & Co. (10) since 1982; Deputy Chairman of Ganden and a director of companies in the Ganden Group.

 

 

 

 

 

 

40


 

 

 

 

 

 

 

Name & Address

 

Age

 

Position

 

Current Principal Occupation &
Material Positions in Past 5 Years

Shay Livnat (11)
26 Shalva Street
Herzlia Pituach 46705
Israel

 

49

 

Director

 

Current principal occupation: President of Zoe Holdings Ltd. (12)
Material positions in past 5 years: Director of various companies in the IDB Group, Taavura group and Avraham Livnat (13) group of companies.

Dori Manor*
17 Kerem Hazeim
Street, Savion 56536,
Israel

 

40

 

Director

 

Current principal occupation: Chief Executive Officer of companies in the automotive sector of David Lubinski Ltd. (14) (“Lubinski”) group.
Material positions in past 5 years: a director of IDBH, IDBD and DIC since May 2003; director of various companies in the Lubinski group and in family companies.

Ari Bronshtein

 

38

 

Director

 

Current principal occupation: Vice President of DIC.
Material positions in past 5 years: Vice President and head of Economics and Business Development Division of Bezeq Israeli Telecommunications Company (“Bezeq”) (15) from 2004 until 2005 and Director of Finance and Investments at Bezeq from 2000 until 2003.

Arie Ovadia
10 Harav Amiel Street
Tel Aviv 62223
Israel

 

59

 

Director

 

Current principal occupation: Director of companies.
Material positions in past 5 years: Chairman of the Phoenix Holdings Ltd. (16).

Amos Shapira
10 Hagavish Street
Industrial Zone
Netanya 42140
Israel

 

59

 

Director

 

Current principal occupation: Chief Executive of Cellcom Israel Ltd.
Material positions in past 5 years: Chief Executive officer of El Al Israel Airlines Ltd (17) from 2002 to 2005.

Tida Shamir

 

47

 

Director

 

Current principal occupation: Attorney—Partner of the law firm, Tida Shamir & Co, Law Offices since 1992.
Material positions in past 5 years: Attorney—Partner of the law firm, Tida Shamir & Co, Law Offices since 1992.

 

 

 

 

 

 

41


 

 

 

 

 

 

 

Name & Address

 

Age

 

Position

 

Current Principal Occupation &
Material Positions in Past 5 Years

Doron Birger

 

56

 

President and Chief Executive Officer

 

Current principal occupation: President and Chief Executive Officer of Elron.
Material positions in past 5 years: President and Chief Executive Officer of Elron, Chairman of Given Imaging Ltd. from August 2002 until June and director of companies held by Elron (“Elron Group”).

Moshe Fourier

 

60

 

Vice President and Chief Technology Officer

 

Current principal occupation: Vice President and Chief Technology Officer of Elron.
Material positions in past 5 years: Vice President and Chief Technology Officer of Elron.

Rinat Remler

 

36

 

Vice President, Chief Financial Officer

 

Current principal occupation: Vice President, Chief Financial Officer of Elron.
Material positions in past 5 years: Director of Finance of Elron.

Assaf Topaz

 

37

 

Vice President

 

Current principal occupation: Vice President of Elron.
Material positions in past 5 years: Director of business development of Elron.

Yair Cohen

 

53

 

Vice President

 

Current principal occupation: Vice President of Elron.
Material positions in past 5 years: Brigadier General of the Special Unit 8200, the central military intelligence unit of the Israeli Defense Forces since 2001, head of elite 8200 military intelligence unit

Zvika Slovin

 

42

 

Vice President

 

Current principal occupation: Vice President of Elron.
Material positions in past 5 years: Founder and CEO of Tactile Technologies (Israel) Ltd. (18); Chief Executive Officer of Quantomix Ltd. (19)


 

 

*

 

 

 

Dual citizen of Israel and France.

 

(1)

 

 

 

Clal Tourism, a subsidiary of IDBD, is a private Israeli company that deals in the fields of tourism, travel and investment and management of hotels. Its address is 3 Hamelakha St., Tel-Aviv, 67215, Israel.

 

(2)

 

 

 

DIC, a subsidiary of IDB Development, is an Israeli company, holding investments in companies located in Israel operating mainly in the fields of advanced technology, industry, real estate, communications and commerce. Its address is 3 Azrieli Center, Triangular Tower,
Tel Aviv 67023, Israel.

 

(3)

 

 

 

NetVision Ltd., an affiliate of IDBH, is an Israeli public company whose shares are traded on the TASE. Its main field of activity is providing internet services and solutions in Israel and international telephony services. Its address is Omega Centre, Matam Haifa, Israel.

42


 

(4)

 

 

 

Cellcom Israel Ltd. is an Israeli public company whose shares are traded on the TASE and NYSE; it is a subsidiary of CII and its main field of activity is providing cellular communications services in Israel. Its address is 10 Hagavish St., A.T., Netanya 42507, Israel.

 

(5)

 

 

 

Koor Industries Ltd., an affiliate of IDBD, is a public Israeli company whose shares are traded on the TASE; it is one of the largest holding companies in Israel investing in companies active in a variety of activities in Israel. Its address is 3 Azrieli Center, Triangular Tower, Floor 43 Tel Aviv 67023, Israel.

 

(6)

 

 

 

Nochi Dankner is the brother of Shelly Bergman who holds through a wholly-owned company approximately 4.23% of the outstanding shares of IDBH.

 

(7)

 

 

 

Ganden is an Israeli company, holding investments mainly in Israeli companies that operate primarily in the fields of aviation, tourism and real estate. Ganden is controlled by Nochi Dankner (who is also the Chairman of IDBH, IDBD, DIC and CII) and his sister Shelly Bergman. Ganden holds, directly and through a wholly-owned subsidiary, approximately 52.04% of the outstanding shares of IDBH. Its address is 3 Azrieli Center, Triangular Tower, Tel Aviv 67023, Israel.

 

(8)

 

 

 

Bank Hapoalim B.M. is an Israeli commercial bank. Its address is Bank Hapoalim Building,
63 Yehuda Halevy Street, Tel Aviv 65781, Israel.

 

(9)

 

 

 

Dankner-Lusky is an Israeli law firm that was merged with the Israeli law firm of Goldfarb, Levy, Eran, Meiri, Tzafrir & Co. Its address is 2 Weizmann Street, Tel Aviv 64239, Israel.

 

(10)

 

 

 

Fischer, Behar, Chen, Well, Orion & Co. is an Israeli law firm. Its address is 3 Daniel Frisch, Tel Aviv 64731, Israel.

 

(11)

 

 

 

Shay Livnat and Zvi Livnat are the sons of Avraham Livnat, who controls Avraham Livnat Ltd. that holds, directly and through a wholly-owned subsidiary approximately 12.36% of the outstanding shares of IDBH.

 

(12)

 

 

 

Zoe Holdings is a holding company that manages a diverse portfolio of international telecommunications operations and hi-tech companies.

 

(13)

 

 

 

Avraham Livnat, is the controlling shareholder of Avraham Livnat Ltd. and father of Zvi Livnat, the co-CEO of CII and a director of IDBH, IDBD and CII and Shai Livnat, is a director of IDBD and CII.

 

(14)

 

 

 

Lubinski is an Israeli company engaged primarily in the import to and marketing in Israel of motor vehicles. Its address is 103 Kahnman Street, Bney Brak 51553, Israel.

 

(15)

 

 

 

Bezeq is an Israeli public company whose shares are traded on the TASE, its main field of activity is to supply a variety of communications services in the State if Israel. Its address is 132 Menahem Road, Tel Aviv, Israel.

 

(16)

 

 

 

The Phoenix Holding Ltd. is an Israeli public company whose shares are traded on the TASE, its main fields of activity are general and life insurance. Its address is 53 Hashalom Way, Givatayim 53454, Tel-Aviv, Israel.

 

(17)

 

 

 

El Al Israel Airlines Ltd. is an Israeli public company whose shares are traded on the TASE, its main field of activity is the aerial transport of cargo and passengers between Israel and abroad. Its address is Ben-Gurion Aiport, Lod 70100, P.O. Box 41, Israel.

 

(18)

 

 

 

Tactile Technologies (Israel) Ltd. is an Israeli private company, its main field of activity is the development of medical instrumentation. Its address is 10/1 Prof. Menahem Flaut St, Rehovot 76706, Israel.

 

(19)

 

 

 

Quantomix Ltd. is an Israeli private company, its main field of activity is development which allows imaging of cells in an electronic microscope—biotechnology. Its address is 12 Hamada St, Rehovot 76703, Israel.

43


Directors and Executive Officers
of
Discount Investment Corporation Ltd.

Unless otherwise indicated, all of DICs directors, executive officers and other senior office holders are citizens of Israel and their address is 3 Azrieli Center, 44th Floor, The Triangular Tower, Tel-Aviv 67023, Israel.

 

 

 

 

 

 

 

Name & Address

 

Age

 

Position

 

Current Principal Occupation &
Material Positions in Past 5 Years

Nochi Danker
3 Azrieli Center
The Triangular Tower, 45th Floor
Tel-Aviv 67023
Israel

 

53

 

Chairman of the Board of Directors

 

Current principal occupation: Chairman and Chief Executive Officer of IDBH; Chairman of IDBD, DIC and CII; director of companies.
Material positions in past 5 years: Director of various companies in the IDB Group since May 2003; Chairman and Chief Executive Officer of various companies in the Ganden Group; a director, including Chairman of Credit Committee of Bank Hapoalim B.M. from November 1997 until May 2003; and a partner in the law office of Danker-Lusky until 2004.

Avraham Fischer
3 Azrieli Center
The Triangular Tower,
45th Floor
Tel-Aviv 67023
Israel

 

51

 

Director

 

Current principal occupation: Executive Vice President of IDBH, Deputy Chairman of IDB Development, Co-Chief Executive Officer of CII.
Material positions in past 5 years: Director of various companies in the IDB Group since May 2003; co-managing partner of Fischer, Behar, Chen, Well, Orion & Co. since 1982; Deputy Chairman of Ganden and a director of affiliates of Ganden.

Zvi Livnat (20)

 

54

 

Director

 

Current principal occupation: Executive Vice President of IDBH; Co-Chief Executive Officer of CII. Deputy- Chairman of IDBD.
Material positions in past 5 years: Director of companies in the IDB group, Taavura group and Avraham Livnat group. Vice President—Commerce of Taavura from 1979 until June 2003.

 

 

 

 

 

 

44


 

 

 

 

 

 

 

Name & Address

 

Age

 

Position

 

Current Principal Occupation &
Material Positions in Past 5 Years

Isaak Manor* (21)
26 Hagderot Street,
Savion 56526,
Israel

 

66

 

Director

 

Current principal occupation: Chairman of companies in the automotive sector of the Lubinski Group.
Material positions in past 5 years: Deputy chairman of IDBH and a director of IDBD and various companies in the IDB Group since May 2003; a director of Union Bank of Israel Ltd. (22); a director of various companies in the Lubinski group and in family companies.

Dori Manor
17 Kerem Hazeim
Street, Savion 56536,
Israel

 

40

 

Director

 

Current principal occupation: CEO of companies in the automotive sector of the Lubinski group.
Material positions in past 5 years: Director of IDBH, IDBD and DIC since May 2003; a director of Elron since August 2003; and a director of various companies in the Lubinski group and in family companies.

Zehava Dankner
64 Pinkas Street,
Tel Aviv 62157,
Israel

 

75

 

Director

 

Current principal occupation: Director of companies.
Material positions in past 5 years: Member of the executive committee of Beautiful Israel Council; Director of companies in the IDB group.

Eliahu Cohen

 

75

 

Director

 

Current principal occupation: Director and Chief Executive Officer of IDBD.
Material positions in past 5 years: CEO of IDBH from February 2003 until December 2003; a director of IDBH, IDBD, Property and Building Corporation Ltd. (“PBC”) (23) and DIC; Chairman of CIEH; Chairman of Clal Medical Insurance and of affiliates of CIEH.

Gideon Lahav
124 Ehad Haam Street,
Tel Aviv 65208

 

78

 

Director

 

Current principal occupation: Director of companies
Material positions in past 5 years: Director of Cellcom Israel Ltd. from 2002 until 2004 and in 2005; director of Koor Industries Ltd, Paz Oil Company Ltd. (24) and the First Bank of Israel Ltd. (25)

Moshe Arad
14 Shay Agnon Street,
Tel Aviv 65208,
Israel

 

73

 

External Director

 

Current principal occupation: Director of companies.
Material positions in past 5 years: Vice President of Hebrew University of Jerusalem, director and member of audit committee of Elbit Systems Ltd. (26)

 

 

 

 

 

 

45


 

 

 

 

 

 

 

Name & Address

 

Age

 

Position

 

Current Principal Occupation &
Material Positions in Past 5 Years

Adiel Rosenfeld
42 Ha’Alon Street,
Timrat 23840,
Israel

 

53

 

Director

 

Current principal occupation: Representative in Israel of the Aktiva Group; (27) President of the Haifa University Friends Association.
Material positions in past 5 years: A director of various companies in the IDB Group since 2004; a member of the board of governors of the Haifa University.

Gideon Dover
11 Hamaalot Street,
Herzliya B 46583,
Israel

 

63

 

External Director

 

Current principal occupation: Chief Executive Officer of Dover Medical Device and Science Ltd. (28)
Material positions in past 5 years: Director of I. B. T. International Business Technology Ltd. (29) and Quantum Technologies Ltd. (30)

Prof. Niv Ahituv
Tel Aviv University Building
Tel Aviv University
69978,
Israel

 

63

 

External Director

 

Current principal occupation: Professor of the Business Faculty of Tel Aviv University.
Material positions in past 5 years: Director of Companies.

Jacob Schimmel
17 High Field Gardens
London W11 9HD
United Kingdom

 

45

 

Director

 

Current principal occupation: Director of UKI Investments. (31)
Material positions in past 5 years: Director of various companies in the IDB Group.

Refael Bisker

 

56

 

Director

 

Current principal occupation: Chairman of PBC, Co-Chairman of Shufersal Ltd.
Material positions in past 5 years: Director of various companies in the IDB Group.

Shaul Ben Zeev
Taavura Junction,
Ramle, 72102,
Israel

 

51

 

Director

 

Current principal occupation: Chief Executive Officer of Avraham Livnat Ltd. and Director of Business Development of Taavura Holdings Ltd. (32)
Material positions in past 5 years: Director of various companies in the IDB Group since 2003 as well as other companies.

 

 

 

 

 

 

46


 

 

 

 

 

 

 

Name & Address

 

Age

 

Position

 

Current Principal Occupation &
Material Positions in Past 5 Years

Ami Erel
3 Azrieli Center
The Triangular Tower,
44nd Floor
Tel-Aviv 67023
Israel

 

61

 

President & Chief Executive Officer

 

Current principal occupation: President & Chief Executive Officer of DIC, Chairman of NetVision Ltd., Cellcom Israel Ltd. and Koor Industries Ltd.
Material positions in past 5 years: Chairman of Elron from November 1999 to January 2007. Chief Executive Officer of Elron from November 1999 to December 2001. Chief Executive Officer of NetVision Ltd. from March until September 2007, director of various companies in the DIC Group.

Oren Lieder

 

59

 

Senior Vice President & Chief Financial Officer

 

Current principal occupation: Senior Vice President & Chief Financial Officer of DIC.
Material positions in past 5 years: Vice President & Chief Financial Officer of DIC. Director of various companies in the DIC Group.

Raanan Cohen

 

40

 

Vice President

 

Current principal occupation: Vice President & Chief Financial Officer of DIC. Chief Executive Officer of Koor Industries Ltd.
Material positions in past 5 years: Chief Executive Officer of Scailex Corporation Ltd. (33) from 2004 until 2006 and director of various companies in the DIC Group.

Michel Dahan

 

50

 

Vice President & Comptroller

 

Current principal occupation: Vice President & Comptroller of DIC.
Material positions in past 5 years: Vice President & Comptroller.

Ari Bronshtein

 

38

 

Vice President

 

Current principal occupation: Vice President of DIC.
Material positions in past 5 years: Vice President and head of Economics and Business Development Division of Bezeq from 2004 until 2005 and Director of Finance and Investments at Bezeq from 2000 until 2003.

 

 

 

 

 

 

47


 

 

 

 

 

 

 

Name & Address

 

Age

 

Position

 

Current Principal Occupation &
Material Positions in Past 5 Years

Itzhak Ravid
32 A Habarzel Street
Tel Aviv 69710

 

53

 

Internal Auditor

 

Current principal occupation: Senior Partner of Raveh, Ravid and Co., Accountants.
Material positions in past 5 years: Senior Partner of Raveh, Ravid and Co., accountants since 1988. Internal controller of Hamlet (Israel—Canada) Ltd. and the Israeli Institute for Democracy; director of various companies.


 

 

*

 

 

 

Dual citizen of Israel and France.

 

(20)

 

 

 

See footnote 11.

 

(21)

 

 

 

Isaac Manor is the husband of Ruth Manor, who is the controlling shareholder of Manor Holdings B.A. Ltd. (that holds directly and through a majority-owned subsidiary 12.35% of the outstanding shares of IDBH) and they are the parents of Dori Manor.

 

(22)

 

 

 

Union Bank of Israel Ltd. is an Israeli commercial bank. Its address is 6 Ahuzat Bait Street, Tel Aviv 65143, Israel.

 

(23)

 

 

 

PBC is an Israeli real-estate company operating in the fields of revenue-generating assets, residential construction and infrastructures. Its address is 14 Beit Hashoeva Lane, Tel Aviv 65814, Israel.

 

(24)

 

 

 

Paz Oil Company Ltd. is an Israeli public company whose shares are traded on the TASE, its main fields of activity are fueling and trade, direct marketing and refinement. Its address is
12 Giborey Israel St., Netanya 42504, Israel.

 

(25)

 

 

 

First Bank of Israel Ltd. is an Israeli commercial bank. Its address is 9 Ehad Ha’am St, Shalom Tower, Tel-Aviv 65251, Israel.

 

(26)

 

 

 

Elbit Systems Ltd. is an Israeli public company whose shares are traded on the TASE and Nasdaq, its main fields of activity is the development and manufacturing of weapons systems and electronics for the military field. Its address is Science Industries Center, Haifa 31053, Israel.

 

(27)

 

 

 

The Aktiva Group is an international organization engaged, through its group companies, primarily in financial investments and services. Its principal offices’ address is Aktiva Holdings BV, Strawinskylaan 1001, Amsterdam, The Netherlands 1077XX.

 

(28)

 

 

 

Dover Medical Device and Science Ltd. is an Israeli private company, its main field of activity is import and marketing of medical and science equipment. Its address is 11 Hama’alot St., Herziliya 46583, Israel.

 

(29)

 

 

 

I. B. T. International Business Technology Ltd. is a private Israeli company, its main fields of activity are engineering and development. Its address is 10 Karlibach St., Tel-Aviv 67132, Israel.

 

(30)

 

 

 

Quantum Technologies Ltd. is an Israeli private company, its main field of activity is the import and marketing of medical equipment. Its address is 11 Hama’a lot St., Herziliya 46583, Israel.

 

(31)

 

 

 

The UKI Investment Group is an international investment group based in London, U.K., and is engaged primarily in holding investments mainly in companies that operate in the field of real estate. Its address is 54-56 Euston Street, London NW1 2ES, United Kingdom.

 

(32)

 

 

 

Taavura Holdings Ltd. is an Israeli company, engaged in road haulage and logistics and holds investments in Israeli companies that operate in various commercial and industrial activities. Its address is P.O.B. 320, Industrial Zone, Ramle 72102, Israel.

 

(33)

 

 

 

Scailex Corporation Ltd. is an Israeli public company whose shares are traded on the TASE and OTCBB, its main fields of activity is the management of its financial assets, locating business opportunities and holding the shares of Oil Refineries Ltd. Its address is 3 Azrieli Center, Triangular Tower, Floor 43 Tel Aviv 67023, Israel.

48


Directors and Executive Officers
of
IDB Development Corporation Ltd. (“IDBD”)

Unless otherwise indicated, all of IDBD directors, executive officers and other senior office holders are citizens of Israel and their address is 3 Azrieli Center, 45th Floor, The Triangular Tower, Tel-Aviv 67023, Israel.

 

 

 

 

 

 

 

Name & Address

 

Age

 

Position

 

Current Principal Occupation &
Material Positions in Past 5 Years

Nochi Danker

 

53

 

Chairman of the Board of Directors

 

Current principal occupation: Chairman and Chief Executive Officer of IDBH; Chairman of IDBD, DIC and CII; director of companies.
Material positions in past 5 years: Director of various companies in the IDB Group since May 2003; Chairman and Chief Executive Officer of various companies in the Ganden Group; a director, including Chairman of Credit Committee of Bank Hapoalim B.M. from November 1997 until May 2003; and a partner in the law office of Danker-Lusky. until 2004.

Irit Izakson
15 Great Matityahou Cohen Street,
Tel-Aviv 62268,
Israel

 

56

 

Director

 

Current principal occupation: Director of companies.
Material positions in past 5 years: Director of companies.

Refael Bisker

 

56

 

Director

 

Current principal occupation: Chairman of PBC, Co-Chairman of Shufersal Ltd.
Material positions in past 5 years: Director of various companies in the IDB Group.

Avraham Ben Joseph
87 Haim Levanon Street,
Tel Aviv 69345,
Israel

 

80

 

Director

 

Current principal occupation: Director of companies.
Material positions in past 5 years: Director of companies.

Zehava Dankner
64 Pinkas Street,
Tel Aviv 62157,
Israel

 

75

 

Director

 

Current principal occupation: Director of companies.
Material positions in past 5 years: Member of the executive committee of Beautiful Israel Council; Director of companies in the IDB Group.

Eliahu Cohen

 

75

 

Director & Chief Executive Officer

 

Current principal occupation: CEO of IDBD.
Material positions in past 5 years: Chief Executive Officer of IDBH from February 2003 until December 2003; a director of IDBH, IDBD, PBC and DIC; Chairman of CIEH; Chairman of Clal Medical Insurance and of affiliates of CIEH.

 

 

 

 

 

 

49


 

 

 

 

 

 

 

Name & Address

 

Age

 

Position

 

Current Principal Occupation &
Material Positions in Past 5 Years

Zvi Livnat

 

54

 

Deputy-Chairman of the Board of Directors

 

Current principal occupation: Executive Vice President of IDBH; Deputy- Chairman of IDBD and Co-Chief Executive Officer of CII.
Material positions in past 5 years: Director of companies in the IDB group, Taavura group and Avraham Livnat group. Vice President—Commerce of Taavura from 1979 until June 2003.

Shay Livnat
26 Shalva Street
Herzlia Pituach 46705
Israel

 

49

 

Director

 

Current principal occupation: President and founder of Zoe Holdings Ltd.
Material positions in past 5 years: Director of various companies in the IDB Group, Taavura group and Avraham Livnat group of companies.

Amos Malka
18 Nahal Soreq Street,
Modi’in 71700,
Israel

 

55

 

External Director

 

Current principal occupation: Chairman of Plasan Sasa Ltd., manufacture of amoured solutions.
Material positions in past 5 years: Chairman of Albar Mimunit Services Ltd. (34) from 2005 until 2007. Chief Executive Officer of the Elul Group Ltd. (35) from 2002 until 2006.

Dori Manor*
17 Kerem Hazeim Street,
Savion 56536,
Israel.

 

40

 

Director

 

Current principal occupation: Chief Executive Officer of companies in the automotive sector of the Lubinski group.
Material positions in past 5 years: Director of IDBH, IDBD and DIC since May 2003; director of various companies in the Lubinski group and in family companies.

Isaak Manor*
26 Hagderot Street,
Savion 56526,
Israel

 

66

 

Director

 

Current principal occupation: Chairman of companies in the automotive sector of the Lubinski group.
Material positions in past 5 years: Deputy chairman of IDBH and a director of IDBD and various companies in the IDB Group since May 2003; a director of Union Bank of Israel Ltd.; a director of various companies in the Lubinski group and in family companies.

50


 

 

 

 

 

 

 

Name & Address

 

Age

 

Position

 

Current Principal Occupation &
Material Positions in Past 5 Years

Professor Yoram Margalioth,
16 Ha’efroni Street,
Raanana 43724,

 

45

 

External Director

 

Current principal occupation: Senior lecturer (expert on tax laws) at the Faculty of Law in the Tel Aviv University.
Material positions in past 5 years: Advisor to the World bank in 2003. Vice President of the International Tax Program at Harvard University from 2002 to 2003.

Avraham Fischer

 

51

 

Deputy Chairman of the Board of Directors

 

Current principal occupation: Executive Vice President of IDBH, Deputy Chairman of IDBD, Co-Chief Executive Officer of ClI.
Material positions in past 5 years: Director of various companies in the IDB Group since May 2003; co-managing partner of Fischer, Behar, Chen, Well, Orion & Co. since 1982; Deputy Chairman of Ganden and a director of companies in the Ganden Group.

Jacob Schimmel
17 High Field Gardens,
London W11 9HD,
United Kingdom

 

45

 

Director

 

Current principal occupation: Director of UKI Investments.
Material positions in past 5 years: Director of various companies in the IDB Group.

Lior Hannes

 

44

 

Senior Executive Vice President

 

Current principal occupation: Senior Executive Vice President of IDBD, Chief Executive Officer of IDB Investments (UK) Ltd.
Material positions in past 5 years: Director of IDBH and CIEH and various other companies in the IDB Group and Ganden Group since 2003. Chairman of Clal Tourism until January 2007.

Ari Raved

 

 

 

Vice President

 

Current principal occupation: Vice President of IDBD.
Material positions in past 5 years: Vice President of IDBD; managerial positions at Bank Leumi Le-Israel Ltd.

Haim Gavrieli

 

37

 

Executive Vice President

 

Current principal occupation: Vice President of IDBD.
Material positions in past 5 years: Personal assistant to Chairman of the Board of Directors until 2005. Assistant to the Chairman of Ganden until 2003. Director of various other companies in the IDB Group and Ganden group of companies since 2003.

51


 

 

 

 

 

 

 

Name & Address

 

Age

 

Position

 

Current Principal Occupation &
Material Positions in Past 5 Years

Dr. Eyal Sogelnik

 

45

 

Executive Vice President & Chief Financial Officer

 

Current principal occupation: Executive Vice President & Chief Financial Officer of IDBD; Chief Financial Officer of IDBH.
Material positions in past 5 years: Director of corporations division of Israeli Securities Authority until 2005. Chief Accountant of the Israeli Securities Authority until 2003.

Haim Tabouch

 

38

 

Vice President & Comptroller

 

Current principal occupation: Vice President & Comptroller of IDBD; Comptroller of IDBH.
Material positions in past 5 years: Vice President & Comptroller, Director of Clal Tourism from 2007; Auditor at Somekh Chaiken until 2003.

Inbal Zion

 

38

 

Vice President and Corporate Secretary

 

Current principal occupation: Vice President and Corporate Secretary of IDBD; Corporate Secretary of IDBH.
Material positions in past 5 years: Attorney and partner of Raved, Magrisso, Benkel & Co., law firm until March 2005.

Ilan Amit

 

65

 

Internal Auditor

 

Current principal occupation: Internal Auditor of IDBD and IDBH.

 

 

 

 

 

 

Material positions in past 5 years: Internal Auditor of companies in the IDBD Group.


 

 

*

 

 

 

Dual citizen of Israel and France.

 

(34)

 

 

 

Albar Mimunit Services Ltd. is an Israeli private company, its main fields of activity are financing activities, leasing and management of a fleet of cars. Its address is 64 Mivza Kadesh St., Bnei Brak 51200, Israel.

 

(35)

 

 

 

Elul Group Ltd. is an Israeli private company, its main field of activity is providing comprehensive services of business development, marketing, sales, consulting, outsourcing management, technical and engineering after-sales support, program management and ILS—Integrated Logistic Services. Its address is 35 Shaul Hamelkh Ave., Beit America, Tel-Aviv 64927, Israel.

52


Directors and Executive Officers
of
IDB Holding Corporation Ltd. (“IDBH”)

Unless otherwise indicated, all of IDBH’s directors, executive officers and other senior office holders are citizens of Israel and their address is 3 Azrieli Center, 45th Floor, The Triangular Tower, Tel-Aviv 67023, Israel.

 

 

 

 

 

 

 

Name & Address

 

Age

 

Position

 

Current Principal Occupation &
Material Positions in Past 5 Years

Nochi Danker

 

53

 

Chairman of the Board of Directors & Chief Executive Officer

 

Current principal occupation: Chairman and Chief Executive Officer of IDBH; Chairman of IDBD, DIC and CII; director of companies
Material positions in past 5 years: Director of various companies in the IDB Group since May 2003; Chairman and CEO of various companies in the Ganden Group; a director, including Chairman of Credit Committee of Bank Hapoalim B.M. from November 1997 until May 2003; and a partner in the law office of Danker-Lusky. until 2004.

Refael Bisker

 

56

 

Director

 

Current principal occupation: Chairman of PBC; Co-Chairman of Shufersal Ltd.
Material positions in past 5 years: Director of various companies in the IDB Group.

Shaul Ben Zeev
Taavura Junction,
Ramle 72102,
Israel

 

61

 

Director

 

Current principal occupation: Chief Executive Officer of Avraham Livnat Ltd.
Material positions in past 5 years: Director of various companies in the IDB Group since 2003 as well as other companies.

Zehava Dankner
64 Pinkas Street,
Tel Aviv 62157,
Israel

 

75

 

Director

 

Current principal occupation: Director of companies.
Material positions in past 5 years: Member of the executive committee of Beautiful Israel Council; Director of companies in the IDB group.

Zvi Dvoresky
12 Harofeh Street
Ahuza, Haifa 34366

 

72

 

External Director

 

Current principal occupation: Chief Executive Officer of Beit Kranot Trust Ltd. (37)
Material positions in past 5 years: Chief Executive Officer of Beit Kranot Trust Ltd.

Lior Hannes

 

44

 

Director

 

Current principal occupation: Senior Executive Vice President of IDBD; Chief Executive Officer of IDB Investments (UK) Ltd.

 

 

 

 

 

 

53


 

 

 

 

 

 

 

Name & Address

 

Age

 

Position

 

Current Principal Occupation &
Material Positions in Past 5 Years

 

 

 

 

 

 

Material positions in past 5 years: Director of IDBH and CIEH and various other companies in the IDB Group and Ganden Group since 2003. Chairman of Clal Tourism until January 2007.

Eliahu Cohen

 

75

 

Director

 

Current principal occupation: Director and Chief Executive Officer of IDBD.
Material positions in past 5 years: Chief Executive Officer of IDBH from February 2003 until December 2003; a director of IDBH, IDBD, PBC and DIC; Chairman of CIEH until March 2008; Chairman of Clal Medical Insurance and of affiliates of CIEH.

Zvi Livnat

 

54

 

Director & Executive Vice President

 

Current principal occupation: Director & Executive Vice President of IDBH; Deputy-Chairman of IDBD and Co-Chief Executive Officer of CII.
Material positions in past 5 years: Director of companies in the IDB group, Taavura group and Avraham Livnat group. Vice President—Commerce of Taavura from 1979 until June 2003.

Shmuel Lahman
9A Kehillat Gitomer,
Tel Aviv, 69405

 

64

 

External Director

 

Current principal occupation: Information Technology consultant.
Material positions in past 5 years: Director of companies

Dori Manor*
17 Kerem Hazeim Street,
Savion 56536,
Israel

 

40

 

Director

 

Current principal occupation: CEO of companies in the automotive sector of the Lubinski group.
Material positions in past 5 years: a director of IDBH, IDBD and DIC since May 2003; director of various companies in the Lubinski group and in family companies.

Isaak Manor
26 Hagderot Street,
Savion 56526,
Israel

 

66

 

Director

 

Current principal occupation: Chairman of companies in the automotive sector of the Lubinski group.
Material positions in past 5 years: Deputy Chairman of IDBH and a director of IDBD and various companies in the IDB group since May 2003; a director of Union Bank of Israel Ltd.; a director of various companies in the Lubinski group and in family companies.

 

 

 

 

 

 

54


 

 

 

 

 

 

 

Name & Address

 

Age

 

Position

 

Current Principal Occupation &
Material Positions in Past 5 Years

Arie Mientkavich

 

65

 

Vice Chairman

 

Current principal occupation: Chairman of Elron, Deputy Chairman of Gazit Globe Ltd. and Chairman of Gazit Globe Israel (Development) Ltd., a real estate investment group.
Material positions in past 5 years: Deputy Chairman of IDBH since May 2006 and Chairman of Clal Tourism since January 2007. Chairman of Israel Discount Bank Ltd. and several subsidiaries from 1997 to 2006.

Meir Rosen
8 Openheimer Street,
Ramat Aviv,
Tel Aviv
Israel

 

77

 

Director

 

Current principal occupation: Attorney.
Material positions in past 5 years: Attorney.

Jacob Schimmel
17 High field gardens,
London W11 9HD,
United Kingdom

 

45

 

Director

 

Current principal occupation: Director of UKI Investments.
Material positions in past 5 years: director of various companies in the IDB Group.

Avraham Fischer

 

51

 

Executive Vice President

 

Current principal occupation: Executive Vice President of IDBH, Deputy Chairman of IDBD, Co-Chief Executive Officer of CII.
Material positions in past 5 years: Director of various companies in the IDB group since May 2003; co-managing partner of Fischer, Behar, Chen, Well, Orion & Co. since 1982; deputy chairman of Ganden and a director of companies in the Ganden Group.

Dr. Eyal Sogelnik

 

45

 

Chief Financial Officer

 

Current principal occupation: Chief Financial Officer of IDBH; Vice President & Chief Financial Officer of IDBD.
Material positions in past 5 years: Director of corporations division of Israeli Securities Authority until 2005. Chief Accountant of the Israeli Securities Authority until 2003.

Haim Tabouch

 

38

 

Comptroller

 

Current principal occupation: Comptroller of IDBH & Comptroller of IDBD.
Material positions in past 5 years: Vice President & Comptroller, Director of Clal Tourism Ltd. from 2007; Auditor at Somekh Chaiken until 2003.

 

 

 

 

 

 

55


 

 

 

 

 

 

 

Name & Address

 

Age

 

Position

 

Current Principal Occupation &
Material Positions in Past 5 Years

Ilan Amit

 

65

 

Internal Auditor

 

Current principal occupation: Internal Auditor of IDBH and IDBD.
Material positions in past 5 years: Internal Auditor of companies in the IDB Group.

 

*

 

 

 

Dual citizen of Israel and France.

 

(37)

 

 

 

Beit Kranot Trust Ltd. is an Israeli private company, whose main field of activity is investments. Its address is 16 Herzl St., Haifa 33121, Israel.

56


B. ELRON’S CONTROLLING SHAREHOLDERS

DIC and IDBH

DIC, an indirect majority owned subsidiary of IDBH owns 48.6% of Elron and has the ability, in effect, to elect the members of Elron’s board of directors and to significantly influence its business. Both DIC and IDBH are Israeli companies. DIC holds investments in various entities, operating primarily in the fields of communications, technologies, industries and commerce. IDBH is a holding company that, through DIC, holds investments in various entities, operating primarily in the fields of insurance, real estate, high-tech, electronics, communications, industries and commerce.

Each of DIC’s and IDBH’s respective shares are listed on the TASE.

The principal address of DIC and IDBH is 3 Azrieli Center, Triangular Tower, Tel Aviv 67023, Israel.

C. CONTROLLING PERSONS

IDBH is controlled as follows: (i) Ganden Holdings Ltd. (“Ganden”), a private Israeli company controlled by Nochi Dankner (who is also a director of Elron and the chairman of IDBH and DIC) and his sister Shelly Bergman. Ganden holds, directly and through a wholly-owned subsidiary, approximately 52.04% of the outstanding shares of IDBH; (ii) Shelly Bergman, who holds through a wholly-owned company approximately 4.23% of the outstanding shares of IDBH; (iii) Avraham Livnat Ltd. (“Livnat”), a private Israeli company controlled by Avraham Livnat (whose son, Zvi Livnat, is a director of IDBH and DIC and whose son, Shay Livnat, is a director of Elron). Livnat holds, directly and through a wholly-owned subsidiary approximately 12.36% of the outstanding shares of IDBH and (iv) Manor Holdings B.A. Ltd. (“Manor”), a private company controlled by Ruth Manor (whose husband, Isaac Manor, is the deputy chairman of IDBH and a director of DIC, and their son, Dori Manor, is a director of IDBH, DIC and Elron). Manor holds directly and through a majority-owned subsidiary 12.35% of the outstanding shares of IDBH.

Subsidiaries of Ganden, Livnat and Manor have entered into a shareholders agreement with respect to approximately 31.02%, 10.34% and 10.34%, respectively, of the outstanding shares of IDBH owned by them, constituting in the aggregate approximately 51.7% of the equity and voting power of IDBH for the purpose of maintaining and exercising control of IDBH as a group. The term of the shareholders agreement expires in May 2023. Their additional holdings in IDBH are not subject to the shareholders agreement.

57


The U.S. Depositary for the offer is:

AMERICAN STOCK TRANSFER
& TRUST COMPANY

 

 

 

 

 

By Hand/Overnight Courier:
American Stock Transfer & Trust Company
Operations Center
Attn: Reorganization Department
6201 15th Avenue
Brooklyn, New York 11219

 

By Facsimile
(to Eligible Institutions only)

718-234-5001
Confirm by Telephone:

Toll-free (877) 248-6417
(718) 921-8317

 

By Mail:
American Stock Transfer & Trust Company
Operations Center
Attn: Reorganization Department
P.O. Box 2042
New York, New York 10272-2042

The Israeli Depositary for the offer is:

Clal Finance Batucha Investment Management Ltd.

 

 

 

By Hand/Overnight Courier/Mail:
Clal Finance Batucha Investment
Management Ltd.
Rubinstein House
37 Menachem Begin Road
Tel Aviv 65220, Israel
Attn: Avi Avivi

 

By Facsimile Transmission:
+972-3-565-3533
Confirm by Telephone:

+972-3-565-3529/30

The Information Agent for the offer is:

MACKENZIE PARTNERS, INC.
105 Madison Avenue
New York, New York 10016
call collect 212-929-5500
or
toll free 800-322-2885
Email: proxy@mackenziepartners.com

Our Israeli legal counsel is:

GROSS, KLEINHENDLER, HODAK, HALEVY, GREENBERG & CO.
LAW OFFICES

One Azrieli Center
Round Building
Tel Aviv 67021, Israel
Tel: +972-3-607-4444
Fax: +972-3-607-4411
Attn: Eytan Greenberg, Adv.
Dr. Shachar Hadar, Adv.


EX-99.(A)(1)(B) 3 c53577_ex99a1b.htm 3B2 EDGAR HTML -- c53577_ex99a1b.htm

LETTER OF TRANSMITTAL
TO TENDER ORDINARY SHARES
of

GIVEN IMAGING LTD.

PURSUANT TO THE OFFER TO PURCHASE DATED MAY 16, 2008
by

ELRON ELECTRONIC INDUSTRIES LTD.

THE INITIAL OFFER PERIOD AND WITHDRAWAL RIGHTS WILL EXPIRE AT 10:00 A.M., NEW YORK TIME, AND 5:00 P.M., ISRAEL TIME, ON MONDAY, JUNE 16, 2008, UNLESS THE OFFER IS EXTENDED.

The U.S. Depositary for the offer is:

American Stock Transfer & Trust Company

 

 

 

 

 

By Hand/Overnight Courier:

 

By Facsimile
(to Eligible Institutions only):

 

By Mail:

American Stock Transfer & Trust Company
Operations Center
Attn: Reorganization Department
6201 15th Avenue
Brooklyn, New York 11219

 


(718) 234-5001
Confirm by Telephone:
Toll-free (877) 248-6417
(718) 921-8317

 

American Stock Transfer & Trust Company
Operations Center
Attn: Reorganization Department
P.O. Box 2042
New York, New York 10272-2042

DELIVERY OF THIS LETTER OF TRANSMITTAL TO AN ADDRESS OTHER THAN AS SET FORTH ABOVE WILL NOT CONSTITUTE VALID DELIVERY.

PLEASE READ THE INSTRUCTIONS ACCOMPANYING THIS LETTER OF TRANSMITTAL CAREFULLY BEFORE COMPLETING THIS LETTER OF TRANSMITTAL. IF APPLICABLE TO YOU, MAKE SURE YOU COMPLETE (1) THE DECLARATION OF STATUS FOR ISRAELI INCOME TAX PURPOSES (THE “DECLARATION FORM”) INCLUDED HEREIN TO PREVENT ISRAELI WITHHOLDING TAX OF UP TO 25% AND/OR (2) SUBSTITUTE FORM W-9 INCLUDED HEREIN OR THE APPROPRIATE IRS FORM W-8, AS APPLICABLE, TO PREVENT U.S. BACKUP WITHHOLDING TAX OF 28%, IN EACH CASE, ON ANY CASH PAYMENT PAYABLE TO YOU PURSUANT TO THE OFFER.

SUBJECT TO APPLICABLE LAW, THE OFFER IS NOT BEING MADE TO (NOR WILL TENDER OF SHARES BE ACCEPTED FROM OR ON BEHALF OF) HOLDERS IN ANY JURISDICTION IN WHICH THE MAKING OR THE ACCEPTANCE OF THE OFFER WOULD NOT BE IN COMPLIANCE WITH THE LAWS OF SUCH JURISDICTION.

 

 

 

 

 

Name(s) and Address(es) of Registered Holder(s)

 

DESCRIPTION OF SHARES TENDERED

 

   

Share Certificate
No(s)., if available*

 

Number of Shares
Represented by
Certificate**

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 TOTAL SHARES
 
F

 

 

 

*

 

 

 

Need not be completed by shareholders delivering ordinary shares of Given Imaging by book-entry transfer.

 

**

 

 

 

Unless otherwise indicated, it will be assumed that all shares evidenced by each certificate delivered to the U.S. Depositary are being tendered. See Instruction 4.


F Shareholders of Given Imaging must complete this Letter of Transmittal (i) if certificates evidencing shares are to be forwarded with this letter or (ii) unless an agent’s message (as defined in Section 3 of the Offer to Purchase, as referred to below) is utilized, if delivery of shares is to be made by book-entry transfer to an account maintained by American Stock Transfer & Trust Company, as depositary (the “U.S. Depositary”) at The Depository Trust Company (the “Book-Entry Transfer Facility” or “DTC”). Delivery of documents to DTC or any other party does not constitute delivery to the U.S. Depositary.

Shareholders whose certificates evidencing shares are not immediately available or who cannot deliver their certificates and all other documents required hereby to the U.S. Depositary prior to 10:00 a.m., New York time, or 5:00 p.m., Israel time, on the Initial Completion Date or Final Expiration Date (as defined in Section 1 of the Offer to Purchase), as applicable, or who cannot complete the procedure for delivery by book-entry transfer on a timely basis will not be able to tender their shares pursuant to guaranteed delivery procedure. See Instruction 2.

NOTE: SIGNATURES MUST BE PROVIDED BELOW

 

 

 

£

 

Check here if shares are being delivered by book-entry transfer to the U.S. Depositary’s account at The Depository Trust Company and complete the following:

 

 

Name of Tendering Institution:        

 

 

Account Number:        

 

 

Transaction Code Number:        

IMPORTANT: This Letter of Transmittal, properly completed and duly executed (together with any required signature guarantees (or, in the case of a book-entry transfer, an agent’s message) and certificates or confirmation of book-entry transfer and all other required documents) must be received by the U.S. Depositary prior to 10:00 a.m., New York time, or 5:00 p.m., Israel time, on the Initial Completion Date or Final Expiration Date, as applicable. Delivery of this Letter of Transmittal to an address other than as set forth above, will not constitute a valid delivery.

2


Ladies and Gentlemen:

The undersigned hereby tenders to Elron Electronics Industries Ltd. (the “Purchaser”), the above-described ordinary shares, par value NIS 0.05 per share (the “Shares”) of Given Imaging Ltd. (“Given Imaging”), pursuant to the Purchaser’s offer to purchase 5.0% of the issued and outstanding Shares at $16.54 per Share, net to the seller in cash, less any required withholding taxes and without interest, upon the terms of, and subject to the conditions to, the Offer to Purchase, dated May 16, 2008 (the “Offer to Purchase”) and this Letter of Transmittal (which, as amended from time to time, together constitute the “Offer”), receipt of which is hereby acknowledged.

Upon the terms of, and subject to the conditions to, the Offer (and if the Offer is extended or amended, the terms of any such extension or amendment), and subject to, and effective upon, acceptance for payment of Shares tendered herewith, in accordance with the terms of the Offer, the undersigned hereby sells, assigns and transfers to or upon the order of the Purchaser all right, title and interest in and to, and any and all claims in respect of or arising or having arisen as a result of the undersigned’s status as a holder of, all Shares that are being tendered hereby (and any and all non-cash dividends, distributions, rights, other Shares or other securities issued or issuable in respect thereof on or after May 16, 2008 (collectively, “Distributions”)) and irrevocably appoints the U.S. Depositary the true and lawful agent and attorney-in-fact of the undersigned with respect to the tendered Shares (and all Distributions), with full power of substitution (such power of attorney being deemed to be an irrevocable power coupled with an interest), to (1) deliver certificates evidencing the tendered Shares (and all Distributions), or transfer ownership of the tendered Shares (and all Distributions) on the account books maintained by The Depository Trust Company, together, in either case, with all accompanying evidences of transfer and authenticity, to or upon the order of the Purchaser, (2) present the tendered Shares (and all Distributions) for transfer on the books of Given Imaging, and (3) receive all benefits and otherwise exercise all rights of beneficial ownership of the tendered Shares (and all Distributions), all in accordance with the terms of the Offer.

By executing this Letter of Transmittal, the undersigned hereby irrevocably appoints the designees of the Purchaser as the attorney and proxy of the undersigned, each with full power of substitution, to the full extent of the undersigned’s rights with respect to the Shares tendered. This proxy and power of attorney is coupled with an interest in the tendered Shares, is irrevocable and is granted in consideration of, and is effective upon, the acceptance for payment of the tendered Shares by the Purchaser in accordance with other terms of the Offer. Acceptance for payment will revoke all other proxies and powers of attorney granted by the undersigned at any time with respect to the tendered Shares (and all shares and other securities issued in Distributions in respect of the tendered Shares), and no subsequent proxies, powers of attorney, consents or revocations may be given by the undersigned with respect thereto (and if given will not be deemed effective). The undersigned understands that, in order for Shares or Distributions to be deemed validly tendered, immediately upon the Purchaser’s acceptance of the tendered Shares for payment, the Purchaser must be able to exercise all rights, including voting rights, with respect to the tendered Shares (and any and all Distributions), including, without limitation, voting at any meeting of Given Imaging’s shareholders then scheduled.

The undersigned hereby represents and warrants that the undersigned has full power and authority to tender, sell, assign and transfer Shares tendered hereby and all Distributions, that when the tendered Shares are accepted for payment by the Purchaser, the Purchaser will acquire good and unencumbered title to such Shares and Distributions, free and clear of all liens, restrictions, charges and encumbrances, and that none of the tendered Shares and Distributions will be subject to any adverse claim. The undersigned, upon request, will execute and deliver all additional documents deemed by the U.S. Depositary or the Purchaser to be necessary or desirable to complete the sale, assignment and transfer of the tendered Shares and all Distributions. In addition, the undersigned will remit and transfer promptly to the U.S. Depositary for the account of the Purchaser all Distributions in respect of Shares tendered hereby, accompanied by appropriate documentation of transfer, and until receipt of transfer or appropriate assurance of receipt and transfer, the Purchaser will be entitled to all rights and privileges as owner of each such Distribution and may withhold the entire purchase price of the tendered Shares, or deduct from the purchase price, the amount or value of that Distribution as determined by the Purchaser in its sole discretion.

No authority herein conferred or agreed to be conferred will be affected by, and all such authority will survive, the death or incapacity of the undersigned. All obligations of the undersigned in this Letter of

3


Transmittal will be binding upon the heirs, personal representatives, successors and assigns of the undersigned. Except as stated in the Offer to Purchase, this tender is irrevocable. The undersigned understands that the valid tender of Shares pursuant to any one of the procedures described in Section 3 of the Offer to Purchase and in the Instructions to this Letter of Transmittal will constitute the undersigned’s acceptance of the terms of, and conditions to, the Offer. The Purchaser’s acceptance of the tendered Shares for payment will constitute a binding agreement between the undersigned and the Purchaser upon the terms of, and subject to the conditions to, the Offer (and if the Offer is extended or amended, the terms of, or conditions to, any such extension or amendment).

Unless otherwise indicated below in the box entitled “Special Payment Instructions,” please issue the check for the purchase price of all Shares purchased and return all certificates evidencing Shares not tendered or not accepted for payment in the name(s) of the registered holder(s) appearing above under “Description of Shares Tendered.” Similarly, unless otherwise indicated below in the box entitled “Special Delivery Instructions,” please mail the check for the purchase price of all Shares purchased and return all certificates evidencing Shares not tendered or not accepted for payment (and accompanying documents, as appropriate) to the address(es) of the registered holder(s) appearing above under “Description of Shares Tendered” on the reverse of this Letter of Transmittal. In the event that the boxes below entitled “Special Payment Instructions” and “Special Delivery Instructions” are both completed, please issue the check for the purchase price of all Shares purchased and return all certificates evidencing Shares not tendered or not accepted for payment in the name(s) of, and deliver such check and return such certificates (and any accompanying documents, as appropriate) to, the person(s) so indicated. Unless otherwise indicated below in the box entitled “Special Payment Instructions,” please credit any Shares tendered hereby and delivered by book-entry transfer that are not accepted for payment by crediting the account at The Depository Trust Company. The undersigned recognizes that the Purchaser has no obligation, pursuant to the Special Payment Instructions, to transfer any Shares from the name of the registered holder(s) if the Purchaser does not accept for payment any Shares tendered hereby.

4


IF ANY SHARE CERTIFICATES REPRESENTING SHARES THAT YOU OWN HAVE BEEN LOST, STOLEN OR DESTROYED, SEE INSTRUCTION 2.

SIGN HERE
(and complete a Substitute Form W-9 or the appropriate Form W-8 (as applicable), and a Declaration Form (Declaration of Status for Israeli Income Tax Purposes), as applicable. See “IMPORTANT TAX INFORMATION”.)

X  Dated:  , 2008     

(Must be signed by registered holder(s) exactly as name(s) appear(s) on certificates or on a security position listing by person(s) authorized to become registered holder(s) by certificates and documents transmitted herewith. If signature is by a trustee, executor, administrator, guardian, attorney-in-fact, officer of a corporation or other person acting in a fiduciary or representative capacity, please provide the following information and see Instruction 5.)

Name(s):  
     Please Print     

Capacity (full title):  

Address:  

 
     Please Include Zip Code     

Daytime Area Code and Telephone No:  

Taxpayer Identification or
Social Security No.:  
     (See Substitute Form W-9 below)     

Guarantee of Signature(s)
(See Instructions 1 and 5)

FOR USE BY FINANCIAL INSTITUTIONS ONLY.

Financial Institutions: Place Medallion Guarantee in Space Below


FOR USE BY U.S. DEPOSITARY/PURCHASER ONLY

 

 

 

By power-of-attorney from the Purchaser, the U.S. Depositary hereby sets its corporate seal to indicate acceptance of the tendered Shares by the Purchaser:
 

 

 

5


If you do not wish to have the check for the purchase price of the Shares and the certificate evidencing Shares not tendered or not purchased issued in the name of the record holder(s) of the Shares, please complete the “Special Payment Instructions” below. If the check for the purchase price of the tendered Shares and the certificate evidencing Shares not tendered or not purchased are to be registered in the name of anyone other than the registered holder or mailed to any person(s) other than the person(s) signing this Letter of Transmittal, the certificate(s) must be endorsed and signatures guaranteed.

 

SPECIAL PAYMENT INSTRUCTIONS
(See Instructions 1, 5, 6 and 7)

Fill in ONLY if check for the purchase price of the shares and the certificate evidencing shares not tendered or not purchased are to be issued in the name of someone other than the registered holder(s). Please Print.

Name:

 

(First, Middle & Last Name)

Address:

 

(Number and Street)

 

(City, State and Zip)

Tax Identification or Social Security Number (See Substitute Form W-9 below):  

 

If you wish to have the check delivered to someone other than the record holder(s) or to an address other than the address specified in “Description of Shares Tendered” please complete the “Special Delivery Instructions” below and the check will be mailed to the address(es) indicated.

 

SPECIAL DELIVERY INSTRUCTIONS
(See Instructions 1, 5, 6 and 7)

Fill in ONLY if check for the purchase price of shares purchased and certificates evidencing shares not tendered or not purchased are to be delivered to someone other than the undersigned or to the undersigned at an address other than that shown above. Please Print.

Deliver check(s) to:

Name:

 

(First, Middle & Last Name)

Address:

 

(Number and Street)

 

(City, State and Zip)

Tax Identification or Social Security Number (See Substitute Form W-9 below):  

 

6


TO BE COMPLETED BY ALL TENDERING SHAREHOLDERS

PAYER’S/ REQUESTER’S NAME: American Stock Trust & Transfer Company, as U.S. Depositary

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBSTITUTE
Form W-9

 

 

 

Part 1 – Please print or type

 

 

 

 

 

 

 

 

 

 

 

 

 

   

 

 

Name (as shown on your income tax return):

 

 

 

 

 

 

 

 

 

 

 

 

 

   

 

 

Business name, if different from the above:

 

 

 

 

 

 

 

 

 

 

 

 

 

   

 

 

Check the appropriate box:  £ Individual/Sole proprietor  £ Corporation  £ Partnership
£
Limited liability Company. Enter the tax classification (D=disregarded entity, C=corporation, P=partnership) ____

 

 

 

 

 

 

 

   

 

 

£ Other

 

 £ Exempt payee

 

 

 

 

 

 

 

 

 

 

 

 

 

   

 

 

Address (number, street, and apt. or suit no.):

 

 

 

 

 

 

 

 

 

 

 

 

 

   

 

 

City, State, and ZIP code:

 

 

 

 

 

 

 

 

 

 

 

 

 

   

 

 

Part 2 – Taxpayer Identification Number (TIN)

 

 Social Security Number:

   

 

 

Enter your TIN in the appropriate box. The TIN provided must match the name given on Part 1 to avoid backup withholding. For individuals, this is your social security number (SSN). For other entities, it is your employer identification number (EIN).

 

 
 Employer Identification Number:

 

 

 

 

 

 

 

 

 

 

 

 

 

   

 

 

CERTIFICATION:
Under penalties of perjury, I certify that: (1) The number shown on this form is my correct TIN, and (2) I am not subject to backup withholding because (a) I am exempt from backup withholding, or (b) I have not been notified by the IRS that I am subject to backup withholding as a result of a failure to report all interest or dividends, or (c) the IRS has notified me that I am no longer subject to backup withholding, and (3) I am a U.S. citizen or other U.S. person (including a U.S. resident alien).
Certification Instructions—You must cross out item (2) above if you have been notified by the IRS that you are subject to backup withholding because of underreporting interest or dividends on your tax return. However, if after being notified by the IRS that you were subject to backup withholding, you received another notification from the IRS that you were no longer subject to backup withholding, do not cross out item (2).
     Also see instructions in the enclosed Guidelines     
The Internal Revenue Service does not require your consent to any provision of this document other than the certifications required to avoid backup withholding.

 

 

 

 

 

 

 

 

 

 

 

 

 

   

 

 

Sign
Here

 

Signature of U.S. Person:

 

Date:

7


For assistance in completing this form, call the U.S. Depositary at (718) 921-8200 and also see Instruction 9 and the section entitled “Important Tax Information.”

 

NOTE:

 

 

 

FAILURE TO COMPLETE AND RETURN THIS SUBSTITUTE FORM W-9 MAY RESULT IN UNITED STATES BACKUP WITHHOLDING OF 28% OF ANY CASH PAYMENT (IF ANY) MADE TO YOU WITH RESPECT TO ORDINARY SHARES, NIS 0.05 PAR VALUE PER SHARE, OF GIVEN IMAGING SURRENDERED. PLEASE REVIEW THE ENCLOSED GUIDELINES FOR CERTIFICATION OF TAXPAYER IDENTIFICATION NUMBER ON SUBSTITUTE FORM W-9 FOR ADDITIONAL DETAILS.

 

NOTE:

 

 

 

IF YOU ARE ELIGIBLE FOR AN EXEMPTION FROM ISRAELI WITHHOLDING TAX, OR A REDUCED WITHHOLDING RATE, FAILURE TO COMPLETE AND RETURN THE ENCLOSED DECLARATION FORM MAY RESULT IN ISRAELI WITHHOLDING OF 25% OF ANY CASH PAYMENT (IF ANY) MADE TO YOU WITH RESPECT TO ORDINARY SHARES, NIS 0.05 PAR VALUE PER SHARE, OF GIVEN IMAGING SURRENDERED. PLEASE REVIEW THE ENCLOSED DECLARATION FORM AND THE INSTRUCTIONS TO THIS LETTER FOR ADDITIONAL DETAILS.

8


INSTRUCTIONS
Forming Part of the Terms and Conditions of the Offer

1. Guarantee of Signatures. All signatures on this Letter of Transmittal must be guaranteed by a firm which is a member of the Securities Transfer Agents Medallion Program, or by any other “eligible guarantor institution,” as such term is defined in Rule 17Ad-15 promulgated under the Securities Exchange Act of 1934, as amended (each of the foregoing being an “Eligible Institution”), unless (a) this Letter of Transmittal is signed by the registered holder(s) of shares (which term, for purposes of this document, will include any participant in The Depository Trust Company whose name appears on a security position listing as the owner of shares) tendered hereby and such holder(s) has (have) not completed the box entitled “Special Payment Instructions” or “Special Delivery Instructions” on the reverse of this Letter of Transmittal or (b) the shares are tendered for the account of an Eligible Institution. See Instruction 5.

2. Delivery of Letter of Transmittal and Certificates. This Letter of Transmittal is to be used (i) if certificates are to be forwarded with it, (ii) by Holders of Restricted Shares or (iii) if tenders are to be made pursuant to the procedures for tenders by book-entry transfer pursuant to the procedure set forth in Section 3 of the Offer to Purchase. Certificates evidencing all physically tendered shares, or a confirmation of a book-entry transfer into the U.S. Depositary’s account at The Depository Trust Company of all shares delivered by book-entry transfer, as well as a properly completed and duly executed Letter of Transmittal and any other documents required by this Letter of Transmittal, must be received by the U.S. Depositary at one of its addresses set forth below prior to 10:00 a.m., New York time, or 5:00 p.m., Israel time, on the Initial Completion Date or Final Expiration Date (as defined in Section 1 of the Offer to Purchase), as applicable. If certificates are forwarded to the U.S. Depositary in multiple deliveries, a properly completed and duly executed Letter of Transmittal must accompany each delivery.

Shareholders whose certificates are not immediately available, who cannot deliver their certificates and all other required documents to the U.S. Depositary prior to 10:00 a.m., New York time, or 5:00 p.m., Israel time, on the Initial Completion Date or Final Expiration Date, as applicable, or who cannot complete the procedure for delivery by book-entry transfer on a timely basis will not be able to tender their shares pursuant to guaranteed delivery procedure.

The method of delivery of this Letter of Transmittal, certificates and all other required documents, including delivery through The Depository Trust Company, is at the option and risk of the tendering shareholder, and the delivery will be deemed made only when actually received by the U.S. Depositary. If delivery is by mail, registered mail with return receipt requested, properly insured, is recommended. In all cases, sufficient time should be allowed to ensure timely delivery.

All questions as to the validity, form, eligibility (including time of receipt) and acceptance for payment of any tender of shares will be determined by the Purchaser, in its sole discretion. This determination will be final and binding on all parties. The Purchaser reserves the absolute right to reject any or all tenders that it determines not to be in proper form or the acceptance for payment of which may be unlawful. The Purchaser also reserves the absolute right, in its sole discretion, to waive any defect or irregularity in any tender of shares of any particular shareholder, whether or not similar defects or irregularities are waived in the case of other shareholders. A tender of shares will not have been made until all defects and irregularities have been cured or waived. None of the Purchaser, the Depositaries, the Information Agent, the Israeli legal counsel or any other person will be under any duty to give notification of any defects or irregularities in tenders of shares or incur any liability for failure to give any notification.

No alternative, conditional or contingent tenders will be accepted, and no fractional shares will be purchased. By execution of this Letter of Transmittal, all tendering shareholders waive any right to receive any notice of the acceptance of their shares for payment.

If any share certificate has been lost, destroyed or stolen, the shareholder should promptly notify the U.S. Depositary. The shareholder then will be instructed as to the steps that must be taken in order to replace the share certificate. This Letter of Transmittal and related documents cannot be processed until the procedures for replacing lost or destroyed share certificates have been followed.

IMPORTANT: IF YOU SUBMIT A LETTER OF TRANSMITTAL, BY WHICH YOU TENDER YOUR SHARES, AND THEREAFTER YOU DELIVER TO US A NOTICE OF OBJECTION WITH RESPECT TO THOSE SHARES, WE WILL DISREGARD YOUR LETTER OF TRANSMITTAL. SIMILARLY, IF

9


YOU SUBMIT TO US A NOTICE OF OBJECTION WITH RESPECT TO YOUR SHARES AND THEREAFTER YOU DELIVER TO US A LETTER OF TRANSMITTAL BY WHICH YOU TENDER THOSE SHARES, WE WILL DISREGARD YOUR NOTICE OF OBJECTION. IF YOU SUBMIT A LETTER OF TRANSMITTAL AND A NOTICE OF OBJECTION CONCURRENTLY WITH RESPECT TO THE SAME SHARES, THE NOTICE OF OBJECTION WILL BE DISREGARDED.

3. Inadequate Space. If the space provided on the reverse of this Letter of Transmittal under “Description of Shares Tendered” is inadequate, the certificate numbers, the number of shares evidenced by such certificates and the number of shares tendered should be listed on a separate signed schedule and attached to this Letter of Transmittal.

4. Partial Tenders (not applicable to shareholders who tender by book-entry transfer). If fewer than all shares evidenced by any certificate delivered to the U.S. Depositary with this Letter of Transmittal are to be tendered, fill in the number of shares that are to be tendered in the box entitled “Number of Shares Tendered.” In such cases, new certificate(s) evidencing the remainder of shares that were evidenced by the certificates delivered to the U.S. Depositary with this Letter of Transmittal will be sent to the person(s) signing this Letter of Transmittal, unless otherwise provided in the box entitled “Special Delivery Instructions” on the reverse of this Letter of Transmittal, as soon as practicable after the Initial Completion Date or Final Expiration Date, as applicable, or the termination of the offer. All shares evidenced by certificates delivered to the U.S. Depositary will be deemed to have been tendered unless otherwise indicated.

5. Signatures on Letter of Transmittal; Stock Powers and Endorsements. If this Letter of Transmittal is signed by the registered holder(s) of shares tendered hereby, the signature(s) must correspond with the name(s) as written on the face of the certificates evidencing the tendered shares without alteration, enlargement or any other change whatsoever.

If any tendered shares are held of record by two or more persons, all of those named persons must sign this Letter of Transmittal. If any tendered shares are registered in different names, it will be necessary to complete, sign and submit as many separate Letters of Transmittal as there are different registrations of those tendered shares.

If this Letter of Transmittal is signed by the registered holder(s) of tendered shares, no endorsements of certificates or separate stock powers are required, unless payment is to be made to, or certificates evidencing shares not tendered or not accepted for payment are to be issued in the name of, a person other than the registered holder(s). If the Letter of Transmittal is signed by a person other than the registered holder(s) of the certificate(s) evidencing shares tendered, the tendered certificate(s) must be endorsed or accompanied by appropriate stock powers, in either case signed exactly as the name(s) of the registered holder(s) appear(s) on the certificate(s). Signatures on the certificate(s) and stock powers must be guaranteed by an Eligible Institution.

If this Letter of Transmittal is signed by a person other than the registered holder(s) of tendered shares, the certificate(s) evidencing tendered shares must be endorsed or accompanied by appropriate stock powers, in either case signed exactly as the name(s) of the registered holder(s) appear(s) on such certificate(s). Signatures on such certificate(s) and stock powers must be guaranteed by an Eligible Institution.

If this Letter of Transmittal or any certificate or stock power is signed by a trustee, executor, administrator, guardian, attorney-in-fact, officer of a corporation or other person acting in a fiduciary or representative capacity, that person should so indicate when signing, and proper evidence satisfactory to the Purchaser of that person’s authority so to act must be submitted.

6. Share Transfer Taxes. The amount of any share transfer taxes (whether imposed on the registered holder(s), or such other person, or otherwise) payable on account of the transfer will be deducted from the purchase price of the tendered Shares purchased, unless evidence satisfactory to the Purchaser of the payment of the taxes, or that the transfer is not subject to tax, is submitted. The Purchaser will only be liable for share transfer taxes with respect to the sale and transfer of any Shares if such taxes are expressly imposed by applicable law on the Purchaser. Except as provided in this Instruction 6, it will not be necessary for transfer tax stamps to be affixed to the certificates evidencing tendered shares.

7. Special Payment and Delivery Instructions. If a check for the purchase price of any tendered shares is to be issued in the name of, and/or certificate(s) evidencing shares not tendered or not accepted for payment are to be issued in the name of and/or returned to, a person other than the person(s) signing this Letter of

10


Transmittal or if a check or any such certificate is to be sent to a person other than the signor of this Letter of Transmittal or to the person(s) signing this Letter of Transmittal but at an address other than that shown in the box entitled “Description of Shares Tendered” on the reverse of this Letter of Transmittal, the appropriate boxes on this Letter of Transmittal must be completed.

8. Questions and Requests for Assistance or Additional Copies. Questions and requests for assistance may be directed to the Information Agent at the address or telephone numbers set forth below. Additional copies of the Offer to Purchase, this Letter of Transmittal, the Guidelines for Certification of Taxpayer Identification Number on Substitute Form W-9, the Declaration Form (“Declaration of Status for Israeli Income Tax Purposes”), and other documents related to the Offer may be obtained from the Information Agent.

9. Substitute Form W-9, Appropriate Form W-8. Each holder surrendering certificates for payment, including a Holder of Restricted Shares, is required to provide the U.S. Depositary with a correct Taxpayer Identification Number (“TIN”) on Substitute Form W-9 (provided herein) and certify under penalties of perjury that such number is correct and indicate whether such holder is subject to backup withholding as provided in the certification instructions in part 2 of the form. Each holder must date and sign the Substitute W-9 in the spaces indicated. Failure to provide the information on the form may subject the holder to a 28% federal income tax withholding on the purchase price and to a $50 penalty imposed by the Internal Revenue Service. Each holder who is not a U.S. Holder (as defined in Section 5 of the Offer to Purchase) must complete and submit the applicable Form W-8 in order to be exempt from the 28% federal income tax backup withholding due on payments with respect to the Shares. The appropriate Form W-8 may be obtained from the Information Agent and the U.S. Depositary. Shareholders that are not U.S. Holders are urged to consult their tax advisor regarding the appropriate IRS Form W-8 in light of their particular circumstances.

10. Declaration Form (“Declaration of Status for Israeli Income Tax Purposes”). Each holder surrendering certificates for payment who is eligible for an exemption from Israeli withholding tax, or a reduced withholding rate, as described in Section 2 and Section 5 of the Offer to Purchase, is required to complete the Declaration Form included in this letter. See also “Important Tax Information” below and the instructions to the Declaration Form. Each holder must date and sign the Declaration Form in the spaces indicated. Failure to provide the information on the form may subject the holder to a 25% Israeli income tax withholding on the purchase price.

11. Additional Offer Period. Promptly following the Initial Completion Date (as defined in the Offer to Purchase), the Purchaser will publicly announce whether or not the conditions to the offer have been satisfied or, subject to applicable law, waived by the Purchaser. As required by Israeli law, if the conditions to the offer have been satisfied or, subject to applicable law, waived by the Purchaser and if, with respect to each share owned by a shareholder: (a) he or she has not yet responded to the offer, (b) he or she has notified the Purchaser of his or her objection to the Offer, or (c) he or she has tendered such share but have withdrawn his or her tender prior to 10:00 a.m., New York time, or 5:00 p.m., Israel time, on the Initial Completion Date, such shareholder will be afforded an additional four calendar-day period, until 10:00 a.m., New York time, or 5:00 p.m., Israel time, on the Final Expiration Date, during which period he or she may tender each such share. See Section 1 of the Offer to Purchase.

IMPORTANT TAX INFORMATION

United States

Under U.S. federal income tax law, a shareholder whose tendered shares are accepted for payment is generally required to provide the U.S. Depositary (as payer) with the shareholder’s correct TIN on Substitute Form W-9. If a shareholder is an individual, the TIN generally is the shareholder’s social security number. If the U.S. Depositary is not provided with the correct TIN, the shareholder may be subject to a penalty imposed by the Internal Revenue Service and payments that are made to the shareholder with respect to shares purchased pursuant to the offer may be subject to backup withholding of 28%. In addition, if a shareholder makes a false statement that results in no imposition of backup withholding, and there was no reasonable basis for making such statement, a penalty may also be imposed by the Internal Revenue Service.

Many shareholders (including, among others, corporations and certain foreign individuals) are not subject to these backup withholding and reporting requirements. In order for a foreign individual to qualify as an exempt recipient, that individual must submit a statement on the appropriate IRS Form W-8, signed under

11


penalties of perjury, attesting to that individual’s exempt status. Forms of those statements can be obtained from the Information Agent and the U.S. Depositary. See the enclosed “Guidelines for Certification of Taxpayer Identification Number on Substitute Form W-9” for additional instructions. A tax advisor should be consulted as to that shareholder’s qualification for exemption from backup withholding and the procedure for obtaining such exemption, including the appropriate IRS Form W-8 in light of such shareholder’s circumstances.

If backup withholding applies, the U.S. Depositary is required to withhold 28% of any payments made to the shareholder. Backup withholding is not an additional tax. Rather, the federal income tax liability of persons subject to backup withholding will be reduced by the amount of tax withheld. If withholding results in an overpayment of taxes, a refund may be obtained if the required information is furnished to the Internal Revenue Service.

Purpose of Substitute Form W-9. To prevent backup withholding on payments that are made to a shareholder with respect to shares purchased in the offer, each shareholder is required to notify the U.S. Depositary of such shareholder’s correct TIN by completing the Substitute Form W-9 certifying that (a) the TIN provided on Substitute Form W-9 is correct, and (b)(i) that shareholder has not been notified by the Internal Revenue Service that he, she or it is subject to backup withholding as a result of a failure to report all interest or dividends or (ii) the Internal Revenue Service has notified the shareholder that the shareholder is no longer subject to backup withholding.

What Number to Give the U.S. Depositary. Each shareholder, including Holder of Restricted Shares, is required to give the U.S. Depositary the TIN (e.g., social security number or employer identification number) of the record holder of tendered shares. If shares are in more than one name or are not in the name of the actual owner, consult the enclosed “Guidelines for Certification of Taxpayer Identification Number on Substitute Form W-9” for additional guidance on which number to report.

Israel

The gross proceeds payable to a tendering shareholder in the Offer will generally be subject to Israeli withholding tax at the rate of 20% or 25% of the shareholder’s gain on such sale. The Purchaser has obtained an approval from the Israeli Tax Authority, or the ITA, with respect to the withholding tax rates applicable to shareholders as a result of the purchase of shares in the Offer. The approval provides, among other things, that (1) tendering shareholders who acquired their Given Imaging shares after Given Imaging’s initial public offering on Nasdaq (i.e., after October 3, 2001) and who certify that they are NOT “residents of Israel” for purposes of the Israeli Income Tax Ordinance [New Version], 5721-1961, or the Ordinance, will not be subject to Israeli withholding tax, (2) eligible Israeli brokers or financial institutions holding the Given Imaging shares solely on behalf of a tendering shareholder will not be subject to Israeli withholding tax, (3) tendering shareholders who are Israeli residents and who acquired their Given Imaging shares prior to Given Imaging’s initial public offering on Nasdaq, will be subject to Israeli withholding tax at a rate of 25% of the amount received by the tendering shareholders pursuant to the offer, (4) tendering shareholders who are NOT “residents of Israel” and who acquired their Given Imaging shares prior to Given Imaging’s initial public offering on Nasdaq, will be subject to Israeli withholding tax at a rate of 25% of the amount received by the tendering shareholders unless the tendering shareholders submit an A-114 Form approving such shareholders’ residence in a country with whom Israel has a tax treaty which exempts Israeli capital gains tax, duly signed by the tendering shareholders and authorized by the tax authority of such country, in which event such tendering shareholders will not be subject to Israeli withholding tax. and (5) tendering shareholders who are not described in clauses (1),(2), (3) and (4) above, will be subject to Israeli withholding tax at a fixed rate of 8.61% of the amount received by the tendering shareholders pursuant to the offer. Notwithstanding the foregoing, should any tendering shareholder present the U.S. Depositary with a valid approval from the Israeli tax authority applying withholding tax at a lesser rate than those described above or otherwise granting a specific exemption from Israeli withholding tax, the U.S. Depositary will act in accordance with such approval. The Israeli withholding tax is not an additional tax. Rather, the Israeli income tax liability of shareholders subject to Israeli withholding will be reduced by the amount of Israeli tax withheld. If Israeli withholding tax results in an overpayment of Israeli taxes, the holder may apply to the ITA in order to obtain a refund. However, the Purchaser cannot assure you whether and when the ITA will grant such refund.

Purpose of Declaration Form. To prevent withholding of Israeli income tax on payments that are made to a shareholder with respect to shares purchased in the offer or to be eligible to a reduced withholding rate of

12


8.61%, as applicable, each shareholder is required to notify the U.S. Depositary of such shareholder’s exemption, or eligibility, by completing and signing the Declaration Form included in this letter below. The Declaration Form should be completed by holders of Shares, who: (i) certify that they are NOT “residents of Israel” for purposes of the Ordinance, and either (A) acquired their Shares after the Given Imaging ’s initial public offering on Nasdaq (i.e., after October 3, 2001), or (B) acquired their Shares prior to Given Imaging’s initial public offering on Nasdaq and submit an A-114 Form approving that they are residents of a country with which Israel has a tax treaty which exempts Israeli capital gains tax, duly signed by the tendering shareholder and authorized by the tax authority of such country or (ii) are banks, brokers or financial institutions that are “residents of Israel” within the meaning of that term in Section 1 of the Ordinance, holding Shares solely on behalf of beneficial shareholder(s), and are subject to the provisions of the Ordinance and regulations promulgated thereunder relating to the withholding of Israeli tax, including with respect to the cash payment (if any) made to them with respect to Shares tendered by such beneficial shareholder(s) and accepted for payment by the Purchaser pursuant to the Offer. Further, each “resident of Israel” who is eligible to a reduced withholding rate of 8.61% is also acquired to notify the U.S. Depositary of such shareholder’s eligibility, by completing and signing the Declaration Form included in this letter below.

The foregoing description of certain tax withholding is only a summary and is qualified by all the terms of, and conditions to, the Offer set forth in the Offer to Purchase. In this respect, you are urged to read Section 2 and Section 5 of the Offer to Purchase.

(Declaration Form Immediately Follows)

13


 

DECLARATION OF STATUS FOR ISRAELI INCOME TAX PURPOSES
u
Do not send this form to the IRS  u See separate instructions on the back cover of this form
u
Read this form together with the Offer to Purchase and Letter of Transmittal accompanying this form

 

PAYER’S NAME: American Stock Trust & Transfer Company, as U.S. Depositary

Who may use this form and why?

Holders of Shares who wish to tender their Shares pursuant to the Offer to Purchase and the related Letter of Transmittal (which, as amended from time to time, together constitute the “Offer”) may use this form if they tender their Shares in the Offer to the U.S. Depositary and they are either:

 

 

 

 

Non-Israeli Residents: If (A) (i) you certify that you are NOT a “resident of Israel” (as defined under Section 1 of the Israeli Income Tax Ordinance [New Version], 5721-1961 (the “Ordinance”) (See Instruction II)) for purposes of the Ordinance, or (ii) you are a corporation that is NOT a “resident of Israel”, and Israeli residents are NOT “controlling shareholders” (as defined under Section 68A of the Ordinance (See Instruction III)) of you, nor are Israeli residents the beneficiaries of, or are entitled to, 25.0% or more of your revenues or profits, whether directly or indirectly; and (B) (i) you acquired your Shares after Given Imaging’s initial public offering on Nasdaq (i.e., after October 3, 2001) or (ii) you acquired your Shares prior to Given Imaging’s initial public offering on Nasdaq and submit an A-114 Form approving that you are a resident of a country with which Israel has a tax treaty which exempts Israeli capital gains tax, duly signed by the tendering shareholder and authorized by the tax authority of such country, will not be subject to Israeli withholding tax, you may be eligible for a full exemption from Israeli withholding tax with respect to the gross proceeds payable to you (if any) pursuant to the Offer. By completing this form in a manner that would substantiate your eligibility for such exemption, you will allow the Purchaser, the U.S. Depositary, your broker or any other withholding agent, or their authorized representatives to exempt you from such Israeli withholding tax; or

 

 

 

 

A Bank, Broker or Financial Institution Resident in Israel: If you are a bank, broker or financial institution resident in Israel that (1) is holding the Shares solely on behalf of beneficial shareholder(s) (so-called “street name” holders), and (2) is subject to the provisions of the Ordinance and regulations promulgated thereunder relating to the withholding of Israeli tax, including with respect to the cash payment (if any) made by you to your beneficial shareholder(s) with respect to Shares tendered by them and accepted for payment by the Purchaser pursuant to the Offer (an “Eligible Israeli Broker”), you may be eligible for a full exemption from Israeli withholding tax with respect to the cash payment transmitted to you. By completing this form in a manner that would substantiate your eligibility for such exemption, you will allow the Purchaser, the U.S. Depositary, your broker or withholding agent, or their authorized representatives, to exempt you from such Israeli withholding tax. Consequently, even though the U.S. Depositary will not deduct any Israeli withholding tax from you, pursuant to the provisions of the Ordinance and regulations promulgated thereunder, to which you are subject, you may be required to withhold Israeli tax, as applicable, from the cash payment (if any) made by you to your beneficial shareholder(s). NOTE: AN ELIGIBLE ISRAELI BROKER MAY COMPLETE THIS FORM IF IT IS HOLDING THE SHARES SOLELY ON BEHALF OF HIS CLIENTS, THE BENEFICIAL SHAREHOLDERS; OR

 

 

 

 

Israeli Residents: If you are a “resident of Israel” (as defined under Section 1 of the Ordinance) and you acquired your Shares after Given Imaging’s initial public offering on Nasdaq (i.e., after October 3, 2001), you may be eligible for a reduced Israeli withholding tax rate with respect to the gross proceeds payable to you (if any) pursuant to the Offer. By completing this form in a manner that would substantiate your eligibility for such reduced rate, you will allow the Purchaser, the U.S. Depositary, your broker or any other withholding agent, or their authorized representative to withhold Israeli tax at a reduced rate.

 

 

 

 

 

PLEASE NOTE THAT IF YOU PROVIDE A DECLARATION FORM, YOU ALSO CONSENT TO THE PROVISION OF YOUR DECLARATION FORM TO THE PURCHASER AND/OR THE U.S. DEPOSITARY AND TO THE ISRAELI TAX AUTHORITY (THE “ITA”), IN CASE THE ITA SO REQUESTS, FOR PURPOSES OF AUDIT OR OTHERWISE.

To whom should you deliver this form?

 

 

 

 

If you wish to submit this form and (1) you hold your Shares directly, i.e., you are a registered holder, complete and sign this form and mail or deliver it to the U.S. Depositary (together with the Letter of

14


 

 

 

 

Transmittal by which you tender your Shares) at one of its addresses set forth below, or (2) you hold your Shares through a broker, dealer, commercial bank, financial institution, trust company or other nominee (a “Broker”), complete and sign this form and mail or deliver it (together with the instruction letter by which you tender your Shares) to such Broker.

Until when should I deliver this form?

 

 

 

 

As described above, this form should be delivered together with the Letter of Transmittal or instruction letter by which you tender your Shares prior to 10:00 a.m., New York time, or 5:00 p.m., Israel time, on the Initial Completion Date or Final Expiration Date (as such terms are defined in the Offer to Purchase), as applicable.

You are urged to consult your own tax advisors to determine the particular tax consequences to you should you tender your Shares in the Offer, including, without limitation, the effect of any state, local or foreign income and any other tax laws and whether or not you should use this form.

15


 

 

 

 

 

 

 

 

 

 

 

PART I

 

Identification and details of Shareholder (including Eligible Israeli Brokers) (see instructions)

 

1. Name:

 

2. Type of Shareholder (more than one box may be applicable):

 

(please print full name)

 

£

 

Corporation (or Limited

 

£

 

Bank

 

 

 

 

 

 

Liability Company)

 

£

 

Broker

 

 

 

 

£

 

Individual

 

£

 

Financial Institution

 

 

 

 

£

 

Trust

 

 

 

 

 

 

 

 

£

 

Partnership

 

 

 

 

 

 

 

 

£

 

Other:

 

 

 

 

 

 

 

 

 

 

_________________

 

 

 

 

3. For individuals only:

 

4. For all other Shareholders:

 

Date of birth: ______/_____/______
                       month / day / year

 

Country of incorporation or organization:

 

Country of residence:

 

Registration number of corporation (if applicable):

 

 

 

 

 

 

 

 

 

 

 

Country of citizenship:

 

 

 

 

 

 

 

 

 

Taxpayer Identification or
Social Security No (if applicable):

 

Country of residence:

 

5. Permanent Address (state, city, zip or postal code, street, house number, apartment number):

 

6. Mailing Address (if different from above):

 

7. Telephone Number (country code, area code and number):

 

8. I hold the Shares of Given Imaging (mark X in the appropriate place):

£ directly, as a Registered Holder

£ through a Broker. If you marked this box, please state the name of your Broker: _________________

 

 

 

 

 

 

PART II

 

Declaration by Non-Israeli Shareholders (see instructions) u Eligible Israeli Brokers should not complete this Part II

 

A. To be completed only by Individuals. I hereby declare that: (if the statement is correct, mark X in the following box) (note: only if the statements in (i) A.1 and (ii) A.2 or A.3 are marked as correct you may be eligible for an exemption from Israeli tax withholding)

 

A.1

 

£

 

I am NOT a “resident of Israel” within the meaning of that term in Section 1 of the Ordinance (See Instruction II), which means, among other things, that:

   

 

 

the State of Israel is neither my place of residence nor that of my family,

   

 

 

I was NOT present (nor am I planning to be present) in Israel for 183 days or more during this tax year,

   

 

 

I was NOT present in Israel for 30 days or more during this tax year, and

   

 

 

The total period of my presence in Israel during this tax year and the two previous tax years is less than 425 days or more in total; and

A.2

 

£

 

I acquired the Shares after the initial public offering of Given Imaging on Nasdaq (i.e., after October 3, 2001); or

A.3

 

£

 

I acquired the Shares prior to the initial public offering of Given Imaging on Nasdaq and am resident of a country with whom Israel has a tax treaty exempting Israeli capital gains tax and I have attached an A-114 Form duly signed by me and authorized by the tax authority of such country.

 

B. To be completed by Corporations. I hereby declare that: (if correct, mark X in the following box.) (note: only if the statements in (i) B.1 and (ii) B.2 and (iii) B.3 or B.4 are marked as correct you may be eligible for an exemption from Israeli tax withholding)

 

B.1

 

£

 

I am NOT a “resident of Israel” within the meaning of that term in Section 1 of the Ordinance (See Instruction II), which means, among other things, that:

   

 

 

I was NOT incorporated in Israel and was NOT registered with/formed at the Israeli Registrar of Companies, the Israeli Fellowship Societies Registrar or the Israeli Partnerships Registrar, and

   

 

 

the “control and management” of my business is NOT located in Israel; and

B.2

 

£

 

Israeli residents are NOT “controlling shareholders” of me within the meaning of that term in Section 68A of the Ordinance (See Instruction III), which means, among other things, that Israeli residents do NOT hold 25.0% or more of any “means of control” of me within the meaning of that term in Section 88 of the Ordinance; nor are Israeli residents the beneficiaries of, or are entitled to, 25.0% or more of my revenues or profits, whether directly or indirectly; and

B.3

 

£

 

I acquired the Shares after the initial public offering of Given Imaging on Nasdaq (i.e., after October 3, 2001); or

B.4

 

£

 

I acquired the Shares prior to the initial public offering of Given Imaging on Nasdaq and am resident of a country with whom Israel has a tax treaty exempting Israeli capital gains tax and I have attached an A-114 Form duly signed by me and authorized by the tax authority of such country.

 

C. To be completed by Partnerships. I hereby declare that: (if correct, mark X in the following box.) (note: only if the statements in (i) C.1 and (ii) C.2 and (iii) C.3 or C.4 are marked as correct you may be eligible for an exemption from Israeli tax withholding)

 

16


 

 

 

 

 

C.1 £ NO partner (in the partnership), whether an individual or a corporation, is a “resident of Israel” within the meaning of that term in Section 1 of the Ordinance (See Instruction II); and

C.2 £ NO partner (in the partnership) that is a corporation has Israeli residents that are “controlling shareholders” within the meaning of that term in Section 68A of the Ordinance (See Instruction III), nor are Israeli residents the beneficiaries of, or are entitled to, 25.0% or more of the revenues or profits of such partner, whether directly or indirectly; and

C.3 £ I acquired the Shares after the initial public offering of Given Imaging on Nasdaq (i.e., after October 3, 2001); or

C.4 £ I acquired the Shares prior to the initial public offering of Given Imaging on Nasdaq and am resident of a country with whom Israel has a tax treaty exempting Israeli capital gains tax and I have attached an A-114 Form duly signed by me and authorized by the tax authority of such country.

 

D. To be completed by Trusts. I hereby declare that: (if correct, mark X in the following box) (note: only if the statements in (i) D.1 and (ii) D.2 or D.3 are marked as correct you may be eligible for an exemption from Israeli tax withholding)

 

D.1 £ The Trust was NOT registered in Israel; the settlor of the Trust is NOT an Israeli Resident; and the beneficiaries of the Trust are NOT Israeli Residents; and

D.2 £ I acquired the Shares after the initial public offering of Given Imaging on Nasdaq (i.e., after October 3, 2001); or

D.3 £ I am resident of a country with whom Israel has a tax treaty exempting Israeli capital gains tax and I have attached an A-114 Form duly signed by me and authorized by the tax authority of such country.

 

PART III

 

Declaration by Israeli Bank, Broker or Financial Institution (see instructions) u

 

Non-Israeli Residents should not complete this Part III

 

 

(note: only if all statements are marked as correct you may be eligible for an exemption from Israeli tax withholding)

 

 

 

 

 

 

 

 

I hereby declare that: (if correct, mark X in the following box)

£

 

I am a bank, broker or financial institution that is a “resident of Israel” within the meaning of that term in Section 1 of the Ordinance (See Instruction II), I am holding the Shares solely on behalf of beneficial shareholder(s) and I am subject to the provisions of the Ordinance and the regulations promulgated thereunder relating to the withholding of Israeli tax, including with respect to the cash payment (if any) made by me to such beneficial shareholder(s) with respect to Shares tendered by them and accepted for payment by the Purchaser pursuant to the Offer.

 

PART IV

 

Declaration by Israeli Residents (see instructions) u

 

Eligible Israeli Brokers should
not complete this Part IV

 

I hereby declare that: (if correct, mark X in the following box) (note: only if all statements are marked as correct you may be eligible for a reduced Israeli tax withholding rate)

£

 

I am a “resident of Israel” within the meaning of the term in Section 1 of the Ordinance (See Instruction II).

£

 

I acquired the Shares after the initial public offering on Nasdaq (i.e., after October 3, 2001).

 

PART V

 

Certification. By signing this form, you also declared that:

 

 

You understood this form and completed it correctly and pursuant to the instructions.

 

You provided accurate, full and complete details in this form.

 

You are aware that providing false details constitutes a felony under the Ordinance.

 

You are aware that this form may be provided to the Israeli Tax Authority, in case the Israeli Tax Authority so requests, for purposes of audit or otherwise.

 

You understand that the instructions to this form constitute an integral part thereof.

SIGN HERE u          
 Signature of Shareholder  Date  Capacity in which acting
 (or individual authorized to sign on your behalf)

17


INSTRUCTIONS
Forming Part of the Declaration of Status for Israeli Income Tax Purposes

I. General Instructions. This Declaration Form (Declaration of Status for Israeli Income Tax Purposes), or this Form, should be completed by holders of Shares who wish to tender their Shares pursuant to the Offer, and who: (i) (A) certify that they are NOT “residents of Israel” for purposes of the Ordinance (See Instruction II below), or if the holder of Shares is a corporation then Israeli residents are NOT “controlling shareholders” of such corporation within the meaning of Section 68A of the Ordinance (See Instruction III below), and Israeli residents are NOT the beneficiaries of, or are entitled to, 25.0% or more of the revenues or profits of such corporation, whether directly or indirectly and (B) (i) acquired the Shares after Given Imaging’s initial public offering on Nasdaq (i.e., after October 3, 2001) or (ii) acquired the Shares prior to Given Imaging’s initial public offering on Nasdaq and are residents of a country with whom Israel has a tax treaty exempting Israeli capital gains tax and submits an A-114 Form duly signed by the tendering shareholder and authorized by the tax authority of such country, or (ii) are banks, brokers or financial institutions that are “residents of Israel” within the meaning of that term in Section 1 of the Ordinance, holding Shares solely on behalf of beneficial shareholder(s), and are subject to the provisions of the Ordinance and the regulations promulgated thereunder relating to the withholding of Israeli tax, including with respect to the cash payment (if any) made by them to such beneficial shareholder(s) with respect to Shares tendered by them and accepted for payment by the Purchaser pursuant to the Offer. Israeli residents who are NOT Eligible Israeli Brokers should not use this Form, unless they are eligible to a reduced withholding rate of 8.61%.

Part I (Identification and details of Shareholder). You should complete Item 1, 2 and 5 through 8 and either (i) Item 3, if you are an individual, or (ii) Item 4, if you are a corporation (or limited liability company), trust, partnership or other entity.

Part II (Declaration by Non-Israeli Shareholder). If you are NOT an Israeli resident, you should complete either Section A (for Individuals), Section B (for Corporations), Section C (for Partnerships) or Section D (for Trusts). If you do not mark a box you will be deemed to answer that the corresponding item is not correct with respect to you.

Part III (Declaration by Israeli Bank, Broker or Financial Institution). If you are an Eligible Israeli Broker, you should complete this Item.

Part IV (Declaration by Israeli Residents). If you are an Israeli resident and eligible to the reduced withholding rate of 8.61%, you should complete this item.

Part V (Certification). By signing this Form, you also make the statements in Part IV.

Inadequate Space. If the space provided on this Form is inadequate, you should insert such details on a separate signed schedule and attached to this Form.

Determination of Validity. All questions as to the validity, form or eligibility (including time of receipt) of this Form will be, subject to applicable law, determined by the Purchaser, in its sole discretion, which determination will be final and binding on all parties. None of the Purchaser, the U.S. Depositary, the Information Agent or any other person will be under any duty to give notification of any defects or irregularities in any Form or incur any liability for failure to give any such notification. For more details, see Section 5 of the Offer to Purchase.

Questions and Requests for Assistance or Additional Copies. Questions and requests for assistance may be directed to the Information Agent at the address or telephone numbers set forth on the back cover. Additional copies of this Form may be obtained from the Information Agent.

The method of delivery of this Form is at your option and risk, and the delivery will be deemed made only when actually received by your Broker or the U.S. Depositary. If delivery is by mail, registered mail with return receipt requested, is recommended. In all cases, sufficient time should be allowed to ensure timely delivery. No alternative, conditional or contingent Forms will be accepted.

II. Definition of Resident of Israel for Israeli Tax Purposes

Section 1 of the Ordinance defines a “resident of Israel” or a “resident” as follows:

 

“(A)

 

 

 

with respect to an individual – a person whose center of vital interests is in Israel; for this purpose the following provisions will apply:

18


 

(1)

 

 

 

in order to determine the center of vital interests of an individual, account will be taken of the individual’s family, economic and social connections, including, among others:

 

(a)

 

 

 

place of permanent home;

 

(b)

 

 

 

place of residential dwelling of the individual and the individual’s immediate family;

 

(c)

 

 

 

place of the individual’s regular or permanent occupation or the place of his permanent employment;

 

(d)

 

 

 

place of the individual’s active and substantial economic interests;

 

(e)

 

 

 

place of the individual’s activities in organizations, associations and other institutions;

 

(2)

 

 

 

the center of vital interests of an individual will be presumed to be in Israel:

 

(a)

 

 

 

if the individual was present in Israel for 183 days or more in the tax year;

 

(b)

 

 

 

if the individual was present in Israel for 30 days or more in the tax year, and the total period of the individual’s presence in Israel that tax year and the two previous tax years is 425 days or more.

For the purposes of this provision, “day” includes a part of a day.

 

(3)

 

 

 

the presumption in subparagraph (2) may be rebutted either by the individual or by the assessing officer;

 

(4)

 

 

 

. . .;

 

(B)

 

 

 

with respect to a body of persons – a body of persons which meets one of the following:

 

(1)

 

 

 

it was incorporated in Israel;

 

(2)

 

 

 

the “control and management” of its business is exercised in Israel.”

III. Definition of Controlling Shareholder for Purposes of Section 68A of the Ordinance

Section 68A of the Ordinance defines “controlling shareholders” as follows:

“Controlling shareholders” – shareholders that hold, directly or indirectly, alone, or together with another, or together with another Israeli resident, one or more of the means of control at a rate exceeding 25.0%.”

Section 88 of the Ordinance defines the terms “means of control” and “together with another” as follows:

 “Means of control” – in a corporation – each of the following:

 

(1)

 

 

 

the right to profits;

 

(2)

 

 

 

the right to appoint a director or a chief executive officer in the company, or equivalent position holders in another corporation;

 

(3)

 

 

 

a voting right in the general meeting of a company, or in an equivalent body in another corporation;

 

(4)

 

 

 

the right to a portion of the remainder of the assets after settlement of liabilities, upon wind-up;

 

(5)

 

 

 

the right to instruct anyone holding the rights listed in clauses (1) to (4) on the manner in which his right shall be executed; and all, whether by virtue of shares, rights to shares or other rights, or in any other manner, including by way of voting agreements or through a trust.”

“Together with another” – together with a relative, and together with he who is not a relative and they have between them a cooperation on a permanent basis under an agreement regarding material issues of a corporation, directly or indirectly.”

19


 

 

 

 

 

 

 

 

   

 

STATE OF ISRAEL MINISTRY OF FINANCE
INCOME TAX & REAL PROPERTY TAX COMMISSION

 

Form A/114

CLAIM FOR REDUCED RATE OF WITHHOLDING TAX/EXEMPTION
FROM WITHHOLDING TAX IN ISRAEL ON PAYMENTS TO A NON RESIDENT

This form shall be completed and signed by the recipient of income or by an authorized officer or representative of the recipient.

PART A: BASIS OF CLAIM FOR REDUCED RATE OF WITHHOLDING TAX/EXEMPTION FROM WITHHOLDING TAX

 

 

 

£

 

This claim is made pursuant to the Double Tax Convention between Israel and    ,
Article    .

£

 

This claim is not made pursuant to a Double Tax Convention.

PART B: GENERAL NATURE OF THE TRANSACTION AND INCOME

 

1.

 

 

 

Provide a brief description of the transaction involved:  

 

 

 

2.

 

 

 

The income received is from
£
 dividends  £  interest  £  royalties  £  other (specify)  

PART C: THE RECIPIENT

 

1.

 

 

 

Full name of the recipient:  

 

 

2.

 

 

 

Home address or registered office of recipient:  

 

 

 

3.

 

 

 

Identity number, social securiy number, or registration number of recipient:  

 

 

4.

 

 

 

Form of organization of recipient (Company, Partnership, etc.):  

Date of establishment:  

 

5.

 

 

 

Income Tax File number of recipient in place of residence:  

 

6.

 

 

 

Address of local income tax assessing office in recipient’s place of residence:  

 

 

7.

 

 

 

The recipient is a fiscal resident of   (country) since   (date).

 

8.

 

 

 

If the recipient is an individual, has he been present in Israel at any time in the past 3 years for any period exceeding one month?  £  No  £  Yes
If yes, specify the dates and duration of such stays in Israel:  

 

Page 1 of 3


Form A/114

 

9.

 

 

 

Does the recipient conduct business in Israel, directly or indirectly, in any manner?  £  No  £  Yes

Specify:  

 

 

10.

 

 

 

If the recipient is a corpration, is a majority of any class of shares in the recipient controlled, directly or indirectly, by persons who are not fiscal residents of the recipient’s state of residence?  £  No  £  Yes

Specify:  

 

PART D: THE PAYER

 

1.

 

 

 

Full name of the payer of the income:  

 

2.

 

 

 

Home address or registered office of payer:  

 

 

 

3.

 

 

 

Income Tax File number of payer in Israel:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

4.

 

 

 

Does any special relationship exist between the payer of the income and the recipient (for example: family, partnership, corporate control):  £  Yes  £  No

Specify:  

 

PART E: DETAILS OF INCOME RECEIVED

 

 

 

 

 

 

 

 

 

Date of
receipt

 

Place of receipt
(country, city,
bank account number)

 

Amount/Currency

 

Description of Income

 

Method of Calculation
(e.g. rate of interest,
percentage of sales, daily fee)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2.

 

 

 

Have similar items of income been the subject of previous claims?  £  No  £  Yes
If yes, specify dates, amounts and rates of withholding tax approved in the past two instances:  

 

 

 

3.

 

 

 

If the income is a dividend and the recipient claims an additional reduction of withholding tax due to direct ownership in the distributing company (pursuant to a Double Tax Convention), specify nature, extent and duration of such ownership:  

 

 

PART F: DOCUMENTATION

 

 

 

 

 

Attach all relevant documents pertaining to the transaction (for example, contracts and invoices).

List all documents attached:

 

1.

 

 

 

 

2.

 

 

 

 

3.

 

 

Page 2 of 3


Form A/114

PART G: DECLARATIONS OF THE RECIPIENT

 

1.

 

 

 

The recipient declares that:

 

a.

 

 

 

he is the beneficial owner of the income received;

 

b.

 

 

 

he does not carry on business in Israel through a permanent establishment there nor perform independent personal services from a fixed base in Israel, to which the income is effectively connected;

 

c.

 

 

 

all the information provided above is accurate and complete.

 

 

 

 

 

 

Date of Signature

 

Signature of Recipient
or authorized officer or representative

 

2.

 

 

 

Name of authorized officer or representative:  

 

3.

 

 

 

Capacity or Title of authorized officer or representative:  

 

4.

 

 

 

Address of authorized officer or representative:  

 

 

PART H: CERTIFICATION OF FOREIGN INCOME TAX AUTHORITY

This part shall be completed and signed by the Income Tax Authorities of the recipient’s place of residence

 

1.

 

 

 

I certify that:

 

a.

 

 

 

the recipient of the income is a fiscal resident of   (country);

 

b.

 

 

 

the recipient regularly reports his income as required, the most recent income tax return filed being for the year  ;

 

c.

 

 

 

the income concerned £ is   £ is not subject to income tax in   (the recipient’s country of residence).

 

 

 

 

 

 

 

 

 

 

Date of Signature

 

Signature

 

Official Stamp

 

2.

 

 

 

Name of Income Tax Authority official making this certification:  

 

3.

 

 

 

Position or Title of certifying official:  

 

4.

 

 

 

Address of certifying official:  

 

 

Page 3 of 3


This Letter of Transmittal and certificates and any other required documents should be sent or delivered by each shareholder or that shareholder’s broker, dealer, commercial bank, trust company or other nominee to the U.S. Depositary at one of its addresses set forth below.

The U.S. Depositary for the offer is:

 

 

 

 

 

By Hand/Overnight Courier:

 

By Facsimile
(to Eligible Institutions only):

 

By Mail:

American Stock Transfer & Trust Company
Operations Center
Attn: Reorganization Department
6201 15th Avenue
Brooklyn, New York 11219

 


(718) 234-5001
Confirm by Telephone:
Toll-free (877) 248-6417
(718) 921-8317

 

American Stock Transfer & Trust Company
Operations Center
Attn: Reorganization Department
P.O. Box 2042
New York, New York 10272-2042

Questions or requests for assistance may be directed to the Information Agent at its address and telephone number listed below. Additional copies of the Offer to Purchase and this Letter of Transmittal may be obtained from the Information Agent. A shareholder may also contact brokers, dealers, commercial banks or trust companies for assistance concerning the offer.

The Information Agent for the offer is:

105 Madison Avenue
New York, New York 10016
call collect (212) 929-5500
or
toll-free (800) 322-2885


GRAPHIC 4 c53583astlogo.jpg GRAPHIC begin 644 c53583astlogo.jpg M_]C_X``02D9)1@`!`0$`9`!D``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^HKJZM[* MUENKJ:."WA4O)+(P544=22>@J6O`_CWXWDN)X?!6C/.]QO$E]Y&[+97Y8<#[ MV0=Q&/[OO@`XWQ+\8D*;693]TY;DG']WKV%,CF\5P3L)YM;D"G_ M`)86SL&_%@,?D:Q;.YE\/:TMW,Q>]A9MT6,_-R"&8]_IGKUKT#1/'UGJ.$O8 M39-T\UF'E9]-QQ@^WZT`>7:_XK^)-IK]P;&UU"UTB")2]QJD)$*\9+&0(O2!DJ>HZUZM\;O$<&D M?#HH(H;HZC<10HC2':R@^86^4@E?D`.#_$*\F^!4!UWXB%;QR8;.W>^C@0!8 MA*&1`P084$!SR!0!V&@:G\5+C7M,BO([Z'3KVX&[[7:NTMO#G)WND:(#CU`^ MG:O6_$/B!-#_`+/01>=+=WL%MM!&8UDD5#(1UV@L!GU9?6MJN/UG1+G59YM1 METMS>V][;?8Q'=%2\$4DVWN.`#I&U?3$D>-M1M%>-MKJ9U!4 M^A&>#P?RJ*37]&ALQ>2ZM8):D,1,UR@3"L$;YLXX8A3Z$@=:YZ/PW=7>MSZC M>6D8CFU0RM%*X<_94MO+5."0-TP$F.G///%4M&\'W=DFGV6HV:7MHNGHDD12,MN+(0`"-R\]%:@#H;GQ-IMY9%-%U[1)+Z8*+;S;E9$9BQ4< M*V3DJP&#R01VK5;4+)6=6O+<,CJC@RKE6)``//!)8`#U(]:YA]`ODTW1%L;. M*WEDU5-1U6(RCC=ODD&X?>Q(R@>P'UJ!=,\0M_8T2V-O'%;:A<3W0DF&V9BL MQ24J,Y3>R.!][=C(7;F@#I;GQ%H=F&-UK.GP!0Q8RW2+@*^QBV,FJ7:6=O/,_[I&=&96.#\P.W``(W$@9&WF?[0G)NY'=6LKR^NY$?45>\L9 M2GF+OG6&)5)`8@`B0;^6Y(/?&6:#H.N^']6U&Y>S@OI;FV,RRK*%CCG>XGEE MC4-\W(DB&<`-Y0R1@4`=#HNNKJ6IZM:R3VX:"\>.VB#`2-$B(KL1GD"7S!D< M<`=0:Q?$?B3Q#I>L+:6L&E1V\UM=7,<]X[J(4@5`6D((`!:0=Q@8SS3_``+H M.K>&85L;\&Y$]N+FXO#/O(NV=C*@!YVG<&&.,[R>3S8UK2K_`%RYUVRFL_+M M+K2S8VET2A*-)O$K$;L@']SVY\L^U`&Y:ZYI-[%)+:ZI8W$<1<2/%<(P0IC= MD@\8W+GTW#UI\>JZ=-,L,6H6KRM*T*HLREC(HRR8S]X#DCJ!7+:KX=U"*^'] MD64)B6.PM@\D@&;>.2#_RQD8>@.?7D`V]3U@'R+;3;VT$LTC)),6$@MU$1DWD`^ACZD##@ M^F94\0Z/#;)]IUS32ZQ;WD^T(@("*Y;&[@;65NO`8'."#7(S^&M473ETV"[N M;LP:;=)Y=S,CW&R66$HC.\M%N-'B6V&^[DEFE$ MLOG@(D>\]VV%\XR%VJ`2`*`.CHHHH`XKXE^.[3P/X<:1K@QZE=*RV2"+S"S` MKN..!@!@>3^=?+NE:/K7C:]N=*\,:7F%0+IK43(,;<)N:1RNXY\>,_@A<>,_$]WK5UXI,/G$".!;'-Z9X+^,EI:Q>9=:JEO;[8X[*#58U M+*,<`^9M1<#&1DCCY2*\S_L37M4B:"WL!Y-K/)$((BHV/D;AURYZ#//3':OM MZN+O_A[!/-(/#NH:'#)JEQ9E M)8U=[=V#O&Q'3:.01DCID5Y-JEQ'=:IBN M,-8V%]*]"\&^&(?!WA6RT.";SQ;AM MTQ3:9&9BQ.,G'7UH`W'=8T9W8*B@EF8X`'J:\X\,^)M3N;R;5]0N91IR3?V; M+:O&R.]W+.GDLJ.JE4$,D>>F=Q)'&3W>M:3:Z]HMYI5Z'-M=Q-%)L;#`$=0? M6L"W\'7HUJQUR[UI9]6MPL4LJV@2.>$;N#'N(63YV_>*01TQ@D$`O:T9X=;T MC93RPYG='= M)'P')&#&21COQD#-;EUIL]SK=A?"Z1;>T63]P8LEW88W;MW&!QC'<^V,D>#E M@L_#-I9:C+:0Z&^X".-29_W31G.[(!.]B3@]3WY`!,?%:OJ4.GVMA).IK#_`.%AV>RWE&G7?DSV%MJ`?*?+%,VT M9&[/!(&!R3T!ZU1+Y>1&-^48>4/FR>2>.@ M#IO"8DAL[5;TQV-G?6]S!;)$,+#"BB.'.G6EOH MTT]Q>?:F*-<1J(UM^'R06!;<5&.G)YXJW/XKB2;3UMK.:XCO)XX`X95*L\9E M`P3DD(,GH.1R3G'-:1X6$>KG19=8>X%E9S)=,UN4><74YFE",&^3[J`D;B`W M!4X-;]_X3GN]834HM8FMY8KAYX%6)66/=`(B,'@],Y(R`<#;R2`)8^,FU*&: M2TT2^E\FXN+9U$D.5>+.1]_N0!D9'S#FM+2-<76+R]BAM)D@MA"5N'(VRF2, M28`SG*AESG^\*YRW\-_\(A_8DME<7-XUC8/IMO8I&!]IED97:1WYV`F/)/;' M4]#U6B:6FBZ)9Z;'*\PMHEC,CGER.K'TRBB@`HHHH`__9 ` end GRAPHIC 5 c53583logo.jpg GRAPHIC begin 644 c53583logo.jpg M_]C_X``02D9)1@`!`0$`9`!D``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P"C<:;I>GWW MB+X?ZO>QVNE:S<_VCHNI;@T*2GH&8<=,*?I[@U=&F>/X+^UENO`.DZOK=LJI M:ZX9058+@([?,`S#C!.#Q7-)X5\$^+9VT?2(=4\,>(RI-O::F2T-P1T7)^8$ M_P#Z@:FT[2-`M/`6J7NJ:KXCL+_2)?LEWH\%\%C>$/"G@S3[>[\:YY'TSGCOS57^W_A7_P!" M7JO_`(,F_P`:`+-WKNI:W\)+?7=2NGN=7TG74CM+V0YE5#'OVENI&X`\\\5J M^/88V_:,M+(K_HMUJ.G-/$.%D/R+DCUPS?F?6BB@"AXUNYSK7Q#U/S/]+34( 8-/60@$B!Q*K*,YQD1J,CW]:\JHHH`__9 ` end GRAPHIC 6 mackenzielogosmall.jpg GRAPHIC begin 644 mackenzielogosmall.jpg M_]C_X``02D9)1@`!`0$`9`!D``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^N<\>>(E M\*^"=4U?<%FBA*P9[RM\J?J0?H#71UXY\91-XGOD\+6LC".PTZYUF\V>J(PA M7\6_0@T`Q\P;W)Z2*#U_WJ]K\=>,['P/X;FU2Z*O, M?DMK?=@S2=A].Y/85\T_!CQ'8^%_&T^H:E<""T^P3+(Q/7&U@`.Y)4`#UK6\ MWM7T1KNMV/AS1;K5M2F$5K;)N8]SZ`#N2> M`/>O&?V;-,6+2M>UAQCS)DME8]%"*6;_`-#7\JL^+;R+XD6'B#43=*OAG1+. MY-C'OVF^NUB;][UR40_=]3^(H`ZOX6_$B?XAKJ[36,5I]B>,(J,6)5]V,Y[_ M`"]JF\:?%C0O!]V--"3:EJ[$`65KR5)^Z&/8G/09/M7AOPM\7/X-\)>--0A" MFY,5LEON&?WI,BKQZ#<3_P`!KKO@#X235;F^\::K_I-PL[16QER3YF`SR<]3 M\P`/^]0!VH\1_%6YLOMUOX-TJ",C,U],5\;?$[6Y/%WQ)U2>T#30PL8 M+<(,YCB!R1[$AF_&@#UKP3X@T_X9_"RQO-3>6[UK6F-S;V2$M-,&^6,#T7&# MGU8XR>NEI'A/5]4NI?'/Q'N61+:)I[?2(W(BMHU&[YQG!/'W?^^B>@\]^!FJ MQZC\3F;6`+J\DLV6SEEY,3)CY4'0#8&''0#`KTOX^>(_['\`'3HGVW&JRB$# MOY:_,Y_]!7_@5`&#X;^,/C?QA/'O!]E=_9@&D'VK9L!)"Y+$#/!Z>AJ[X MB^*_B_P=I,=QXB\,6-I=W$X2VMQ=A]\8!,C$JQQ@F,#_`'CZ<\O\*+GQGX7\ M,/-H_@9M2AU&3SQ=M=K&74#:H"GL/F/_``*I?&.C:K\5_&&LPP@12>'M+C7R M8SO4W9PSQ@]^=ZYXY04`>S^"/%EMXT\*VFM6ZB-I`4FA#;O*D'WES^H]B*HZ M]XTFTSQYH/A:QT];J?45::=VDV^1$O\`%C'/W7ZXY`]:\)^!/C%O#OBYM"O' MV66J,(\/QYH_#^2/Q-X_\`%?CB5E^QPO\`V98R-]T1H`7; M/H<*<_[1H`6[\7_%6UBFN)/`>GQ6T09V>34XAM0P'^>2*R_B-X[U+XE:_'X+\'H\]B9,/)&2/M+#J2> MT2]>>N,^E=E>:!IWP:^$NJW%FRR:O<0B%[PKAI)7^4!?15R2![9.30!GZ?\` M'2[U#Q==Z?'IEH=*M/.EEO`[9\F)22X'3+8P!ZL*J^&OBY\1/&+7(T#PIIEV M+;;YI\TQA=V<\\/ M:+92!L"-Y=Y(P.O+OAS:MXK3Q;XLN,XUV=[2T+?PVT8*+CZYY]UK3^,>OR:-X!N+ M2TYO]6<6%N@/)W_>Q_P'(SZD5OZ5:6G@7P#!!,P%OI5CNF=?XBJ[G8?4Y/XT M`?-?PF^&4WC36C=ZC%)'HMD_[\D;3,X_Y9#_`-F]!Z$BNR_:/U**"+P_X?MU M6..-7N#&O`51A$`'IP]9/PZL;_XCZGXBU7Q#KVK6VDVZM,X@O&1$=R6XSD;5 M4-QCCBL[X7>.7T+4]5O=>OKJ]T2VM3^[F_>LTA=1&L88\,1N.,C@$GI0!=\+ M7VH:SX,TGX<^&9-MUJ/F76LWB?=MX6;[N?78%S]0O"]8OK: MQN#=V>G3S1ROC:7K.E7/A:/Q)!"+6QEM?M1+HJLL87< M=V"1P/>N&_X7UX>_LI=4.A>(AIYF\C[4;6/R_,QG;GS.N.<4`?/_`(3T*^\1 M:%XBL].A>>ZA@BNQ"@RSJCX8`=SA\X[XKU'X,_$O0/#/AN?0/$%PVGSPW+R1 MO)$Q5@V,@X!(8$'K[5WFK?&?1-(MHKR71/$4NG3)&T5^E@%@DWKN`5W9*OC!8-X2U:ZT*U MOY(1;M%#J4D#10F5_E4)N`+,,EL8&`M>>?L]>&(]4\1:CK%U$'MK*W,"AAPS MR@@_^.!@?]X5]"^&_$6G^*M"M]8TN1GM9\XWC#*02"&'8Y%]:QW011L))5`+ASMGN99[VR6)-J_P@[^6)(`'&R MTZ'S93&1D.1D!1@C[Q%7_#'B:#Q193W,.GZC8F"=H)(;^#RG#CJ,`D=QWH`^ M;OCEX._X1GQD-6LXRECJA,RE>!',#\X]LY##ZGTK+U_QS)9>"['P/HC-!9P1 M_P#$QG7AKF9CEU'^P"2/?'IU^OV941G=@JJ,DDX`%?*VF>,6U;XI:EXNU*ZO MO[#TZ4WAAA<\HK!(4"D@9+%#CO@T`;?PS^(GP]\"Z&$-MJCZM./]+N3;(2Q_ MNK\_"#]>I]!7^-_CN#Q3I_AZRTP3K;31F^>*5<.224CR`3V#D>S#UKZ#\.>( M+#Q3H%IK.FNS6MRNY0X`9"#@JP!."""#S64?B'X;B@U:YNKW[+:Z7=&SFGF` M"R2@9*QX)+D>@&:`/E7Q:]O#KFG:!+(R66C0QV><$?B&,8_P"`FI_V@/$?]D^!H])BDVW&JR[" M`>?*3#-^NT?B:W?AQX$OO"4^MZCK%Y;WFJ:K<^=)+`&P!R*+749M;CM[&WC6);80%FVYRQW;NISZ=A0!QO@_X5:G<_#6.:_\7RZ3 MHVH)]NN[*.U4?)CAFE+`D%%4X(P,_GY]K]OX6_X1&>?2+\`I>+%963R9F>,! M@]Q+QC:>17VMCC&07(`]. MN(\K71:-X1?3_&^N^)[R[6YN=06.&!0FW[/"H^Y MUYR0I/N*`/`?A]XZN_AA<^)/#^JQL'5)##$02%NT!`'^ZV!S[+5&ST?5=3\? M:/H6FV<=]>:/&MS=13R;4DGW"6;>WL[",^NP5[5XM^$MOXC^(&G>)XIX8UB* M-=V[J?W[)RAR/7`4^PK!\.?"KQMX6U>_U73O$>DF]OL^?+-:LY.6W'&>F3R? MH*`,[XN>(O$MQX3T[PQJ=E:6^KZQ>`?9K.4R`PJ5V`D]VD(_[YK"\'Z?+\5! MIOA2Y$>DZ-X:C5I[9"6GN7)(9LX`'.<^F_OV]//PXU+4/BC9>+M:U*VN8;*% M$AMT1@=ZIU]`-Y9^/:L.7X0^(['QCKFN>'?$5MIHU,R@`1,7178.0.P^8?@. ME`'#>)3XL^$?Q(O=?M;97TR\D,4#,NZ&2#@K$3U5E50!T/RYY%?1VB:@-7T' M3]3$)@^VVT=QY1.2F]0V#[C.*X#Q%X5UC6=(27QWK%K<:3IW^D-9:5:,CW;J M"%W,S$Y).`J@9)[<5K?#_1?$$#7VN^);AH[S4`HATV-_W-C"N=J!1QG!Y^GJ M30!#\9/$?_"._#?4&C?;'^`/!A\3V5IH)D>#^TQ+ MJ-U*H&4AB#10?G*SDCN%'X>T?%#X;7_Q#DT](M9CLK6T#GRF@+[G;'S9!'8` M?G6IX)\!IX1O+^Y-TMPT\4%M#A-OE0Q)M"]>23EB>YH`\-^'WC^Z^&+^)/#V MKHVZ)9&MXSDA+I.-O^ZW'/\`LCUH^&V@-XN^(D.DZSNELM$CDN)H'Z23[QOW M#OF0\^JH!7K/BGX06/B3X@V'B5G[04/'.1C(`4^PJI=?"O6= M+\?W7BSPEKL%I->,[3V]Y"70[SN<9!Y!;G'&"!S0!ZHR*Z%&4,A&"I&01Z4Z MO.-;\#^-?$6GI'>>.6LY3*I>/3K4PQB/N`0VYFS@\G''2O0K:'[-:0P&627R 4T5/,E;+/@8RQ[D]Z`):***`/_]D_ ` end EX-99.(A)(1)(C) 7 c53577_ex99a1c.htm 3B2 EDGAR HTML -- c53577_ex99a1c.htm

OFFER TO PURCHASE FOR CASH
1,462,640 ORDINARY SHARES
of
GIVEN IMAGING LTD.
at
$16.54 NET PER SHARE
by
ELRON ELECTRONIC INDUSTRIES LTD.

THE INITIAL OFFER PERIOD AND WITHDRAWAL RIGHTS WILL EXPIRE AT 10:00 A.M., NEW YORK TIME, AND 5:00 P.M., ISRAEL TIME, ON MONDAY, JUNE 16, 2008, UNLESS THE OFFER IS EXTENDED.

     May 16, 2008

To Brokers, Dealers, Commercial Banks,
 Trust Companies and Other Nominees:

We have been appointed by Elron Electronic Industries Ltd. (the “Purchaser”), to act as Information Agent in connection with the Purchaser’s offer to purchase 5.0% of the issued and outstanding ordinary shares (currently 1,462,640 ordinary shares), par value NIS 0.05 per share (the “Shares”) of Given Imaging Ltd. (“Given Imaging”), at a price of $16.54 per Share, net to the seller in cash, less any required withholding taxes and without interest, upon the terms of, and subject to the conditions to, the Offer to Purchase, dated as of the date hereof (the “Offer to Purchase”) and the related Letter of Transmittal (which, as amended from time to time, together constitute the “Offer”) enclosed herewith. The description of the Offer in this letter is only a summary and is qualified by all the terms of, and conditions to, the Offer set forth in the Offer to Purchase and Letter of Transmittal.

Please furnish copies of the enclosed materials to those of your clients for whose accounts you hold shares registered in your name or in the name of your nominee.

We urge you to contact your clients as promptly as possible. Please note that the initial period of the Offer and withdrawal rights expire at 10:00 a.m., New York time, and 5:00 p.m., Israel time on Monday, June 16, 2008 (the “Initial Completion Date”), unless the Offer is extended.

Your attention is directed to the following:

1. The offer price is $16.54 per Share, net to the seller in cash, less any applicable withholding taxes and without interest.

2. The Purchaser has obtained an approval from the Israeli Tax Authority, or the ITA, with respect to the Israeli withholding tax rates applicable to shareholders as a result of the purchase of Shares pursuant to the Offer. Based on the approval, the U.S. Depositary, as the Purchaser’s agent, may be required to withhold 25% of the gross proceeds payable to shareholders who tender their Shares in the Offer, if your client fails to complete and return the enclosed Declaration of Status for Israeli Income Tax Purposes (the “Declaration Form”). Accordingly, if your client determines to tender his or her Shares in the Offer, you should also request instructions as to whether he or she is eligible for an exemption from Israeli withholding tax or a more favorable Israeli withholding tax rate by completing the Declaration Form.

In general, if your client(s) certifies, by completing the Declaration Form, that it is (1) NOT a “resident of Israel” for purposes of the Israeli Income Tax Ordinance [New Version], 5721-1961 (the “Ordinance”), and (i) acquired the Shares after Given Imaging’s initial public offering on Nasdaq (i.e., after October 3, 2001) or (ii) acquired the Shares prior to Given Imaging’s initial public offering on Nasdaq and submits an A-114 Form approving such shareholder’s residence in a country with whom Israel has a tax treaty which exempts Israeli capital gains tax, duly signed by the tendering shareholder and authorized by the tax authority of such country or (2) a bank, broker or financial institution resident in Israel that (i) is holding the Shares solely on behalf of its beneficial shareholder(s) (so-called “street name” holders), and (ii) is subject to the provisions of the Ordinance and regulations promulgated thereunder relating to the withholding of Israeli tax,


including with respect to the cash payment (if any) made by it to its beneficial shareholder(s) with respect to Shares tendered by them and accepted for payment by the Purchaser pursuant to the Offer (an “Eligible Israeli Broker”), your client is eligible for an exemption from Israeli withholding tax. See Section 2 and Section 5 of the Offer to Purchase. Further, if your client(s) certifies by completing the Declaration Form, that it is (1) a “resident of Israel” for purposes of the Ordinance and (2) acquired the Shares after Given Imaging’s initial public offering on Nasdaq (i.e., after October 3, 2001), your client(s) is eligible for a reduced Israeli withholding tax of 8.61% of the gross proceeds payable to your client(s) pursuant to the Offer.

With respect to U.S. backup withholding taxes, see Section 5 of the Offer to Purchase.

The Purchaser, with the assistance of the U.S. Depositary and the Depository Trust Company (“DTC”), has established a procedure whereby, if (and only as long as you may tender the Shares on behalf of your clients pursuant to the Offer) you tender Shares in the Offer through DTC, you will be able to classify, electronically, the Shares into the following categories: (1) Shares that are tendered on behalf of your clients who certified to you, by completing the Declaration Form, that they are eligible for an exemption from Israeli withholding tax (“Category One Shares”), (2) Shares that are tendered on behalf of your clients who are not eligible for such exemption and are subject to 25% withholding and (3) Shares that are tendered on behalf of your clients who are not eligible for such exemption and are subject to 8.61% withholding (“Category Three Shares”).

By so classifying, through such DTC system, you will be deemed to certify to the U.S. Depositary and to the Purchaser that based on a careful review of the Declaration Forms received by you, the Shares that you classified as Category One Shares, are held by non-Israeli residents meeting the requirements set forth in the Declaration Form and/or Eligible Israeli Broker(s) and the Shares that you classified as Category Three Shares, are held by Israeli residents meeting the requirements set forth in the Declaration Form. You are reminded that the ITA may have the right to audit the Declaration Forms, and if you refuse, Israeli withholding tax may be imposed. If you fail to meet the deadlines for tendering shares in the offer, make untimely classifications or make incorrect classifications, you will be required to claim any withholding tax directly from the ITA. NOTE: A CLIENT OF YOURS THAT IS AN ELIGIBLE ISRAELI BROKER MAY COMPLETE THE DECLARATION FORM IF IT IS HOLDING THE SHARES SOLELY ON BEHALF OF HIS CLIENTS, THE BENEFICIAL SHAREHOLDERS.

For further details, you may approach either us or DTC.

3. The Offer is being made for 5.0% of the issued and outstanding Shares (currently 1,462,640 issued and outstanding Shares).

4. Shareholders may tender their Shares or deliver Notices of Objection until 10:00 a.m., New York time, and 5:00 p.m., Israel Time, on the Initial Completion Date (unless the Offer is extended by the Purchaser). The period from the commencement of the Offer until the Initial Completion Date (as may be extended by the Purchaser) is referred to as the Initial Offer Period.

5. Promptly following the Initial Completion Date, the Purchaser will publicly announce whether or not the conditions to the Offer have been satisfied or, subject to applicable law, waived by the Purchaser. As required by Israeli law, if the conditions to the Offer are satisfied or, subject to applicable law, waived by the Purchaser and if, with respect to each Share held by a shareholder:

 

 

 

 

such shareholder has not yet responded to the Offer,

 

 

 

 

such shareholder has notified the Purchaser (through you) of his or her objection to the Offer, or

 

 

 

 

such shareholder has tendered such Share (through you) but have withdrawn (through you) such tender prior to the Initial Completion Date,

such shareholder will be afforded an additional four calendar-day period following the Initial Completion Date, during which he or she may tender such Share. This additional period is referred to as the Additional Offer Period. These dates will change if the Purchaser decides to extend the Initial Offer Period. Shareholders may withdraw any previously tendered Shares at any time prior to

2


the completion of the Initial Offer Period, but not during the Additional Offer Period. See “Introduction,” Section 1, Section 3 and Section 4 of the Offer to Purchase.

If, with respect to all or any portion of his or her Shares, a shareholder objects to the Offer during the Initial Offer Period and the conditions to the Offer have been satisfied or, subject to applicable law, waived by the Purchaser, such shareholder may tender such Shares during the Additional Offer Period.

6. Conditions to the Offer include, among other things, that:

 

 

 

 

prior to 10:00 a.m., New York time, or 5:00 p.m., Israel time, on the Initial Completion Date, there shall have been validly tendered and not properly withdrawn Shares representing at least 5.0% of the issued and outstanding shares of Given Imaging on the Initial Completion Date (currently, at least 1,462,640 Shares); and

 

 

 

 

as required by Israeli law, at 10:00 a.m., New York time, and 5:00 p.m., Israel time, on the Initial Completion Date, the aggregate number of Shares (excluding the Shares held by the Purchaser, certain of its affiliates and certain of Given Imaging’s affiliates) validly tendered and not properly withdrawn must be greater than the number of Shares represented by Notices of Objection to the Offer.

The Offer is not conditioned on the availability of financing or the approval of the board of directors of Given Imaging. Please see Section 11 of the Offer to Purchase, which sets forth in full the conditions to the Offer and specifies those conditions to the Offer that are waiveable by the Purchaser.

7. If more than 5.0% of the issued and outstanding Shares are validly tendered and not properly withdrawn prior to the expiration of the Additional Offer Period (the “Final Expiration Date”), the Purchaser will purchase no more than 5.0% of the issued and outstanding Shares on a pro rata basis from all tendering shareholders (currently 1,462,640 Shares). In these circumstances, the number of Shares that the Purchaser will purchase from each tendering shareholder will be based on the total number of Shares validly tendered and not properly withdrawn by all shareholders prior to the Final Expiration Date.

8. Promptly following the Final Expiration Date, the Purchaser will announce the results of the Offer and the proration factor, if any. If the Purchaser is unable to promptly determine the final proration results, the Purchaser will announce the preliminary results. Shares accepted for payment pursuant to the Offer will be paid promptly following the calculation of the final proration factor.

Explanation of Notice of Objection. Under Israeli law, the shareholders of Given Imaging may respond to the Offer by accepting the Offer and tendering all or any portion of their Shares in accordance with the Offer to Purchase or by notifying the Purchaser of their objection to the Offer by executing and delivering Notices of Objection. Alternatively, they may simply not respond to the Offer and not tender their Shares. It is a condition to the Offer that, at 10:00 a.m., New York time, and 5:00 p.m., Israel time, on the Initial Completion Date, the aggregate number of Shares tendered in the Offer is greater than the number of shares represented by Notices of Objection. If this and the other conditions to the Offer have been satisfied or, subject to applicable law, waived by the Purchaser, shareholders will be afforded an additional four calendar days to tender their Shares in the Offer, but Notices of Objection will no longer be accepted. See Section 3 of the Offer to Purchase.

IMPORTANT: IF A SHAREHOLDER SUBMITS A NOTICE OF OBJECTION WITH RESPECT TO HIS OR HER SHARES AND THEREAFTER, DELIVERS TO YOU A LETTER OF TRANSMITTAL BY WHICH HE OR SHE TENDERS THOSE SHARES, PLEASE DISREGARD THE NOTICE OF OBJECTION. SIMILARLY, IF A SHAREHOLDER SUBMITS TO YOU A LETTER OF TRANSMITTAL BY WHICH HE OR SHE TENDERS HIS OR HER SHARES AND THEREAFTER, HE OR SHE DELIVERS TO YOU A NOTICE OF OBJECTION WITH RESPECT TO THOSE SHARES, PLEASE DISREGARD THE LETTER OF TRANSMITTAL. IF A SHAREHOLDER SUBMITS A LETTER OF TRANSMITTAL AND A NOTICE OF OBJECTION CONCURRENTLY WITH RESPECT TO THE SAME SHARES, PLEASE DISREGARD THE NOTICE OF OBJECTION.

3


Enclosed for your information and for forwarding to your clients for whom you hold Shares registered in your name or in the name of your nominee, are copies of the following documents:

1. Offer to Purchase;

2. Letter of Transmittal for your use in accepting the Offer and tendering Shares and for the information of your clients;

3. A letter which may be sent to your clients for whose accounts you hold Shares registered in your name or in the name of your nominee, with space provided for obtaining the clients’ instructions with regard to the Offer;

4. Notice of Objection for your use in objecting to the Offer on behalf of your clients;

5. Declaration Form, including Form A114;

6. Guidelines for Certification of Taxpayer Identification Number on Substitute Form W-9; and

7. Return envelope addressed to American Stock Transfer & Trust Company, as U.S. Depositary.

In all cases, payment for shares accepted for payment pursuant to the Offer will be made only after timely receipt by the Depositary of (1) certificates evidencing the Shares (or a confirmation of a book-entry transfer of the shares into the U.S. Depositary’s account at the DTC), (2) the Letter of Transmittal properly completed and duly executed with any required signature guarantees or, in the case of a book-entry transfer, an agent’s message (as described in the Offer to Purchase) and (3) any other required documents. Tender of shares through guaranteed delivery procedures is not allowed.

The Purchaser will not pay any fees or commissions to any broker, dealer or other person in connection with the solicitation of tenders of shares pursuant to the Offer (other than to the U.S. and Israeli Depositaries, Information Agent and its Israeli counsel). However, the Purchaser will, upon request, reimburse you for customary and reasonable mailing and handling expenses incurred by you in forwarding any of the enclosed materials to your clients. The Purchaser will NOT pay or cause to be paid any stock transfer taxes payable with respect to the transfer of shares to it, except as otherwise provided in Instruction 6 of the Letter of Transmittal.

Any inquiries you may have with respect to the Offer should be addressed to the undersigned at our address and telephone numbers set forth on the back cover page of the Offer to Purchase.

Additional copies of the enclosed material may be obtained from us, at the address and telephone number set forth on the back cover page of the Offer to Purchase.

Very truly yours,

ENCLOSURES.

Nothing contained in this letter or in the enclosed documents shall constitute you or any other person as the agent of the Purchaser, the Information Agent or the U.S. Depositary, or of any affiliate of any of them, or authorize you or any other person to use any document or to make any statement on behalf of any of them in connection with the Offer other than the enclosed documents and the statements contained therein.

4


EX-99.(A)(1)(D) 8 c53577_ex99a1d.htm 3B2 EDGAR HTML -- c53577_ex99a1d.htm

OFFER TO PURCHASE FOR CASH
1,462,640 ORDINARY SHARES
of
GIVEN IMAGING LTD.
at
$16.54 NET PER SHARE
by
ELRON ELECTRONIC INDUSTRIES LTD.

THE INITIAL OFFER PERIOD AND WITHDRAWAL RIGHTS WILL EXPIRE AT 10:00 A.M., NEW YORK TIME, AND 5:00 P.M., ISRAEL TIME, ON MONDAY, JUNE 16, 2008, UNLESS THE OFFER IS EXTENDED.

May 16, 2008

To Our Clients:

Enclosed for your consideration are the Offer to Purchase, dated as of the date hereof (the “Offer to Purchase”), and the related Letter of Transmittal, which as amended from time to time, together constitute the “Offer”, in connection with the tender offer of Elron Electronic Industries Ltd. (the “Purchaser”), to purchase 5.0% of the issued and outstanding ordinary shares, par value NIS 0.05 per share (the “Shares”) of Given Imaging Ltd. (“Given Imaging”), at a price of $16.54 per Share less any applicable withholding taxes, and without interest, net to the seller in cash, upon the terms of, and subject to the conditions to, the Offer. The description of the Offer in this letter is only a summary and is qualified by all the terms of, and conditions to, the Offer set forth in the Offer to Purchase and Letter of Transmittal.

We are (or our nominee is) the holder of record of Shares held by us for your account. A tender of your Shares or an objection to the completion of the Offer can be made only by us as the holder of record of the Shares and only pursuant to your instructions. The enclosed Letter of Transmittal is furnished to you for your information only and cannot be used by you to tender Shares held by us for your account.

Please instruct us as to whether you wish us to either (1) tender on your behalf any or all of the Shares held by us for your account, upon the terms of, and subject to the conditions to, the Offer or (2) notify the Purchaser of your objection to the Offer with respect to any or all of the Shares held by us for your account.

If you determine to tender your Shares in the Offer, we also request instructions as to whether you are eligible for an exemption from Israeli withholding tax or a reduced Israeli withholding tax rate by completing the enclosed Declaration of Status for Israeli Income Tax Purposes (the “Declaration Form”). In this respect, as more fully described in the Offer to Purchase, pursuant to Israeli tax law, the Purchaser will withhold 25%, unless you are either eligible for a full exemption or a more favorable Israeli withholding tax rate and complete and submit to us the Declaration Form together with your tender instructions. We are (or our nominee is) the holder of record of Shares held by us for your account and therefore, you may submit the Declaration Form only to us. You are urged to consult your tax advisors regarding the application of Israeli income and withholding taxes (including eligibility for any withholding tax reduction or exemption, and the refund procedure). See Section 5 of the Offer to Purchase, which also sets forth important information with respect to U.S. backup withholding taxes.

Your attention is directed to the following:

1. The offer price is $16.54 per Share less any applicable withholding taxes and without interest, net to you in cash.

2. The Offer is being made for 5.0% of the issued and outstanding Shares (currently 1,462,640 Shares).

3. Shareholders may tender their Shares or deliver Notices of Objection until 10:00 a.m., New York time, and 5:00 p.m., Israel time, on Monday, June 16, 2008 (the “Initial Completion Date”), unless the Offer is extended. The period from the commencement of the Offer until the Initial Completion Date (as may be extended by the Purchaser) is referred to as the Initial Offer Period.


4. Promptly following the Initial Completion Date, the Purchaser will publicly announce whether or not the conditions to the Offer have been satisfied or, subject to applicable law, waived by the Purchaser. As required by Israeli law, if the conditions to the Offer are satisfied or, subject to applicable law, waived by the Purchaser, then if with respect to each Share held by us for your account:

 

u

 

 

 

we have not yet responded to the Offer,

 

u

 

 

 

we have notified the Purchaser of your objection to the Offer, or

 

u

 

 

 

we have tendered such Share on your behalf but have withdrawn such tender prior to the Initial Completion Date,

you will be afforded an additional four calendar-day period following the Initial Completion Date, during which you may instruct us to tender such Share on your behalf. This additional period is referred to as the Additional Offer Period. These dates will change if the Purchaser decides to extend the Initial Offer Period. You may withdraw any previously tendered Shares at any time prior to the completion of the Initial Offer Period, but not during the Additional Offer Period. See “Introduction,” Section 1, Section 3 and Section 4 of the Offer to Purchase.

If, with respect to all or any portion of your Shares, we object on your behalf to the Offer during the Initial Offer Period and the conditions to the Offer have been satisfied or, subject to applicable law, waived by the Purchaser, you may instruct us to tender such Shares on your behalf during the Additional Offer Period.

5. Conditions to the Offer include, among other things, that:

 

 

 

 

prior to 10:00 a.m., New York time, or 5:00 p.m., Israel time, on the Initial Completion Date, there shall have been validly tendered and not properly withdrawn Shares representing at least 5.0% of the issued and outstanding shares of Given Imaging on the Initial Completion Date (currently, at least 1,462,640 Shares); and

 

 

 

 

as required by Israeli law, at 10:00 a.m., New York time, and 5:00 p.m., Israel time, on the Initial Completion Date, the aggregate number of Shares (excluding the Shares held by the Purchaser, certain of its affiliates and certain of Given Imaging’s affiliates) validly tendered and not properly withdrawn must be greater than the number of Shares represented by Notices of Objection to the Offer.

The Offer is not conditioned on the availability of financing or the approval of the board of directors of Given Imaging. Please see Section 11 of the Offer to Purchase, which sets forth in full the conditions to the Offer and specifies those conditions to the Offer that are waiveable by the Purchaser.

6. If more than 5.0% of the issued and outstanding Shares are validly tendered and not properly withdrawn prior to the expiration of the Additional Offer Period (the “Final Expiration Date”), the Purchaser will purchase no more than 5.0% of the issued and outstanding Shares on a pro rata basis from all tendering shareholders (currently 1,462,640 Shares). In these circumstances, the number of Shares that the Purchaser will purchase from each tendering shareholder will be based on the total number of Shares validly tendered and not properly withdrawn by all shareholders prior to the Final Expiration Date. You should consult with your broker or other financial or tax advisors on the possibility of designating the priority in which your Shares will be purchased in the event of proration.

7. Promptly following the Final Expiration Date, the Purchaser will announce the results of the Offer and the proration factor, if any. If the Purchaser is unable to promptly determine the final proration results, the Purchaser will announce the preliminary results. Shares accepted for payment pursuant to the Offer will be paid promptly following the calculation of the final proration factor.

8. Tendering shareholders will generally not be obligated to pay brokerage fees, service fees or commissions with respect to the purchase of Shares by the Purchaser in the Offer. Except as otherwise provided in Instruction 6 to the Letter of Transmittal, share transfer taxes will not be paid by the Purchaser.

2


If you wish to have us tender any or all of your Shares held by us for your account, please (1) so instruct us by completing, executing and returning to us the instruction form contained in this letter and (2) if applicable to you, complete, execute and return to us the Declaration Form enclosed with this letter.

Alternatively, if you wish to notify the Purchaser of your objection to the Offer, please so instruct us by completing, executing and returning to us the objection instruction form contained in this letter by no later than 10:00 a.m., New York time, on the Initial Completion Date. IF YOU DO NOT WISH TO TENDER ANY SHARES OR OBJECT TO THE OFFER, YOU MAY SIMPLY DO NOTHING.

An envelope in which to return your instructions to us is enclosed. If you authorize the tender of your Shares in the Offer, all of your Shares will be tendered unless otherwise specified in your instructions. Your tender instructions (and Declaration Form, if applicable) should be forwarded to us in ample time to permit us to submit a tender on your behalf and, if you completed the Declaration Form, request an exemption from Israeli withholding tax on your behalf, prior to the Initial Completion Date or the Final Expiration Date, as applicable.

If you authorize the objection of your Shares to the Offer, we will object to the Offer with respect to all of your Shares unless otherwise specified in your instructions. Your objection instructions should be forwarded to us in ample time to permit us to submit an objection on your behalf prior to the Initial Completion Date.

The Offer is made solely by the Offer to Purchase and the related Letter of Transmittal and is being made to all of Given Imaging shareholders. The Purchaser is not aware of any jurisdiction where the making of the Offer is prohibited by administrative or judicial action pursuant to any valid state statute. If the Purchaser becomes aware of any valid state statute prohibiting the making of the Offer or the acceptance of Shares pursuant to the Offer, the Purchaser will make a good faith effort to comply with that state statute. If, after its good faith effort, the Purchaser cannot comply with that state statute, subject to applicable law, the Offer will not be made to (nor will tenders be accepted from or on behalf of) holders of Shares in that state. In any jurisdiction where the securities, blue sky or other laws require the Offer to be made by a licensed broker or dealer, the Purchaser will endeavor to make arrangements to have the Offer made on its behalf by one or more registered brokers or dealers licensed under the laws of such jurisdiction.

IMPORTANT: IF YOU SUBMIT A TENDER INSTRUCTION LETTER BY WHICH YOU TENDER SHARES AND THEREAFTER, YOU DELIVER TO US AN OBJECTION INSTRUCTION LETTER WITH RESPECT TO THOSE SHARES, WE WILL DISREGARD YOUR TENDER INSTRUCTION LETTER. SIMILARLY, IF YOU SUBMIT TO US AN OBJECTION INSTRUCTION LETTER WITH RESPECT TO SHARES AND THEREAFTER, YOU DELIVER TO US A TENDER INSTRUCTION LETTER BY WHICH YOU TENDER THOSE SHARES, WE WILL DISREGARD YOUR OBJECTION INSTRUCTION LETTER. IF YOU SUBMIT A TENDER INSTRUCTION LETTER AND AN OBJECTION INSTRUCTION LETTER CONCURRENTLY WITH RESPECT TO THE SAME SHARES, THE OBJECTION INSTRUCTION LETTER WILL BE DISREGARDED.

3


TENDER INSTRUCTION LETTER
with Respect to the Offer
to Purchase for Cash
1,462,640 Ordinary Shares
of
Given Imaging Ltd.

The undersigned acknowledge(s) receipt of your letter and the enclosed Offer to Purchase, dated May 16, 2008 (the “Offer to Purchase”), and the related Letter of Transmittal, which as amended from time to time, together constitute the Offer, in connection with the tender offer of Elron Electronic Industries Ltd. (the “Purchaser”), to purchase 5.0% of the issued and outstanding ordinary shares (currently 1,462,640 shares), par value NIS 0.05 per share (the “Shares”) of Given Imaging Ltd. (“Given Imaging”), at a price of $16.54 per Share less any applicable withholding taxes, and without interest, net to the seller in cash, upon the terms of, and subject to the conditions to, the Offer.

This will instruct you to tender in the Offer the number of Shares indicated below (or, if no number is indicated below, all Shares) that are held by you for the account of the undersigned, upon the terms and subject to the conditions set forth in the Offer.

Number of shares to be tendered: *  

Date:  

 
Signature(s)

 
Please type or print name(s)

 

 
Please type or print address

 

 
Area code and telephone number

 
Taxpayer Identification or Social Security Number

 

 

*

 

 

 

Unless otherwise indicated, it will be assumed that all Shares held by us for your account are to be tendered in the Offer.

PLEASE NOTE THAT THIS TENDER INSTRUCTION LETTER IS TO TENDER YOUR SHARES IN ACCORDANCE WITH THE TERMS AND CONDITIONS DESCRIBED IN THE OFFER TO PURCHASE. IF YOU WISH TO OBJECT TO THE OFFER, PLEASE COMPLETE THE “OBJECTION INSTRUCTION LETTER” AND RETURN IT TO US.

4


OBJECTION INSTRUCTION LETTER
with Respect to the Offer
to Purchase for Cash
1,462,640 Ordinary Shares
of
Given Imaging Ltd.

The undersigned acknowledge(s) receipt of your letter and the enclosed Offer to Purchase, dated May 16, 2008 (the “Offer to Purchase”), and the related Letter of Transmittal, which as amended from time to time, together constitute the Offer, in connection with the tender offer of Elron Electronic Industries Ltd. (the “Purchaser”), to purchase 5.0% of the issued and outstanding ordinary shares (currently 1,462,640 shares), par value NIS 0.05 per share (the “Shares”) of Given Imaging Ltd. (“Given Imaging”), at a price of $16.54 per Share less any applicable withholding taxes, and without interest, net to the seller in cash, upon the terms of, and subject to the conditions to, the Offer.

This will instruct you to object to the Offer with respect to the number of Shares indicated below (or, if no number is indicated below, all shares) that are held by you for the account of the undersigned, upon the terms and subject to the conditions set forth in the Offer.

Number of objecting shares:*  

Date:  

 
Signature(s)

 

 
Please type or print name(s)

 

 
Please type or print address

 
Area code and telephone number

 

*

 

 

  Unless otherwise indicated, it will be assumed that all Shares held by us for your account are to object to the Offer.

Explanation of Objection Instruction Letter. Under Israeli law, the shareholders of Given Imaging may respond to the Offer by accepting the Offer and tendering all or any portion of their shares in accordance with the Offer to Purchase or by notifying the Purchaser of their objection to the Offer by executing and delivering Notices of Objection (which, in your case, is corresponding to this Objection Instruction Letter). Alternatively, they may simply not respond to the Offer and not tender their shares. It is a condition to the Offer that at 10:00 a.m., New York time, and 5:00 p.m., Israel time, on the Initial Completion Date, the aggregate number of shares tendered in the Offer is greater than the number of shares represented by Notices of Objection. If this and the other conditions to the Offer have been satisfied or waived, shareholders will be afforded an additional four calendar days to tender their shares in the Offer, but Notices of Objection will no longer be accepted. See Section 3 of the Offer to Purchase.

THIS OBJECTION INSTRUCTION LETTER SHOULD ONLY BE EXECUTED BY YOU IN THE EVENT THAT YOU OBJECT TO THE OFFER WITH RESPECT TO ALL OR ANY PORTION OF YOUR SHARES. ACCORDINGLY, DO NOT EXECUTE THIS OBJECTION INSTRUCTION LETTER IF (1) YOU WOULD LIKE TO ACCEPT THE OFFER WITH RESPECT TO THOSE SHARES (IN WHICH CASE YOU SHOULD COMPLETE AND EXECUTE THE TENDER INSTRUCTION LETTER) OR (2) YOU DO NOT WISH TO PREVENT THE COMPLETION OF THE OFFER.

5


EX-99.(A)(1)(E) 9 c53577_ex99a1e.htm 3B2 EDGAR HTML -- c53577_ex99a1e.htm

GUIDELINES FOR CERTIFICATION OF TAXPAYER IDENTIFICATION
NUMBER ON SUBSTITUTE FORM W-9

GUIDELINES FOR DETERMINING THE PROPER IDENTIFICATION NUMBER TO GIVE THE PAYOR. Social Security numbers (SSNs) have nine digits separated by two hyphens: i.e., 000-00-0000. Employer identification numbers (EINs) have nine digits separated by only one hyphen: i.e., 00-0000000. The table below will help determine the number to give the payor.

 

 

 

 

 

 

 

 

 

 

 

 


For this type of account:

 

Give the
SOCIAL SECURITY
number of —

 


For this type of account:

 

Give the EMPLOYER
IDENTIFICATION
number of —

 

1.

 

Individual

 

The individual

 

6.

 

Sole proprietorship

 

The owner (3)

2.

 

Two or more
individuals (joint
account)

 

The actual owner of the account or, if combined funds, the first individual on the account (1)

 

7.

 

A valid trust, estate, or pension trust

 

The legal entity (4)

3.

 

Custodian account of a minor (Uniform Gift to Minors Act)

 

The minor (2)

 

8.

 

Corporation or limited ability company electing corporate status on Form 8832

 

The corporation

4.

 

a. The usual revocable savings trust (grantor is also trustee)
b. So-called trust account that is not a legal or valid trust under state law

 

The grantor-trustee (1)
 
The actual owner (1)

 

9.

 

Association, club, religious, charitable, educational, or other tax-exempt organization account

 

The organization

5.

 

Sole proprietorship or disregarded entity owned by an individual

 

The owner (3)

 

10.

 

Partnership or multi- member limited liability company that has not elected corporate status

 

The partnership

 

 

 

 

 

 

11.

 

A broker or registered nominee

 

The broker or nominee

 

 

 

 

 

 

12.

 

Account with the Department of Agriculture in the name of a public entity (such as a state or local government, school district or prison) that receives agriculture program payments

 

The public entity

 

 

(1)

 

 

 

List first and circle the name of the person whose number you furnish. If only one person on a joint account has an SSN, that person’s number must be furnished.

 

(2)

 

 

 

Circle the minor’s name and furnish minor’s SSN.

 

(3)

 

 

 

You must show your individual name, but you may also enter your business or “doing business as” name. You may use either your SSN or EIN (if you have one).

 

(4)

 

 

 

List first and circle the name of the legal trust, estate or pension trust. (Do not furnish the taxpayer identification number (TIN) of the personal representative or trustee unless the legal entity itself is not designated in the account title.)

 

Note:

 

 

 

If no name is circled when there is more than one name, the number will be considered to be that of the first name listed.


GUIDELINES FOR CERTIFICATION OF TAXPAYER IDENTIFICATION NUMBER ON SUBSTITUTE FORM W-9
(Page 2)

OBTAINING A NUMBER

If you don’t have a taxpayer identification number or you don’t know your number, obtain Form SS-5, Application for a Social Security Number Card, or Form SS-4, Application for Employer Identification Number, at the local office of the Social Security Administration or the Internal Revenue Service (“IRS”) and apply for a number. Both forms can be located on the Internet at www.irs.gov

PAYEES EXEMPT FROM BACKUP WITHHOLDING

Payees specifically exempted from backup withholding include the following:

 

 

 

 

An organization exempt from tax under section 501(a) of the Internal Revenue Code of 1986 as amended (the “Code”), any individual retirement account (IRA), or a custodial account under Section 403(b)(7) of the Code if the account satisfies the requirements of Section 401(f)(2) of the Code.

 

 

 

 

The United States or any of its agencies or instrumentalities. A State, the District of Columbia, a possession of the United States, or any of their political subdivisions or instrumentalities.

 

 

 

 

A foreign government or any of its political subdivisions, agencies or instrumentalities.

 

 

 

 

An international organization or any of its agencies or instrumentalities.

Payees that may be exempt from backup withholding include the following:

 

 

 

 

A corporation.

 

 

 

 

A foreign central bank of issue.

 

 

 

 

A registered dealer in securities or commodities registered in the United States, the District of Columbia, or a possession of the United States.

 

 

 

 

A futures commission merchant registered with the Commodity Futures Trading Commission.

 

 

 

 

A real estate investment trust.

 

 

 

 

An entity registered at all times during the tax year under the Investment Company Act of 1940.

 

 

 

 

A common trust fund operated by a bank under section 584(a) of the Code.

 

 

 

 

A financial institution.

 

 

 

 

A middleman known in the investment community as a nominee or custodian or who is listed in the most recent publication of the American Society of Corporate Securities, Inc Nominee List.

 

 

 

  An exempt charitable remainder trust, or a non-exempt trust described in section 4947.

EXEMPT PAYEES DESCRIBED ABOVE SHOULD FILE SUBSTITUTE FORM W-9 TO AVOID POSSIBLE ERRONEOUS BACKUP WITHHOLDING. FURNISH YOUR TAXPAYER IDENTIFICATION NUMBER, CERTIFY THAT YOU ARE EXEMPT FROM BACKUP WITHHOLDING, SIGN AND DATE THE FORM, AND RETURN IT TO THE PAYOR.

IF YOU ARE A NONRESIDENT ALIEN OR A FOREIGN ENTITY NOT SUBJECT TO BACKUP WITHHOLDING, FILE WITH THE PAYOR AN APPROPRIATE INTERNAL REVENUE FORM W-8BEN (CERTIFICATE OF FOREIGN STATUS).

PRIVACY ACT NOTICE—Section 6109 of the Code requires most recipients of dividend, interest, or other payments to give taxpayer identification numbers to payors who must report the payments to the IRS. The IRS uses the numbers for identification purposes and to help verify the accuracy of your tax return. The IRS may also provide this information to the Department of Justice for civil and criminal litigation and to cities, states, and the District of Columbia to carry out their tax laws. Payors must be given the numbers whether or not recipients are required to file tax returns. Payors must generally withhold 28% of taxable interest, dividend, and certain other payments to a payee who does not furnish a taxpayer identification number to a payor. Certain penalties may also apply.

PENALTIES

(1) Failure to Furnish Taxpayer Identification Number. If you fail to furnish your taxpayer identification number to a payor, you are subject to a penalty of $50 for each such failure unless your failure is due to reasonable cause and not to willful neglect.

(2) Civil Penalty for False Information with Respect to Withholding. If you make a false statement with no reasonable basis which results in no imposition of backup withholding, you are subject to a penalty of $500.

(3) Criminal Penalty for Falsifying Information Willfully. Falsifying certifications or affirmations may subject you to criminal penalties including fines and/or imprisonment.

FOR ADDITIONAL INFORMATION CONTACT YOUR TAX CONSULTANT OR THE INTERNAL REVENUE SERVICE.


EX-99.(A)(1)(F) 10 c53577_ex99a1f.htm 3B2 EDGAR HTML -- c53577_ex99a1f.htm

NOTICE OF OBJECTION
to
OFFER TO PURCHASE FOR CASH
1,462,640 ORDINARY SHARES
of
GIVEN IMAGING LTD.
by
ELRON ELECTRONIC IDUSTRIES LTD.

THE INITIAL OFFER PERIOD AND WITHDRAWAL RIGHTS WILL EXPIRE AT 10:00 A.M.,
NEW YORK TIME, AND 5:00 P.M., ISRAEL TIME, ON MONDAY, JUNE 16, 2008, UNLESS THE OFFER IS EXTENDED.

The U.S. Depositary for the offer is:
American Stock Transfer & Trust Company

 

 

 

 

 

         

By Hand/Overnight Courier:

 

By Facsimile
(to Eligible Institutions only):

 

By Mail:

American Stock Transfer & Trust Company
Operations Center
Attn: Reorganization Department
6201 15th Avenue
Brooklyn, New York 11219

 


(718) 234-5001
Confirm by Telephone:
Toll-free (877) 248-6417
(718) 921-8317

 

American Stock Transfer & Trust Company
Operations Center
Attn: Reorganization Department
P.O. Box 2042
New York, New York 10272-2042

DELIVERY OF THIS NOTICE OF OBJECTION TO AN ADDRESS OTHER THAN AS SET FORTH ABOVE WILL NOT CONSTITUTE A VALID DELIVERY.

PLEASE READ THE INSTRUCTIONS ON THE REVERSE SIDE OF THIS NOTICE OF OBJECTION CAREFULLY BEFORE COMPLETING THIS NOTICE OF OBJECTION.

 

 

 

To:

 

Elron Electronic Industries Ltd.
c/o American Stock Transfer & Trust Company

The undersigned hereby notifies you of the undersigned’s objection to the offer by Elron Electronic Industries Ltd. to purchase 1,462,640 ordinary shares, par value NIS 0.05 per share (the “Shares”) of Given Imaging Ltd. (“Given Imaging”), as set forth in the Offer to Purchase, dated May 16, 2008 (as may be amended from time to time, the “Offer to Purchase” and, together with the Letter of Transmittal, the “Offer”) with respect to   (insert number) Shares held by the undersigned. By executing this Notice of Objection, the undersigned acknowledges that the undersigned has read, and agrees to, the terms and conditions of the instructions accompanying this Notice of Objection.

 
Name(s) of Registered Holder(s)

 
Address(es) of Registered Holder(s)

 
Signature(s) of Registered Holder(s)

Date  , 2008

DTC Account Number (if applicable):  

THIS NOTICE OF OBJECTION SHOULD ONLY BE EXECUTED BY YOU IN THE EVENT THAT YOU OBJECT TO THE OFFER WITH RESPECT TO ALL OR ANY PORTION OF YOUR SHARES. ACCORDINGLY, DO NOT EXECUTE THIS NOTICE OF OBJECTION IF (1) YOU WOULD LIKE TO ACCEPT THE OFFER WITH RESPECT TO THOSE SHARES (IN WHICH CASE YOU SHOULD COMPLETE AND EXECUTE THE LETTER OF TRANSMITTAL) OR (2) YOU DO NOT WISH TO PREVENT THE COMPLETION OF THE OFFER.


Shareholders of Given Imaging must complete this Notice of Objection unless an agent’s message is utilized. If delivery of the Notice of Objection is to be made by book-entry transfer to an account maintained by American Stock Transfer & Trust Company, as U.S. Depositary at The Depository Trust Company (the “Book-Entry Transfer Facility” or “DTC”). Delivery of documents to DTC or any other party does not constitute delivery to the U.S. Depositary.

NOTE: SIGNATURES MUST BE PROVIDED BELOW

 

 

 

£

 

Check here if Notice of Objection is being delivered by book-entry transfer to the U.S. Depositary’s account at The Depository Trust Company and complete the following:

 

 

Name of Tendering Institution:  

 

 

Account Number:  

 

 

Transaction Code Number:  

INSTRUCTIONS
Forming Part of the Terms and Conditions of the Offer

1. Explanation of Notice of Objection. Under Israeli law, you may respond to the Offer by accepting the Offer and tendering all or any portion of your Shares in accordance with the Offer to Purchase and the instructions contained in the Letter of Transmittal or by notifying us of your objection to the Offer with respect to all or any portion of your Shares by executing and delivering this Notice of Objection. Alternatively, you may simply do nothing and not tender your Shares or object to the Offer. It is a condition to the Offer that at the completion of the Initial Offer Period (as defined in the Offer to Purchase), the aggregate number of Shares validly tendered in the Offer is greater than the number of Shares represented by Notices of Objection. In making this calculation, we exclude Shares owned by us, certain of our affiliates and certain of Given Imaging’s affiliates. We will make this calculation and announce the results promptly after the Initial Completion Date (as defined in the Offer to Purchase). If this and the other conditions to the Offer have been satisfied or, subject to applicable law, waived by us, shareholders will be afforded an additional four calendar days to tender their Shares in the Offer, but Notices of Objection will no longer be accepted.

If, with respect to all or any portion of your Shares, you object to the Offer during the Initial Offer Period and the conditions to the Offer have been satisfied or, subject to applicable law, waived by us, you may tender such Shares during the Additional Offer Period (as defined in the Offer to Purchase).

Do not send any stock certificates with this Notice of Objection.

2. Delivery of Notice of Objection. If you wish to object to the Offer and you hold your Shares directly, complete and sign this Notice of Objection and mail or deliver it to the U.S. Depositary at one of its addresses set forth on the front of this document prior to 10:00 a.m., New York time, or 5:00 p.m., Israel time, on the Initial Completion Date.

If you wish to object to the Offer and you hold your Shares through a broker, dealer, commercial bank, trust company or other nominee, request such broker, dealer, commercial bank, trust company or other nominee to submit for you the Notice of Objection to the U.S. Depositary prior to 10:00 a.m., New York time, or 5:00 p.m., Israel time, on the Initial Completion Date.

The method of delivery of this Notice of Objection is at the option and risk of the objecting shareholder, and the delivery will be deemed made only when actually received by the U.S. Depositary. If delivery is by mail, registered mail with return receipt requested, is recommended. In all cases, sufficient time should be allowed to ensure timely delivery.

No alternative, conditional or contingent Notices of Objection will be accepted.

3. Signatures on Notice of Objection. If this Notice of Objection is signed by the registered holder(s) of Shares, the signature(s) must correspond with the name(s) as written on the face of the certificate(s) evidencing the Shares without alteration, enlargement or any other change whatsoever.

If any Shares are registered in the name of two or more persons, all of those named persons must sign this Notice of Objection.

2


If any Shares are registered in different names, it will be necessary to complete, sign and submit as many separate Notices of Objection as there are different registrations of those objecting Shares.

If this Notice of Objection is signed by a trustee, executor, administrator, guardian, attorney-in-fact, officer of a corporation or other person acting in a fiduciary or representative capacity, that person should so indicate when signing, and proper evidence satisfactory to us of that person’s authority so to act must be submitted.

4. Withdrawal of Notice of Objection. You may withdraw a previously submitted Notice of Objection at any time prior to 10:00 a.m., New York time, or 5:00 p.m., Israel time, on the Initial Completion Date. For a withdrawal to be effective, a written notice of withdrawal must be timely received by the U.S. Depositary at one of its addresses set forth on the front of this document. Any notice of withdrawal must specify the name of the person(s) who submitted the Notice of Objection to be withdrawn and the number of Shares to which the Notice of Objection to be withdrawn relates. Following the withdrawal of a Notice of Objection, a new Notice of Objection may be submitted at any time prior to 10:00 a.m., New York time, or 5:00 p.m., Israel time, on the Initial Completion Date by following the procedures described above. If Notices of Objection have been delivered pursuant to the procedures for book-entry transfer as set forth above, any notice of withdrawal must also specify the name and number of the account at DTC to be adjusted to reflect the withdrawal of such Shares and otherwise comply with DTC’s procedures.

5. Determination of Validity. All questions as to the form and validity (including time of receipt) of Notices of Objection will be determined by us, in our sole discretion, subject to applicable law, which determination will be final and binding on all parties. None of us or our affiliates or assigns, the U.S. Depositary, the Information Agent, our Israeli counsel or any other person will be under any duty to give notification of any defects or irregularities in any notice or incur any liability for failure to give any such notification.

IMPORTANT: IF YOU SUBMIT A NOTICE OF OBJECTION WITH RESPECT TO SHARES AND THEREAFTER YOU DELIVER TO US A LETTER OF TRANSMITTAL BY WHICH YOU TENDER THOSE SHARES, WE WILL DISREGARD YOUR NOTICE OF OBJECTION. SIMILARLY, IF YOU SUBMIT TO US A LETTER OF TRANSMITTAL BY WHICH YOU TENDER SHARES, AND THEREAFTER YOU DELIVER TO US A NOTICE OF OBJECTION WITH RESPECT TO THOSE SHARES, WE WILL DISREGARD YOUR LETTER OF TRANSMITTAL. IF YOU SUBMIT A LETTER OF TRANSMITTAL AND A NOTICE OF OBJECTION CONCURRENTLY WITH RESPECT TO THE SAME SHARES, THE NOTICE OF OBJECTION WILL BE DISREGARDED.

6. Questions and Requests for Assistance or Additional Copies. Questions or requests for assistance in connection with this Notice of Objection may be directed to the Information Agent at its address and telephone number listed below. Additional copies of the Offer to Purchase, Letter of Transmittal, this Notice of Objection and other offer documents may be obtained from the Information Agent. A shareholder may also contact brokers, dealers, commercial banks or trust companies for assistance concerning the Offer.

The Information Agent for the offer is:

105 Madison Avenue
New York, New York 10016
call collect +1-212-929-5500
or
toll free +1-800-322-2885
Email: proxy@mackenziepartners.com

3


EX-99.(A)(1)(G) 11 c53577_ex99a1g.htm 3B2 EDGAR HTML -- c53577_ex99a1g.htm

 

 

 

 

 

   

DECLARATION OF STATUS FOR ISRAELI INCOME TAX PURPOSES
u
 Do not send this form to the IRS u  See separate instructions on the back cover of this form
u
 Read this form together with the Offer to Purchase and Letter of Transmittal accompanying this form

 

 

 

PAYER’S NAME: American Stock Trust & Transfer Company, as U.S. Depositary

Who may use this form and why?

Holders of ordinary shares, par value NIS 0.05 per share (the “Shares”), of Given Imaging Ltd. (“Given Imaging”) who wish to tender their Shares pursuant to the offer to purchase Shares made by Elron Electronic Industries Ltd. (the “Purchaser”), upon the terms of, and subject to the conditions to, the Offer to Purchase, dated May 16, 2008 (the “Offer to Purchase”) and the related Letter of Transmittal (which, as amended from time to time, together constitute the “Offer”) may use this form if they tender their Shares in the Offer to the U.S. Depositary and they are either:

 

 

 

 

Non-Israeli Residents: If (A) (i) you certify that you are NOT a “resident of Israel” (as defined under Section 1 of the Israeli Income Tax Ordinance [New Version], 5721-1961 (the “Ordinance”) (See Instruction II)) for purposes of the Ordinance, or (ii) you are a corporation that is NOT a “resident of Israel”, and Israeli residents are NOT “controlling shareholders” (as defined under Section 68A of the Ordinance (See Instruction III)) of you, nor are Israeli residents the beneficiaries of, or are entitled to, 25.0% or more of your revenues or profits, whether directly or indirectly; and (B) (i) you acquired your Shares after Given Imaging’s initial public offering on Nasdaq (i.e., after October 3, 2001) or (ii) you acquired your Shares prior to Given Imaging’s initial public offering on Nasdaq and submit an A-114 Form approving that you are a resident of a country with which Israel has a tax treaty which exempts Israeli capital gains tax, duly signed by the tendering shareholder and authorized by the tax authority of such country, will not be subject to Israeli withholding tax, you may be eligible for a full exemption from Israeli withholding tax with respect to the gross proceeds payable to you (if any) pursuant to the Offer. By completing this form in a manner that would substantiate your eligibility for such exemption, you will allow the Purchaser, the U.S. Depositary, your broker or any other withholding agent, or their authorized representatives to exempt you from such Israeli withholding tax; or

 

 

 

 

A Bank, Broker or Financial Institution Resident in Israel: If you are a bank, broker or financial institution resident in Israel that (1) is holding the Shares solely on behalf of beneficial shareholder(s) (so-called “street name” holders), and (2) is subject to the provisions of the Ordinance and regulations promulgated thereunder relating to the withholding of Israeli tax, including with respect to the cash payment (if any) made by you to your beneficial shareholder(s) with respect to Shares tendered by them and accepted for payment by the Purchaser pursuant to the Offer (an “Eligible Israeli Broker”), you may be eligible for a full exemption from Israeli withholding tax with respect to the cash payment transmitted to you. By completing this form in a manner that would substantiate your eligibility for such exemption, you will allow the Purchaser, the U.S. Depositary, your broker or withholding agent, or their authorized representatives, to exempt you from such Israeli withholding tax. Consequently, even though the U.S. Depositary will not deduct any Israeli withholding tax from you, pursuant to the provisions of the Ordinance and regulations promulgated thereunder, to which you are subject, you may be required to withhold Israeli tax, as applicable, from the cash payment (if any) made by you to your beneficial shareholder(s). NOTE: AN ELIGIBLE ISRAELI BROKER MAY COMPLETE THIS FORM IF IT IS HOLDING THE SHARES SOLELY ON BEHALF OF HIS CLIENTS, THE BENEFICIAL SHAREHOLDERS; OR

 

 

 

 

Israeli Residents: If you are a “resident of Israel” (as defined under Section 1 of the Ordinance) and you acquired your Shares after Given Imaging’s initial public offering on Nasdaq (i.e., after October 3, 2001), you may be eligible for a reduced Israeli withholding tax rate with respect to the gross proceeds payable to you (if any) pursuant to the Offer. By completing this form in a manner that would substantiate your eligibility for such reduced rate, you will allow the Purchaser, the U.S. Depositary, your broker or any other withholding agent, or their authorized representative to withhold Israeli tax at a reduced rate.


 

 

 

 

PLEASE NOTE THAT IF YOU PROVIDE A DECLARATION FORM, YOU ALSO CONSENT TO THE PROVISION OF YOUR DECLARATION FORM TO THE PURCHASER AND/OR THE U.S. DEPOSITARY AND TO THE ISRAELI TAX AUTHORITY (THE “ITA”), IN CASE THE ITA SO REQUESTS, FOR PURPOSES OF AUDIT OR OTHERWISE.

To whom should you deliver this form?

 

 

 

 

If you wish to submit this form and (1) you hold your Shares directly, i.e., you are a registered holder, complete and sign this form and mail or deliver it to the U.S. Depositary (together with the Letter of Transmittal by which you tender your Shares) at one of its addresses set forth below, or (2) you hold your Shares through a broker, dealer, commercial bank, financial institution, trust company or other nominee (a “Broker”), complete and sign this form and mail or deliver it (together with the instruction letter by which you tender your Shares) to such Broker.

Until when should I deliver this form?

 

 

 

  As described above, this form should be delivered together with the Letter of Transmittal or instruction letter by which you tender your Shares prior to 10:00 a.m., New York time, or 5:00 p.m., Israel time, on the Initial Completion Date or Final Expiration Date (as such terms are defined in the Offer to Purchase), as applicable.

You are urged to consult your own tax advisors to determine the particular tax consequences to you should you tender your Shares in the Offer, including, without limitation, the effect of any state, local or foreign income and any other tax laws and whether or not you should use this form.

2


 

 

 

 

 

 

 

 

 

 

 

PART I

 

Identification and details of Shareholder (including Eligible Israeli Brokers) (see instructions)

 

1. Name:

 

 

 

2. Type of Shareholder (more than one box may be applicable):

 

 

 

(please print full name)

 

£

 

Corporation (or Limited Liability Company)

 

£
£

 

Bank
Broker

 

 

 

 

£

 

Individual

 

£

 

Financial Institution

 

 

 

 

£

 

Trust

 

 

 

 

 

 

 

 

£

 

Partnership

 

 

 

 

 

 

 

 

£

 

Other:
 

 

 

 

 

 

3. For individuals only:

 

4. For all other Shareholders:

 

Date of birth:  /  /  

 

Country of incorporation or organization:

month / day / year

 

 

 

 

 

 

 

 

 

Country of residence:

 

Registration number of corporation (if applicable):

 

 

 

 

 

Country of citizenship:

 

 

 

 

 

 

 

 

 

Taxpayer Identification or
Social Security No (if applicable):

 

Country of residence:

 

5. Permanent Address (state, city, zip or postal code, street, house number, apartment number):

 

6. Mailing Address (if different from above):

 

7. Telephone Number (country code, area code and number):

 

8. I hold the Shares of Given Imaging (mark X in the appropriate place):£  directly, as a Registered Holder
£
 through a Broker. If you marked this box, please state the name of your Broker:  

 

PART II

 

Declaration by Non-Israeli Shareholders (see instructions) u Eligible Israeli Brokers should not complete this Part II

 

A. To be completed only by Individuals. I hereby declare that: (if the statement is correct, mark X in the following box) (note: only if the statements in (i) A.1 and (ii) A.2 or A.3 are marked as correct you may be eligible for an exemption from Israeli tax withholding)

 

A.1 £  I am NOT a “resident of Israel” within the meaning of that term in Section 1 of the Ordinance (See Instruction II), which means, among other things, that:

 the State of Israel is neither my place of residence nor that of my family,

 I was NOT present (nor am I planning to be present) in Israel for 183 days or more during this tax year,

 I was NOT present in Israel for 30 days or more during this tax year, and

 The total period of my presence in Israel during this tax year and the two previous tax years is less than 425 days or more in total; and

A.2 £  I acquired the Shares after the initial public offering of Given Imaging on Nasdaq (i.e., after October 3, 2001); or

A.3 £  I acquired the Shares prior to the initial public offering of Given Imaging on Nasdaq and am resident of a country with whom Israel has a tax treaty exempting Israeli capital gains tax and I have attached an A-114 Form duly signed by me and authorized by the tax authority of such country.

 

B. To be completed by Corporations. I hereby declare that: (if correct, mark X in the following box.) (note: only if the statements in (i) B.1 and (ii) B.2 and (iii) B.3 or B.4 are marked as correct you may be eligible for an exemption from Israeli tax withholding)

 

B.1 £  I am NOT a “resident of Israel” within the meaning of that term in Section 1 of the Ordinance (See Instruction II), which means, among other things, that:

 I was NOT incorporated in Israel and was NOT registered with/formed at the Israeli Registrar of Companies, the Israeli Fellowship Societies Registrar or the Israeli Partnerships Registrar, and

 the “control and management” of my business is NOT located in Israel; and

B.2 £  Israeli residents are NOT “controlling shareholders” of me within the meaning of that term in Section 68A of the Ordinance (See Instruction III), which means, among other things, that Israeli residents do NOT hold 25.0% or more of any “means of control” of me within the meaning of that term in Section 88 of the Ordinance; nor are Israeli residents the beneficiaries of, or are entitled to, 25.0% or more of my revenues or profits, whether directly or indirectly; and

B.3 £  I acquired the Shares after the initial public offering of Given Imaging on Nasdaq (i.e., after October 3, 2001); or

B.4 £  I acquired the Shares prior to the initial public offering of Given Imaging on Nasdaq and am resident of a country with whom Israel has a tax treaty exempting Israeli capital gains tax and I have attached an A-114 Form duly signed by me and authorized by the tax authority of such country.

 

C. To be completed by Partnerships. I hereby declare that: (if correct, mark X in the following box.) (note: only if the statements in (i) C.1 and (ii) C.2 and (iii) C.3 or C.4 are marked as correct you may be eligible for an exemption from Israeli tax withholding)

 

C.1 £  NO partner (in the partnership), whether an individual or a corporation, is a “resident of Israel” within the meaning of that term in Section 1 of the Ordinance (See Instruction II); and

C.2 £  NO partner (in the partnership) that is a corporation has Israeli residents that are “controlling shareholders” within the meaning of that term in Section 68A of the Ordinance (See Instruction III), nor are Israeli residents the beneficiaries of, or are entitled to, 25.0% or more of the revenues or profits of such partner, whether directly or indirectly; and

C.3 £  I acquired the Shares after the initial public offering of Given Imaging on Nasdaq (i.e., after October 3, 2001); or

3


 

 

 

 

 

 

 

 

 

 

 

C.4 £  I acquired the Shares prior to the initial public offering of Given Imaging on Nasdaq and am resident of a country with whom Israel has a tax treaty exempting Israeli capital gains tax and I have attached an A-114 Form duly signed by me and authorized by the tax authority of such country.

 

D. To be completed by Trusts. I hereby declare that: (if correct, mark X in the following box) (note: only if the statements in (i) D.1 and (ii) D.2 or D.3 are marked as correct you may be eligible for an exemption from Israeli tax withholding)

 

D.1 £  The Trust was NOT registered in Israel; the settlor of the Trust is NOT an Israeli Resident; and the beneficiaries of the Trust are NOT Israeli Residents; and

D.2 £  I acquired the Shares after the initial public offering of Given Imaging on Nasdaq (i.e., after October 3, 2001); or

D.3 £  I am resident of a country with whom Israel has a tax treaty exempting Israeli capital gains tax and I have attached an A-114 Form duly signed by me and authorized by the tax authority of such country.

 

PART III

 

Declaration by Israeli Bank, Broker or Financial Institution (see instructions) u

 

Non-Israeli Residents should
not complete this Part III

 

 

(note: only if all statements are marked as correct you may be eligible for an exemption from Israeli tax withholding)

 

I hereby declare that: (if correct, mark X in the following box)

£

 

I am a bank, broker or financial institution that is a “resident of Israel” within the meaning of that term in Section 1 of the Ordinance (See Instruction II), I am holding the Shares solely on behalf of beneficial shareholder(s) and I am subject to the provisions of the Ordinance and the regulations promulgated thereunder relating to the withholding of Israeli tax, including with respect to the cash payment (if any) made by me to such beneficial shareholder(s) with respect to Shares tendered by them and accepted for payment by the Purchaser pursuant to the Offer.

 

PART IV

 

Declaration by Israeli Residents (see instructions) u

 

Eligible Israeli Brokers should not complete this Part IV

 

I hereby declare that: (if correct, mark X in the following box) (note: only if all statements are marked as correct you may be eligible for a reduced Israeli tax withholding rate)

£

 

I am a “resident of Israel” within the meaning of the term in Section 1 of the Ordinance (See Instruction II).

£

 

I acquired the Shares after the initial public offering on Nasdaq (i.e., after October 3, 2001).

 

PART V

 

Certification. By signing this form, you also declared that:

 

 You understood this form and completed it correctly and pursuant to the instructions.

 You provided accurate, full and complete details in this form.

 You are aware that providing false details constitutes a felony under the Ordinance.

 You are aware that this form may be provided to the Israeli Tax Authority, in case the Israeli Tax Authority so requests, for purposes of audit or otherwise.

 You understand that the instructions to this form constitute an integral part thereof.

 

 

 

 

 

 

 

SIGN HERE u

 

                                 

 

                  

 

                                        

 

 

Signature of Shareholder

 

Date

 

Capacity in which acting

(or individual authorized to sign on your behalf)

 

 

 

 

4


INSTRUCTIONS
Forming Part of the Declaration of Status for Israeli Income Tax Purposes

I. General Instructions. This Declaration Form (Declaration of Status for Israeli Income Tax Purposes), or this Form, should be completed by holders of Shares who wish to tender their Shares pursuant to the Offer, and who: (i) (A) certify that they are NOT “residents of Israel” for purposes of the Ordinance (See Instruction II below), or if the holder of Shares is a corporation then Israeli residents are NOT “controlling shareholders” of such corporation within the meaning of Section 68A of the Ordinance (See Instruction III below), and Israeli residents are NOT the beneficiaries of, or are entitled to, 25.0% or more of the revenues or profits of such corporation, whether directly or indirectly and (B) (i) acquired the Shares after Given Imaging’s initial public offering on Nasdaq (i.e., after October 3, 2001) or (ii) acquired the Shares prior to Given Imaging’s initial public offering on Nasdaq and are residents of a country with whom Israel has a tax treaty exempting Israeli capital gains tax and submit an A-114 Form duly signed by the tendering shareholder and authorized by the tax authority of such country, or (ii) are banks, brokers or financial institutions that are “residents of Israel” within the meaning of that term in Section 1 of the Ordinance, holding Shares solely on behalf of beneficial shareholder(s), and are subject to the provisions of the Ordinance and the regulations promulgated thereunder relating to the withholding of Israeli tax, including with respect to the cash payment (if any) made by them to such beneficial shareholder(s) with respect to Shares tendered by them and accepted for payment by the Purchaser pursuant to the Offer. Israeli residents who are NOT Eligible Israeli Brokers should not use this Form, unless they are eligible to a reduced withholding rate of 8.61%.

Part I (Identification and details of Shareholder). You should complete Item 1, 2 and 5 through 8 and either (i) Item 3, if you are an individual, or (ii) Item 4, if you are a corporation (or limited liability company), trust, partnership or other entity.

Part II (Declaration by Non-Israeli Shareholder). If you are NOT an Israeli resident, you should complete either Section A (for Individuals), Section B (for Corporations), Section C (for Partnerships) or Section D (for Trusts). If you do not mark a box you will be deemed to answer that the corresponding item is not correct with respect to you.

Part III (Declaration by Israeli Bank, Broker or Financial Institution). If you are an Eligible Israeli Broker, you should complete this Item.

Part IV (Declaration by Israeli Residents). If you are an Israeli resident and eligible to the reduced withholding rate of 8.61%, you should complete this item.

Part V (Certification). By signing this Form, you also make the statements in Part IV.

Inadequate Space. If the space provided on this Form is inadequate, you should insert such details on a separate signed schedule and attached to this Form.

Determination of Validity. All questions as to the validity, form or eligibility (including time of receipt) of this Form will be, subject to applicable law, determined by the Purchaser, in its sole discretion, which determination will be final and binding on all parties. None of the Purchaser, the U.S. Depositary, the Information Agent or any other person will be under any duty to give notification of any defects or irregularities in any Form or incur any liability for failure to give any such notification. For more details, see Section 5 of the Offer to Purchase.

Questions and Requests for Assistance or Additional Copies. Questions and requests for assistance may be directed to the Information Agent at the address or telephone numbers set forth on the back cover. Additional copies of this Form may be obtained from the Information Agent.

The method of delivery of this Form is at your option and risk, and the delivery will be deemed made only when actually received by your Broker or the U.S. Depositary. If delivery is by mail, registered mail with return receipt requested, is recommended. In all cases, sufficient time should be allowed to ensure timely delivery. No alternative, conditional or contingent Forms will be accepted.

5


II. Definition of Resident of Israel for Israeli Tax Purposes

Section 1 of the Ordinance defines a “resident of Israel” or a “resident” as follows:

 

“(A)

 

 

 

with respect to an individual—a person whose center of vital interests is in Israel; for this purpose the following provisions will apply:

 

(1)

 

 

 

in order to determine the center of vital interests of an individual, account will be taken of the individual’s family, economic and social connections, including, among others:

 

(a)

 

 

 

place of permanent home;

 

(b)

 

 

 

place of residential dwelling of the individual and the individual’s immediate family;

 

(c)

 

 

 

place of the individual’s regular or permanent occupation or the place of his permanent employment;

 

(d)

 

 

 

place of the individual’s active and substantial economic interests;

 

(e)

 

 

 

place of the individual’s activities in organizations, associations and other institutions;

 

(2)

 

 

 

the center of vital interests of an individual will be presumed to be in Israel:

 

(a)

 

 

 

if the individual was present in Israel for 183 days or more in the tax year;

 

(b)

 

 

 

if the individual was present in Israel for 30 days or more in the tax year, and the total period of the individual’s presence in Israel that tax year and the two previous tax years is 425 days or more.

For the purposes of this provision, “day” includes a part of a day.

 

(3)

 

 

 

the presumption in subparagraph (2) may be rebutted either by the individual or by the assessing officer;

 

(4)

 

 

 

.  .  .  ;

 

(B)

 

 

 

with respect to a body of persons – a body of persons which meets one of the following:

 

(1)

 

 

 

it was incorporated in Israel;

 

(2)

 

 

 

the “control and management” of its business is exercised in Israel.”

III. Definition of Controlling Shareholder for Purposes of Section 68A of the Ordinance

Section 68A of the Ordinance defines “controlling shareholders” as follows:

“Controlling shareholders” – shareholders that hold, directly or indirectly, alone, or together with another, or together with another Israeli resident, one or more of the means of control at a rate exceeding 25.0%.”

Section 88 of the Ordinance defines the terms “means of control” and “together with another” as follows:

“Means of control” – in a corporation – each of the following:

 

(1)

 

 

 

the right to profits;

 

(2)

 

 

 

the right to appoint a director or a chief executive officer in the company, or equivalent position holders in another corporation;

 

(3)

 

 

 

a voting right in the general meeting of a company, or in an equivalent body in another corporation;

 

(4)

 

 

 

the right to a portion of the remainder of the assets after settlement of liabilities, upon wind-up;

 

(5)

 

 

 

the right to instruct anyone holding the rights listed in clauses (1) to (4) on the manner in which his right shall be executed; and all, whether by virtue of shares, rights to shares or other rights, or in any other manner, including by way of voting agreements or through a trust.”

“Together with another” – together with a relative, and together with he who is not a relative and they have between them a cooperation on a permanent basis under an agreement regarding material issues of a corporation, directly or indirectly.”

6


 

 

 

 

 

 

 

 

   

 

STATE OF ISRAEL MINISTRY OF FINANCE
INCOME TAX & REAL PROPERTY TAX COMMISSION

 

Form A/114

CLAIM FOR REDUCED RATE OF WITHHOLDING TAX/EXEMPTION
FROM WITHHOLDING TAX IN ISRAEL ON PAYMENTS TO A NON RESIDENT

This form shall be completed and signed by the recipient of income or by an authorized officer or representative of the recipient.

PART A: BASIS OF CLAIM FOR REDUCED RATE OF WITHHOLDING TAX/EXEMPTION FROM WITHHOLDING TAX

 

 

 

£

 

This claim is made pursuant to the Double Tax Convention between Israel and    ,
Article    .

£

 

This claim is not made pursuant to a Double Tax Convention.

PART B: GENERAL NATURE OF THE TRANSACTION AND INCOME

 

1.

 

 

 

Provide a brief description of the transaction involved:  

 

 

 

2.

 

 

 

The income received is from
£
 dividends  £  interest  £  royalties  £  other (specify)  

PART C: THE RECIPIENT

 

1.

 

 

 

Full name of the recipient:  

 

 

2.

 

 

 

Home address or registered office of recipient:  

 

 

 

3.

 

 

 

Identity number, social securiy number, or registration number of recipient:  

 

 

4.

 

 

 

Form of organization of recipient (Company, Partnership, etc.):  

Date of establishment:  

 

5.

 

 

 

Income Tax File number of recipient in place of residence:  

 

6.

 

 

 

Address of local income tax assessing office in recipient’s place of residence:  

 

 

7.

 

 

 

The recipient is a fiscal resident of   (country) since   (date).

 

8.

 

 

 

If the recipient is an individual, has he been present in Israel at any time in the past 3 years for any period exceeding one month?  £  No  £  Yes
If yes, specify the dates and duration of such stays in Israel:  

 

Page 1 of 3


Form A/114

 

9.

 

 

 

Does the recipient conduct business in Israel, directly or indirectly, in any manner?  £  No  £  Yes

Specify:  

 

 

10.

 

 

 

If the recipient is a corpration, is a majority of any class of shares in the recipient controlled, directly or indirectly, by persons who are not fiscal residents of the recipient’s state of residence?  £  No  £  Yes

Specify:  

 

PART D: THE PAYER

 

1.

 

 

 

Full name of the payer of the income:  

 

2.

 

 

 

Home address or registered office of payer:  

 

 

 

3.

 

 

 

Income Tax File number of payer in Israel:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

4.

 

 

 

Does any special relationship exist between the payer of the income and the recipient (for example: family, partnership, corporate control):  £  Yes  £  No

Specify:  

 

PART E: DETAILS OF INCOME RECEIVED

 

 

 

 

 

 

 

 

 

Date of
receipt

 

Place of receipt
(country, city,
bank account number)

 

Amount/Currency

 

Description of Income

 

Method of Calculation
(e.g. rate of interest,
percentage of sales, daily fee)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2.

 

 

 

Have similar items of income been the subject of previous claims?  £  No  £  Yes
If yes, specify dates, amounts and rates of withholding tax approved in the past two instances:  

 

 

 

3.

 

 

 

If the income is a dividend and the recipient claims an additional reduction of withholding tax due to direct ownership in the distributing company (pursuant to a Double Tax Convention), specify nature, extent and duration of such ownership:  

 

 

PART F: DOCUMENTATION

 

 

 

 

 

Attach all relevant documents pertaining to the transaction (for example, contracts and invoices).

List all documents attached:

 

1.

 

 

 

 

2.

 

 

 

 

3.

 

 

Page 2 of 3


Form A/114

PART G: DECLARATIONS OF THE RECIPIENT

 

1.

 

 

 

The recipient declares that:

 

a.

 

 

 

he is the beneficial owner of the income received;

 

b.

 

 

 

he does not carry on business in Israel through a permanent establishment there nor perform independent personal services from a fixed base in Israel, to which the income is effectively connected;

 

c.

 

 

 

all the information provided above is accurate and complete.

 

 

 

 

 

 

Date of Signature

 

Signature of Recipient
or authorized officer or representative

 

2.

 

 

 

Name of authorized officer or representative:  

 

3.

 

 

 

Capacity or Title of authorized officer or representative:  

 

4.

 

 

 

Address of authorized officer or representative:  

 

 

PART H: CERTIFICATION OF FOREIGN INCOME TAX AUTHORITY

This part shall be completed and signed by the Income Tax Authorities of the recipient’s place of residence

 

1.

 

 

 

I certify that:

 

a.

 

 

 

the recipient of the income is a fiscal resident of   (country);

 

b.

 

 

 

the recipient regularly reports his income as required, the most recent income tax return filed being for the year  ;

 

c.

 

 

 

the income concerned £ is   £ is not subject to income tax in   (the recipient’s country of residence).

 

 

 

 

 

 

 

 

 

 

Date of Signature

 

Signature

 

Official Stamp

 

2.

 

 

 

Name of Income Tax Authority official making this certification:  

 

3.

 

 

 

Position or Title of certifying official:  

 

4.

 

 

 

Address of certifying official:  

 

 

Page 3 of 3


The Payer, as U.S. Depositary, is:

 

 

 

 

 

By Hand/Overnight Courier:

 

By Facsimile
(to Eligible Institutions only)

 

By Mail:

American Stock Transfer & Trust Company
Operations Center
Attn: Reorganization Department
6201 15th Avenue
Brooklyn, New York 11219

 

+1-718-234-5001
Confirm by Telephone:

Toll-free (877) 248-6417
(718) 921-8317

 

American Stock Transfer & Trust
Company
Operations Center
Attn: Reorganization Department
P.O. Box 2042
New York, New York 10272-2042

The Information Agent is:

105 Madison Avenue
New York, New York 10016
call collect +1-212-929-5500
or
toll free +1-800-322-2885
Email: proxy@mackenziepartners.com


EX-99.(A)(5)(A) 12 c53577_ex99a5a.htm ex-2.htm -- Converted by SEC Publisher, created by BCL Technologies Inc., for SEC Filing

EX-99.(a)(5)(A)

 

-FOR IMMEDIATE RELEASE-

ELRON COMMENCES

PARTIAL TENDER OFFER FOR CASH FOR GIVEN IMAGING

Tel Aviv, May 16, 2008 - Elron Electronic Industries Ltd. (TASE & NASDAQ: ELRN), announced today that it is commencing today a tender offer to purchase 1,462,640 ordinary shares of Given Imaging Ltd. (Nasdaq & TASE: GIVN) for $16.54 per share, net to the seller in cash, less any required withholding taxes and without interest. If the tender offer is completed, the total payments made by Elron will aggregate to $24,192,065. If more than the maximum number of shares offered to be purchased in the tender offer are tendered, Elron will purchase shares on a pro rata basis.

The bidder, Elron, currently beneficially owns 8,002,180 Given Imaging shares, representing approximately 27.4% of the issued and outstanding Given Imaging shares or, when taken together with the issued and outstanding Given Imaging shares owned by Elron’s affiliates, 12,721,708 Given Imaging shares, representing approximately 43.5% of the issued and outstanding shares of Given Imaging. If the offer is completed, Elron will beneficially own approximately 32.4% of the issued and outstanding Given Imaging shares, or when taken together with the issued and outstanding Given Imaging shares owned by Elron’s affiliates, approximately 48.5% of the issued and outstanding Given Imaging shares.

On May 15, 2008, the last trading day before commencement of the offer, the closing sale price of the Given Imaging shares was $15.75 on Nasdaq and NIS 54.49 ($15.91 based on an exchange rate of NIS 3.42 per United States dollar as of May 15, 2008) on the Tel Aviv Stock Exchange (“TASE”).

The initial period of the tender offer and withdrawal rights are scheduled to expire at 10:00 a.m., New York time, or 5:00 p.m., Israel time, on June16, 2008, unless the initial period is extended by Elron. As required by Israeli law, if the conditions to the offer have been satisfied as of the completion of the initial offer period, Elron will provide an additional period of four calendar days during which shareholders may tender their shares. However, shareholders will have no withdrawal rights during such additional four-calendar day period.

The tender offer is conditioned upon: (1) Given Imaging shares representing at least 5.0% of the outstanding shares of Given Imaging (currently, 1,462,640 Given Imaging shares) having been validly tendered and not withdrawn prior to the completion of the initial offer period, (2) as required by Israeli law, at the completion of the initial offer period, the aggregate number of shares tendered in the offer (excluding shares held by Elron, certain affiliates of Elron and certain affiliates of Given Imaging) being greater than the number of shares represented by notices of objection to the offer, and (3) certain other conditions specified in the Offer to Purchase relating to the tender offer. The tender offer is not conditioned on the receipt of financing or the approval of the board of directors of Given Imaging.

The complete terms and conditions of the tender offer, including important U.S. and Israeli income and withholding tax considerations relating to the tender offer, are contained in the Offer to Purchase included as an exhibit to the Tender Offer Statement

            The Triangle Building, 42nd Floor, 3 Azrieli Center, Tel-Aviv 67023, Israel
            Tel. 972-3-6075555, Fax. 972-3-6075556 www.elron.com


DRAFT

on Schedule TO filed today with the U.S. Securities and Exchange Commission (SEC) and with the Israeli Securities Authority (ISA). American Stock Transfer & Trust Company is the U.S. Depositary for the offer and Clal Finance Batucha Investment Management Ltd. is the Israeli Depositary for the offer.

Important Information: This is not an offer to buy or the solicitation of an offer to sell any ordinary shares of Given Imaging. The tender offer that is described in this press release will only be made through the Offer to Purchase, Letter of Transmittal and related tender offer documents. All shareholders of Given Imaging should read the tender offer materials, which are being filed today by Elron, and the Tender Offer Solicitation/Recommendation Statement with respect to the tender offer which will be filed in due course by Given Imaging, with the SEC and the ISA. Shareholders of Given Imaging should read the tender offer materials and the Solicitation/Recommendation Statement because they contain important information about the tender offer. The tender offer materials, the Solicitation/Recommendation Statement and other filed documents will be available at no charge on the SEC’s website at http://www.sec.gov and on the ISA’s website at http://www.magna.isa.gov.il, and will also be made available without charge to all shareholders by contacting MacKenzie Partners, Inc., the information agent for the tender offer, at (212) 929-5500 or toll free (800) 322-2885. Shareholders are urged to read these materials carefully before making any decision with respect to the tender offer.


Elron Electronic Industries Ltd. (TASE & NASDAQ: ELRN), a member of the IDB Holding group, is a leading Israel-based technology holding company directly involved in the long-term performance of its group companies. Elron identifies potential technologies, creates strategic partnerships, secures financing, and recruits highly qualified management teams. Elron’s group companies currently comprise a diverse range of publicly-traded and privately held companies primarily in the fields of medical devices, information & communications technology, clean technology and semiconductors. For further information, please visit
www.elron.com

Company Contact:

Rinat Remler, Vice President & CFO

Elron Electronic Industries Ltd.
Tel. 972-3-6075555
elron@elron.net

Any statements in this press release that may be considered forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results to differ materially, including, but not limited to, the effect of general economic conditions, political events and fluctuations in the share price of Given Imaging. For a more detailed description of the risk factors and uncertainties affecting Given Imaging, refer to Given Imaging’s periodic reports filed by Given Imaging with the SEC, which Elron urges investors to consider. Elron undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

 

            The Triangle Building, 42nd Floor, 3 Azrieli Center, Tel-Aviv 67023, Israel
            Tel. 972-3-6075555, Fax. 972-3-6075556 www.elron.com


EX-99.(A)(5)(B) 13 c53577_ex99a5b.htm c53588_corres.htm -- Converted by SEC Publisher, created by BCL Technologies Inc., for SEC Filing

EX-99.(a)(5)(B)

Note: The following is an un-official English translation of the Hebrew Cover Page of the Offer to Purchase that was published in Israel pursuant to Israeli law. The original Cover Page, written in Hebrew, is the exclusive legally binding version and the Offeror (as defined below) assumes no liability for any of the statements or representations made in this translation.

[FORM OF MIFRAT]

  Elron Electronic Industries Ltd. (the “Offeror”) Given Imaging Ltd. (the “Company”)  

In accordance with the Companies Law, 5759-1999 (the “Companies Law”), the Securities Law, 5728-1968, and the Securities Regulations (Tender Offer), 5760-2000 (the “Tender Offer Regulations”), following is a:

Schedule (‘MIFRAT’) of a Special Offer to Purchase by the Offeror, of

1,462,640 ordinary shares of NIS 0.05 par value each (the “Shares”) of the Company, held by the Company’s shareholders (the “Offerees”), representing approximately 5% of the voting rights in the Company and its issued and paid-up capital as of the Schedule's date, at a price of 16.54 U.S. dollars per share, subject to any lawful withholding tax (the “Offer to Purchase”).

The Company’s shares are listed both on the Tel Aviv Stock Exchange Ltd. (the “TASE”) and on the Nasdaq Global Market in the United States (“Nasdaq”). This Offer to Purchase is, therefore, subject to both Israeli and U.S. law. In accordance with an exemption granted by the Israeli Securities Authority (the “ISA”), this Schedule (with the exception of this cover statement) is identical to the Schedule (Offer to Purchase) that is being published by the Offeror in the United States (the “Schedule”), and includes additional details that are not mandated by the Tender Offer Regulations.

As of the Schedule’s date, the Offeror is the beneficial owner of 8,002,180 Shares of the Company, representing approximately 27.4% of the Company’s voting rights and its issued and outstanding shares, and together with companies affiliated with the Offeror, a total of 12,721,708 Shares of the Company representing approximately 43.5% of the Company’s voting rights and its issued and paid-up capital.1 Should the Offer to Purchase be accepted, then following the consummation of the offer, the Offeror will own, directly and indirectly, 9,464,820 Shares of the Company, representing – as of the above date – approximately 32.4% of the Company’s voting rights and its issued and paid-up capital and together with companies affiliated with the Offeror, a total of 14,184,348 Shares of the Company representing approximately 48.5% of the Company’s voting rights and its issued and paid-up capital.

•     Shareholders of the Company who hold their shares through a TASE member, and are interested in expressing their position regarding the Offer to Purchase, shall do so via the TASE member with whom their securities deposits are managed, and the TASE member will notify the Israeli Depositary (as defined below) as specified in Section 3 of the Schedule.

•     Shareholders of the Company who are listed as shareholders in the Shareholders Register maintained by the Company in Israel (“Listed Holders”), who are interested in expressing their position regarding the Offer to Purchase, shall do so via Clal Finance Batucha Investment Management Ltd. (the “Israeli Depositary”),2 at its offices in Rubinstein House, 37 Menachem Begin Road, Tel Aviv 65220, as specified in Section 3 of the Schedule.
Additional contact information regarding the Israeli Depositary appears on the last page of the Schedule.

•     Shareholders of the Company who are neither Listed Holders, nor hold their shares via a TASE member, and who are interested in expressing their position regarding the Offer to Purchase, shall do so via the U.S. Depositary, as specified in Section 3 of the Schedule.

The results of the Offer to Purchase shall be determined, as specified in Section 1 of the Schedule, in consideration of the aggregate amount of shares included in Acceptance Notices and Notices of Objection as specified in Section 3 of the Schedule, to be delivered to the Offeror by the Offerees via the Depositaries.


1 As of the Schedule’s date, the Offeror's holding in the Company together with its affiliates represents approximately 43.5% of the voting rights in the Company and its issued and paid-up capital. For additional information see the Schedule under “Beneficial Ownership of Shares”.

2 The Israeli Depositary is controlled by IDB Development Corporation Ltd.


As specified in Section 11 of the Schedule, the Offeror’s undertaking to buy shares in the Offer to Purchase in accordance with this Schedule is subject to the following conditions: (a) minimum tenders by Offerees of at least 1,462,640 shares, currently representing 5.0% of the Company’s issued and outstanding shares and voting rights (the “Minimum Acceptance Condition”),3 such that following the consummation of the offer, the Offeror shall be the beneficial owner of Shares representing approximately 32.4% of the Company’s voting rights and issued and paid-up capital and together with companies affiliated with the Offeror approximately 48.5% of the Company’s voting rights and issued and paid-up capital; and (b) pursuant to Section 331 of the Companies Law, the acceptance of the Offer to Purchase by a majority of votes from among those Offerees who shall have expressed their position with regard thereto (which count of Offerees’ votes shall exclude the votes of a controlling shareholder in the Offeror, the owners of a controlling parcel of shares in the Company or of persons on their behalf or on behalf of the Offeror, including their relatives and corporations under their control). For additional details regarding the Offeror’s right to withdraw from the Offer to Purchase, see Section 11 of the Schedule.

In the event that the aggregate number of shares for which Acceptance Notices shall have been received shall exceed 1,462,640, namely, the aforementioned maximum number of shares which the Offeror has undertaken to purchase, the Offeror shall buy from each Offeree having delivered an Acceptance Notice, a prorated portion of the shares represented in such notice, in accordance with the ratio between the maximum number of shares which the Offeror had undertaken to purchase as aforesaid, and the aggregate number of shares for which Acceptance Notices as provided in this Schedule (including in the United States), shall have been received.

As specified in Section 11(b) of the Schedule, if any circumstances occur of which the Company did not know, or could not have known, or did not foresee, or could not have foreseen, causing the terms of the Offer to Purchase to become materially different from the terms which a reasonable offeror would have proposed had he known of such circumstances as of the Schedule date, the Offeror shall be entitled to withdraw the Offer to Purchase, until the Last Date of Acceptance (as defined hereunder), and shall report the withdrawal of the Offer to Purchase to the ISA and to the TASE, and shall, within one business day, publish a notice on the withdrawal from the Offer the Purchase and the circumstances thereof in two daily newspapers having a mass circulation and published in Israel in the Hebrew language.

In accordance with Section 331 of the Companies Law, the Offer to Purchase is a Special Tender Offer addressed to all Offerees, and the Offerees may give notice of their acceptance of the Offer to Purchase or of their objection thereto, as specified in Section 3 of the Schedule. If the Offer to Purchase is accepted, the Offerees who shall have given no notice of their position regarding the Offer to Purchase, or shall have objected thereto, may accept the Offer within a four-day period following the Last Date of Acceptance (as defined below). As of the Schedule Date, Discount Investment Corporation Ltd., Arie Mientkavich, Chairman of the board of directors of the Offeror and Doron Birger, President and Chief Executive Officer, have given notice of their intent not to participate in the Offer.

The Last Date of Acceptance, up to which Acceptance Notices or Notices of Objection to the Offer to Purchase may be delivered, is Monday, June 16, 2008 at 17:00, Israel time (the “Last Date of Acceptance”).

Schedule Date: May 16, 2008


3 The number of shares in the Minimum Acceptance Percentage may increase during the acceptance period as a result of the exercise of options that were allocated by the Company to its employees and officeholders, which may be exercised for the Company’s shares, and/or as a result of the issuance of restricted shares to employees and officeholders of the Company.

2


EX-99.(A)(5)(C) 14 c53577_ex99a5c.htm c53577_ex99a5c.htm

EX-99.(a)(5)(C)

 

Note:       The following are un-official English translations of the Hebrew Acceptance and Objection Notices and Share Transfer Deed that were published in Israel pursuant to Israeli law. The originals of these documents, written in Hebrew, are the exclusive legally binding versions and the Offeror (as defined below) assumes no liability for any of the statements or representations made in this translation.

[FORM OF NOTICES]

NOTICE OF AN UNLISTED HOLDER

An offeree who accepts the tender offer should fill out Part A of this notice, and an offeree who objects to the tender offer should fill out part B of this notice.

To:      Elron Electronic Industries Ltd. (the “Offeror”)
  Through TASE Member _______________Ltd.

Re: Ordinary Shares of Given Imaging Ltd. (the “Company”)
_______________

PART A

I refer to the Schedule (offer to purchase) dated May 16, 2008 of the Offeror, whereby the Offeror offered to buy 1,462,640 ordinary shares par value NIS 0.05 each of the Company (the “Schedule”). Whereas I own and hold, through you, in Deposit No. ____________ at your branch no. _____, ______ ordinary shares par value NIS 0.05 each of the Company, and whereas I wish to accept the tender offer of the Offeror included in the Schedule, in respect of ______________(*) shares of the Company, notice of acceptance of an unlisted holder, as defined in Section 3 of the Schedule, is hereby given accordingly, as well as an undertaking to transfer the aforementioned shares, i.e.____________(*) shares of the Company (the “Shares”) to the Offeror, in accordance with the provisions of the Schedule.

I hereby declare and undertake that the Shares are free of any lien, attachment, debt, pledge or any third party right on the date of giving this notice of acceptance, and that these Shares will be in that condition on the date of their transfer to the name of the Offeror according to the Schedule.

Please transfer the consideration for the above Shares to my account at – ___________, No. _____ , ______________ branch.

I am aware that a precondition for the purchase of the Shares by the Offeror and payment of their consideration in accordance with the Schedule, is the correctness of this declaration.

 
ID No. / Company number
 
Full name
 
Signature

 

 

 


_______________

PART B

I refer to the Schedule dated May 16, 2008 of the Offeror whereby the Offeror offered to buy 1,462,640 ordinary shares par value NIS 0.05 each of the Company (the “Schedule”). Whereas I own and hold, through you, in Deposit No. ____________ at your branch no. _____, ______ ordinary shares par value NIS 0.05 each of the Company, and whereas I wish to object to the tender offer of the Offeror included in the Schedule, in respect of _________(*) shares of the Company, notice of objection of an unlisted holder as defined in Section 3 of the Schedule, is hereby given accordingly.


 
ID No. / Company number
 
Full name
 
Signature

 

 


 
(*)       

The Offeree should insert the maximum number of shares in respect of which the notice is given, i.e. the full amount of shares in the above securities deposit, or a smaller quantity, as the holder wishes.

 

NOTICE OF A TASE MEMBER

To:           Elron Electronic Industries Ltd. (the “Offeror”)
  Via Clal Finance Batucha Management Ltd.

 

Re: Ordinary shares of Given Imaging Ltd. (the “Company”)

We refer to the Schedule (offer to purchase) dated May 16, 2008 of the Offeror, whereby the Offeror offered to buy 1,462,640 ordinary shares par value NIS 0.05 each of the Company (the “Schedule”). Whereas we received notices of unlisted holders in respect of a total of __________ ordinary shares par value NIS 0.05 each of the Company from their holders and owners (the “Sum Total of the Shares”), notice of a TASE Member as set forth in Section 3 of the Schedule is hereby given in connection with the above Shares, as follows:

Out of the Sum Total of the Shares, we received notices of acceptance to the tender offer in respect of a total quantity of _________ ordinary shares par value NIS 0.05 each of the Company (the “Acceptance Shares”). We hereby declare and undertake that the Acceptance Shares are free of any lien, attachment, debt, pledge or any third party right on the date of giving this notice of acceptance, and that the Acceptance Shares will be in that condition on the date of their transfer to the name of the Offeror according to the Schedule. If the offer is accepted, please transfer the consideration for the Acceptance Shares to our account in the TASE clearing house.

For the remainder of the shares out of the Sum Total of the Shares, i.e. ____________ ordinary shares par value NIS 0.05 each of the Company, we received notices of objection.

We are aware that a precondition for the purchase of the Acceptance Shares by the Offeror and payment of their consideration in accordance with the Schedule, is the correctness of this declaration.

 
TASE member number
 
Name of TASE member
 
Stamp and signature
 
Date

 

 

 

 

 



NOTICE OF A LISTED HOLDER

An Offeree who accepts the tender offer should fill out Part A of this notice, and an offeree who objects to the tender offer should fill out part B of this notice.

To:           Elron Electronic Industries Ltd. (the “Offeror”)
  Via Clal Finance Batucha Management Ltd.


Re: Ordinary shares of Given Imaging Ltd. (the “Company”)

_______________

PART A

I refer to the Schedule (offer to purchase) dated May 16, 2008 of the Offeror, whereby the Offeror offered to buy 1,462,640 ordinary shares par value NIS 0.05 each of the Company (the “Schedule”).

Whereas I own / hold power of attorney for transactions in respect of / ________ ordinary shares par value NIS 0.05 of the Company, which are marked from No. __________ to No. _________ inclusive, which are registered in the name of _____________, and whereas I wish to accept the tender offer of the Offeror included in the Schedule, in respect of _________(*) shares of the Company, notice of acceptance of a registered holder, as defined in Section 3 of the Schedule, is hereby given accordingly, and an undertaking to transfer the aforementioned shares, i.e. ____________ (*) shares of the Company (the “Shares”), under the share transfer deed attached hereto, and all in accordance with the terms and conditions of the aforementioned tender offer / the Shares are held by virtue of notarized power of attorney from ____________, the owner and holder of the Shares, which was presented to _____________ and a copy of which, approved by a notary, is attached to this notice of acceptance. (**)

I hereby declare and undertake that the Shares are free of any lien, attachment, debt, pledge or any third party right on the date of giving this notice of acceptance, and that these Shares will be in that condition on the date of their transfer to the name of the Offeror according to the Schedule. Please transfer the consideration for the above Shares to bank account no. __________ in the name of ______________, at Bank _________________, branch __________ (branch no. ______).

I am aware that a precondition for the purchase of the Shares by the Offeror and payment of the consideration in accordance with the Schedule, is the correctness of this declaration.

Attached: 1. Share transfer deeds for the Shares; 2. Share certificate/s no./s _____________ for the Shares; 3. A notarized copy of the notarized power of attorney (where relevant).

 

 
Full name
 
Signature
 
ID No. / Company No.
 
Address

 

 

 

 

 

_______________

 



PART B

I refer to the Schedule (offer to purchase) dated May 16, 2008 of the Offeror, whereby the Offeror offered to buy 1,462,640 ordinary shares par value NIS 0.05 each of the Company (the “Schedule”).

Whereas I own / hold power of attorney for transactions in respect of ________ ordinary shares par value NIS 0.05 each of the Company, which are marked from No. __________ to No. _________ inclusive, which are registered in the name of _____________, and since I wish to object to the tender offer of the Offeror included in the Schedule, in respect of _________(*) shares of the Company, notice of objection as defined in Section 3 of the Schedule, to which photocopies of the share certificate/s are attached, is hereby given accordingly.

 
Full name
 
Signature
 
ID No. / Company No.

 

 

 


 
(*)

The Offeree should insert the maximum number of shares in respect of which the notice is given, i.e. the full amount of shares in the above securities deposit, or a smaller quantity, as the Holder wishes.

(**)     

Delete superfluous language.

 

SHARE TRANSFER DEED

I/We the undersigned, _____________________________, I.D. No./Company No. ______________, of __________________ Street no. ___ in _______________, in consideration of USD _________ which was paid to me/us by Elron Electronic Industries Ltd. (the “Transferee”), hereby transfer to the Transferee __________ ordinary shares par value NIS 0.05 each, in certificate/certificates no/s._____________, of Given Imaging Ltd., to be held by the Transferee, its legal representatives and recipients of transfers from it, in accordance with all the terms and conditions by which I/we held them at the time of signing this deed.

And the undersigned, the Transferee, agrees to accept the above shares in accordance with the terms and conditions.

In witness whereof we have affixed our signatures in ______________ on ____ ____, 2008


         
  Signature of the Transferee   Signature of the Transferor/s


EX-99.D 15 c53577_ex99d.htm 3B2 EDGAR HTML -- c53577_ex99d.htm

Ex-99(d)

Description of Registration Rights Agreement

Introduction

On July 18, 2007, a Registration Rights Agreement among Given Imaging Ltd. (“Given Imaging”), Elron Electronic Industries Ltd. (“Elron”), Discount Investment Corporation Ltd. (“DIC”) and RDC Rafael Development Corporation Ltd. (“RDC”). This Registration Rights Agreement has replaced earlier registration rights granted by Given Imaging to Elron, DIC, RDC, entities affiliated with OrbiMed Capital LLC and other shareholders in connection with a private placement completed in September 2000, before Given Imaging’s initial public offering. These earlier registration rights expired in October 2006.

The Registration Rights Agreement provides the affiliated shareholders means for liquidity that are otherwise not available to them under applicable law given their ownership level. At the same time, it increases the likelihood that a sale by the affiliated shareholders will be coordinated with Given Imaging and not disrupt the ordinary activity in the market for shares of Given Imaging due to the sale of a large number of shares at one time or during a short period.

The main terms of the registration rights agreement are as follows:

Demand Registration Rights

At the request of one or more of the affiliated shareholders holding at least 5% of the then outstanding ordinary shares of Given Imaging, Given Imaging must use its best efforts to register any or all of these shareholders’ ordinary shares on the condition that the minimum aggregate offering price of the shares to be registered is at least $15 million. Given Imaging must also give notice of the registration to other affiliated shareholders and include in the registration any ordinary shares that they request to include. This registration also may include ordinary shares offered by Given Imaging for its own account and by its directors and officers. Given Imaging may only be requested to carry out two of these demand registrations.

In connection with any such demand registration, the managing underwriter may limit the number of shares offered for marketing reasons. In such case, the managing underwriter must exclude first any shares to be registered by Given Imaging for the company’s own account and, second, any shares to be registered by its directors and officers. Thereafter, the shares to be registered by the affiliated shareholders would be reduced pro rata among the affiliated shareholders requesting inclusion of their shares according to the number of shares held by each of them.

Incidental Registration Rights

The affiliated shareholders also have the right to request that Given Imaging include their ordinary shares in any registration statements filed by it in the future for the purposes of a public offering, subject to specified limitations. The managing underwriter may limit the number of shares offered for marketing reasons. In this case, the managing underwriter must exclude first any shares to be registered by Given Imaging, unless Given Imaging initiated the registration, second the shares that the affiliated shareholders have requested to include in the registration, and third the shares of the party initiating the registration.

Form F-3 Registration Rights

At the request of an affiliated shareholder, Given Imaging must make its best efforts to register such shareholder’s ordinary shares on Form F-3. Given Imaging must also give notice of the registration to other affiliated shareholders to whom it has granted registration rights and include in the registration any ordinary shares they request to include. These demand rights may only be exercised if nine months have passed since the last registration that Given Imaging filed in which the affiliated shareholder requesting registration was entitled to include its shares. The minimum aggregate offering price of the shares to be registered is $15 million, in case of an underwritten offering, or $5.0 million, in case of a non-underwritten offering. The managing underwriter may limit the number of shares offered for marketing reasons. In such case, the rights of each shareholder to include its ordinary shares in the registration are allocated in the same manner as in a demand registration described above.


Termination

All registration rights will expire on the fifth anniversary of the agreement. With respect to any shareholder, registration rights will expire if that shareholder can sell all of its ordinary shares within a 90 day period under Rule 144 under the United States Securities Act of 1933, as amended.

Expenses

Generally, Given Imaging will pay all expenses incurred in carrying out the above registrations, as well as the fees and expenses of one legal counsel for the selling shareholders in each registration.


-----END PRIVACY-ENHANCED MESSAGE-----